Mise en page 1 - ISTH 2009

POSTER PRESENTATIONS 

TUESDAY, 10 JULY 2007 

* Presenting Author 

Coagulation factors and inhibitors 

Tissue factor, TFPI, Factor VII 

P-T-001 

P-T-002 

P-T-003 

P-T-004 

P-T-006 

P-T-007 

P-T-008 

P-T-009 

P-T-010 

P-T-011 

P-T-012 

P-T-013 

THE HAEMOSTASIS REGISTRY – AUSTRALIAN AND NEW ZEALAND EXPERIENCE 

WITH RFVIIA 

L. E. Phillips (AU), J. Isbister, S. Dunkley*, J. McNeil, P. Cameron 

COAGULATION FACTOR VII LEVELS ARE MODULATED BY THE BIOLOGICAL CLOCK 

M. Pinotti* (IT), C. Bertolucci, I. Colognesi, E. Frigato, V. Pasquali, P. Renzi, A. Foa, 

F. Bernardi 

BLOOD COAGULATION REACTIONS ON NANOSCALE MEMBRANE SURFACES 

V. S. Pureza* (US), A. W. Shaw, S. G. Sligar, J. H. Morrissey 

VIRAL MYOCARDITIS IS A HYPERCOAGULATIVE STATE. INCREASED TISSUE 

FACTOR EXPRESSION AND PLASMA THROMBOGENICITY 

U. Rauch (DE), S. Antoniak*, U. Boltzen, A. Kallwellis-Opara, P. Bobbert, A. Riad, 

W. Poller, M. Pauschinger, H. Schultheiss 

TISSUE FACTOR DEPENDENT INITIATION OF PLATELET AND FIBRIN THROMBUS 

FORMATION 

A. Zampolli* (US), W. Ruf, Z. M. Ruggeri 

USE OF RECOMBINANT FACTOR VIIA IN CARDIOSURGERY PATIENTS, INCLUDING 

NEONATES AND INFANTS UNDER 1 YEAR OF AGE 

N. N. Samsonova* (RU), L. A. Bokeria, G. Lobacheva, K. Diasamidze, L. G. Klimovich, 

E. Kozar, M. Plushch 

HEME INDUCES TISSUE FACTOR EXPRESSION IN HUMAN LUNG MICROVASCULAR 

ENDOTHELIAL CELLS: RELATIONSHIP TO CLINICAL HEMOLYTIC STATES 

Y. B. N. Setty* (US), S. Gayen-Betal, J. Zhang, S. Kulkarni, M. Stuart 

BLOOD FLOW SUPPRESSES FEEDBACK ACTIVATION OF EXTRINSIC TENASE BY 

FACTOR XA AND PREVENTS CLOTTING 

A. M. Shibeko* (RU), O. E. Avilov, M. A. Panteleev, E. S. Lobanova, F. I. Ataullakhanov 

ELEVATED LEVELS OF FACTOR VIIA-ANTITHROMBIN COMPLEXES IN PATIENTS WITH 

PREVIOUS MYOCARDIAL INFARCTION 

A. Silveira* (SE), D. Scanavini, S. Boquist, C. Ericsson, J. H. Morrissey, A. Hamsten 

EXPRESSION OF THE TFPI V264M MUTANT IN VASCULAR CELL CULTURES 

INVOLVES STABILITY OF MRNA 

G. Skretting* (NO), T. Lien, T. O. Andersen, P. M. Sandset, N. Iversen 

EFFECT OF GLYCOPEGYLATION ON THE PHARMACOKINETIC PROPERTIES OF 

FVIIA 

B. B. Sorensen* (DK), D. Karpf, A. V. Groth, B. V. Bysted, M. B. Hermit, M. Tranholm, 

S. E. Bjørn, K. Kinealy, D. Zopf, R. J. Bayer, M. S. Kalo, H. R. Stennicke 

DETERMINATION OF TISSUE FACTOR ORIGIN USING SIRNA KNOCKDOWN 

APPROACH IN HUMAN PERIPHERAL BLOOD WHITE CELLS 

M. Sovershaev* (NO), E. Egorina, H. Devold, J. Olsen, B. Østerud 

236



P-T-014 

P-T-015 

P-T-016 

P-T-017 

P-T-018 

P-T-019 

P-T-020 

P-T-021 

CLEARANCE OF FACTOR VIIA (FVIIA) IN THE MOUSE IS NOT AFFECTED BY ALPHA 

2-MACROGLOBULIN GENE DELETION OR ACTIVE-SITE BLOCKAGE OF FVIIA 

A. Steinoe* (DK), D. M. Karpf, E. H. N. Olsen, M. Tranholm, L. C. Petersen, 

H. R. Stennicke, M. Ezban, B. B. Sorensen 

RECOMBINANT ACTIVATED HUMAN FACTOR VII (FVIIA) BINDS TO THE ENDOTHELIAL 

PROTEIN C RECEPTOR (EPCR) ON HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS 

(HUVEC) 

A. Steinoe* (DK), B. B. Sorensen, H. R. Stennicke 

DEVELOPMENT OF LONG-ACTING FVIIA DERIVATIVES BY GLYCOPEGYLATION 

H. R. Stennicke (DK), R. J. Bayer, M. S. Kalo, H. Ostergaard*, P. K. Holm, K. Kinealy, 

B. B. Sørensen, S. E. Bjørn, D. Zopf 

A CODING SNP AT THE GPI-ATTACHMENT SITE IN THE TFPI-BETA-SPECIFIC EXON IS 

ASSOCIATED WITH TFPI LEVELS 

H. L. Vos* (NL), A. Van Hylckama Vlieg, F. R. Rosendaal, P. M. Sandset 

CHANGES OF TISSUE FACTOR PATHWAY IN PATIENTS WITH ACUTE MYOCARDIAL 

INFARCTION 

R. Wang* (CN), B. Wen, Y. Ma, P. Pen, H. Li, D. Zhong, L. Li 

SIGNAL TRANSDUCTION PATHWAYS OF INTERLEUKIN-6 INDUCING TISSUE FACTOR 

EXPRESSION IN VASCULAR ENDOTHELIAL CELLS 

Z. Wen* (CN), B. Li, X. He, Y. Sun, H. Zhang, X. Tang, J. Hu, H. Wang, S. He 

CONSTRUCTION AND IDENTIFICATION OF LENTIVIRUS - MEDIATED RNAI VECTORS 

CONTAINING HUMAN TISSUE FACTOR 

S. L. Xiong* (CN), J. Bao, L. Zheng, F. Y. Zeng, Y. R. Qiu, Q. Wang 

MECHANISMS OF THROMBUS FORMATION DIFFER BETWEEN ATHEROSCLEROTIC 

AND NORMAL ARTERIES IN HYPERCHOLESTEROLEMIC RABBITS 

A. Yamashita* (JP), S. Matsuda, M. Takahashi, T. Sumi, K. Nishihira, T. Imamura, 

K. Kitamura, Y. Asada 

Tuesday Posters 

Factor VIII, Factor V 

P-T-022 

P-T-023 

P-T-024 

P-T-025 

SITE-SPECIFIC PEGYLATION OF RFVIII RESULTS IN PROLONGED IN VIVO EFFICACY 

J. E. Murphy* (US), C. Pan, T. Barnett, B. Mei, J. Strauss, H. Tjandra, L. Tang, 

P. Esmon, J. Newgren, K. Landskroner, M. Parmathi, J. Severs, J. Teare, H. Jiang, 

B. Devens, G. Pierce, K. Konstantinov, M. Fournel 

ASSOCIATION OF BLOOD PRESSURE AND FACTOR VIII IN LEIDEN THROMBOPHILIA 

STUDY (LETS) AND CARDIOVASCULAR HEALTH STUDY (CHS) 

A. Y. Nossent* (NL), N. L. Smith, J. C. J. Eikenboom, R. M. Bertina, F. R. Rosendaal, 

B. M. Psaty 

FVIII CONCENTRATES OF RECOMBINANT ORIGIN SHOW A HIGHER THROMBIN 

SENSITIVITY THAN PLASMA-DERIVED FVIII CONCENTRATES BUT NEARLY 

IDENTICAL APC-MEDIATED INACTIVATION KINETICS 

B. Poetzsch* (DE), J. Mueller, I. Dücker, J. Oldenburg 

IMMUNOGLOBULIN ISOTYPES AND FUNCTIONAL ANTI-FVIII ANTIBODIES IN 

RESPONSE TO FVIII TREATMENT IN TWO STRAINS OF HEMOPHILIA A MICE 

M. Qadura* (CA), M. Othman, A. Labelle, E. Burnett, C. Hough, D. Lillicrap, P. Thompson 

P-T-026 

BIOLOGICAL ACTIVITY OF PEGYLATED FACTOR VIII 

L. Regan* (US), X. Jiang, P. Ramsey, J. Severs, S. Sompalli, N. Samuels, J. Teare, 

A. Tollner, L. Tang 

237



P-T-027 

P-T-028 

P-T-029 

P-T-030 

P-T-031 

P-T-032 

P-T-033 

P-T-034 

P-T-035 

P-T-036 

P-T-037 

P-T-038 

P-T-039 

A NOVEL RECOMBINANT B-DOMAIN-DELETED FACTOR VIII EXPRESSED IN A HUMAN 

CELL LINE 

H. Sandberg* (SE), I. Agerkvist, E. Lindner, K. Martinelle, S. Winge 

DISCOVERY OF COMPOUNDS THAT INHIBIT FACTOR VA-MEMBRANE INTERACTION 

BY IN SILICO SCREENING 

K. Segers* (NL), O. Sperandio, M. Sack, R. Fischer, M. M. Miteva, J. Rosing, 

G. A. F. Nicolaes, B. O. Villoutreix 

THE ROLE OF THROMBIN EXOSITES I AND II IN THE ACTIVATION OF HUMAN 

COAGULATION FACTOR V 

K. Segers* (NL), B. Dahlbäck, P. E. Bock, G. Tans, J. Rosing, G. A. F. Nicolaes 

FACTOR V DEFICIENCY DUE TO A NOVEL HOMOZYGOUS MUTATION:FV N468S, BUT 

NO BLEEDING TENDENCY 

K. Shinozawa* (JP), K. Amano, O. Takamiya, N. Shiozaki, T. Ando, I. Seita, K. Ogata, 

T. Suzuki, H. Inaba, K. Fukutake 

COMBINED FACTOR V AND FACTOR VIII DEFICIENCY: MUTATION ANALYSIS AND 

ETHNICAL BACKGROUND OF FIVE PATIENTS 

K. Sittinger* (DE), C. Geisen, M. Watzka, V. Ivaskevicius, C. Heller, G. Kappert, 

H. J. Laws, B. Zieger, E. Seifried, J. Oldenburg, J. G. Kadar 

EFFICACY AND SAFETY OF FVIII WITH PEGYLATED LIPOSOMES IN HAEMOPHILIA A 

J. Spira* (SE), O. P. Pluyshch, T. A. Andreeva, R. N. Khametova 

3D STRUCTURES OF MEMBRANE-BOUND FACTOR VIII 

S. Stoilova-McPhie* (UK), C. D. J. Parmenter, G. Kemball-Cook 

A CRYO-ELECTRON MICROSCOPY STUDY OF RECOMBINANT FVIII BINDING TO PS 

LIPOSOMES 

C. D. J. Parmenter (UK), M. C. Cane, G. Kemball-Cook, S. Stoilova-McPhie* 

MUTATIONS AT THE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN 

(LRP) BINDING SITE OF THE FVIII A2 DOMAIN DID NOT REDUCE LRP BINDING OR 

INCREASE HALF-LIFE OF NON-ACTIVATED FVIII 

L. Tang* (US), J. E. Murphy, T. Barnett, B. Mei, M. Pamarthi, J. Strauss, J. Tjandra, 

Y. Chen, O. Dryga, G. Medvedeff, J. Nixon, D. Chamberlain, J. Newgren, M. Fournel 

PEGYLATION PROTECTS FACTOR VIII FROM THE INHIBITION OF ANTIBODY 

INHIBITORS 

L. Tang* (US), C. Pan, H. Atwal, J. Nixon, T. Barnett, J. E. Murphy, B. Mei, M. Fournel 

FACTOR V MUTATIONS, SER234LEU AND ARG413CYS, ARE ASSOCIATED WITH 

FACTOR V DEFICIENCY AND A BLEEDING TENDENCY 

X. Wang* (CN), P. Jin, Q. Ding, H. Wang 

ABSENCE OF INHIBITOR FORMATION IN PREVIOUSLY TREATED HAEMOPHILIA 

A PATIENTS TREATED WITH A DOUBLE VIRUS INACTIVATED, PLASMA DERIVED 

FACTOR VIII/VWF CONCENTRATE IN PROSPECTIVE CLINICAL STUDIES 

J. Windyga* (PL), A. Klukowska, M. Jansen, J. Feddern 

ALLELIC FREQUENCY AND MINOR VARIATIONS OF THE FACTOR V R2 HAPLOTYPE 

IN JAPANESE POPULATION 

T. Yamazaki* (JP), H. Okada, Y. Toyoda, S. Kunishima, M. Hamaguchi, H. Saito, 

T. Kojima 

238



P-T-040 

RESIDUES 311-325 ON THE HEAVY CHAIN OF FVA REPRESENT AN ACTIVATED 

PROTEIN C BINDING REGION 

S. Yegneswaran* (US), Y. Kojima, M. J. Heeb, A. J. Gale, J. H. Griffin 

Factor XIII and tissue transglutaminase 

P-T-041 

P-T-042 

P-T-043 

P-T-044 

P-T-045 

CEREBRAL THROMBOSIS ASSOCIATED WITH HETEROZYGOUS FV LEIDEN 

MUTATION AND HIGH LIPOPROTEIN A LEVEL IN A GIRL WITH FACTOR XIII 

DEFICIENCY 

M. Akbalik (TR), F. Duru, T. Fisgin, H. Tasdemir, L. Incesu, D. Albayrak*, H. Ozyurek 

EVALUATION OF A NEW, AUTOMATED QUANTITATIVE FACTOR XIII ASSAY 

K. Alhomsi (US), R. O. Salem, K. A. Morin*, E. M. Van Cott 

A NOVEL MUTATION IN EXON 10 OF FACTOR XIII SUBUNIT B 

L. R. Alvarado* (US), D. J. Nugent, A. E. Lovejoy, P. Nakagawa, L. B. Hsieh, 

J. Chediak, S. A. Williams 

FACTOR XIII PHARMACOKINETICS 

L. R. Alvarado* (US), P. Nakagawa, L. B. Hsieh, D. J. Nugent 

FXIII VARIANTS WITH ALTERED THROMBIN ACTIVATION RATES 

M. D. Andersen* (DK), M. Kjalke, S. Bang, I. Lautrup-Larsen, P. Becker, A. S. Andersen, 

I. V. Diers, R. Røjkjær, O. H. Olsen, H. R. Stennicke 

P-T-046 

P-T-047 

P-T-048 

TRANSIENT ACTIVATION OF BLOOD COAGULATION FACTOR XIII BY 

POLYMORPHONUCLEAR GRANULOCYTE ELASTASE 

Z. Bagoly* (HU), F. Fazakas, G. Haramura, E. Tóth, L. Muszbek 

GENERATION AND EXPRESSION OF RECOMBINANT FACTOR XIII-B MUTANTS 

I. Balogh* (HU), E. Dzsudzsak, E. Ajzner, A. Fekete, A. Csapo, J. Kappelmayer 

SECRETION OF COAGULATION FACTOR XIIIA FROM HAEMATOPOIETIC CELLS 

P. A. Cordell* (UK), P. J. Grant, R. J. Pease 


P-T-049 

P-T-050 

P-T-051 

P-T-052 

P-T-053 

A NOVEL DELETION MUTATION (C.1254 DEL33BP OR C.1251DEL33BP) IN THE F13A 

GENE CAUSING SEVERE FACTOR XIII DEFICIENCY 

Q. Ding* (CN), X. Wang, J. Wu, H. Chen, H. Wang 

DETERMINATION OF PLASMA COAGULATION FACTOR XIII WITH THE NOVEL 

FLUOROGENIC ISOPEPTIDASE ASSAY 

K. Oertel (DE), A. Hunfeld, E. Specker, C. Reiff, R. Seitz, R. Pasternack, J. Dodt* 

FACTOR XIIIA-V34L AND FACTOR XIIIB-H95R GENE VARIANTS AND SURVIVAL AFTER 

MYOCARDIAL INFARCTION 

D. Gemmati* (IT), F. Federici, G. Campo, M. L. Serino, M. Valgimigli, G. Guardigli, 

P. Ferraresi, F. Bernardi, R. Ferrari, G. L. Scapoli, L. Catozzi 

EFFECT OF RECOMBINANT FACTOR XIII-A ON ENDOTHELIAL BARRIER FUNCTION 

M. Gruda* (US), S. Turman, E. H. N. Olsen 

PRODUCTION AND CHARACTERIZATION OF MONOCLONAL ANTIBODIES AGAINST 

THE B SUBUNIT OF FACTOR XIII THAT INHIBIT THE FORMATION OF 

HETEROTETRAMERIC COMPLEX OF A AND B SUBUNITS 

É. Katona* (HU), A. Csapó, I. Szabó, G. Haramura, L. Muszbek 

239



Factor VII activating protease 

P-T-054 

P-T-055 

P-T-056 

P-T-057 

P-T-058 

INVESTIGATION OF HUMAN RECOMBINANT FVIIA METABOLISM IN A PERFUSED RAT 

LIVER MODEL 

R. Appa* (DK), M. S. Christensen 

STRUCTURE-FUNCTION ANALYSIS OF THE BINDING PROPERTIES AND ENZYMATIC 

ACTIVITY OF FACTOR VII ACTIVATING PROTEASE (FSAP) USING RECOMBINANT 

MUTANT PROTEINS 

L. Muhl* (DE), T. Weimer, K. T. Preissner, S. M. Kanse 

THE CHANGE AND MUTUAL RELATIONS BETWEEN PROTEIN Z AND PARTIAL 

INFLAMMATORY FACTORS IN CEREBRAL INFARCTION 

X. Pan* (CN) 

THE FACTOR VII ACTIVATING PROTEASE (FSAP) POLYMORPHISM (G534E) IS 

ASSOCIATED WITH A DECREASED RISK FOR RESTENOSIS AFTER PERCUTANEOUS 

CORONARY INTERVENTION 

D. Pons* (NL), S. M. Kanse, M. P. M. De Maat, P. A. F. M. Doevendans, 

R. J. De Winter, R. A. Tio, J. W. Jukema 

FVII ACTIVITY AND R353Q POLYMORPHISM IN ASIAN INDIAN FAMILIES WITH 

CORONARY ARTERY DISEASE 

J. Shanker* (IN), P. Ganapathy, V. S. Rao, B. K. Natesha, M. Mukherjee, V. V. Kakkar 

Markers of coagulation activation 

P-T-059 

P-T-060 

P-T-061 

P-T-062 

P-T-063 

P-T-064 

HEMOSTASIS DISORDERS MARKERS IN INTRACRACRANIAL MENONGIOMAS (IM) 

PATIENTS 

M. A. Aloeva* (GE), E. O. Vorobyova, G. E. Magalashvili 

D-DIMER IN PATIENTS WITH ACUTE LEUKEMIA AFTER TRANSPLANTATION OF 

HEMATOPOIETIC STEM CELLS 

V. A. Atamonov (RU), T. V. Vavilova*, L. M. Fregatova, L. S. Zubarovskaya, 

E. V. Semenova, S. N. Bondarenco 

QUALITATIVE DETECTION OF PROTHROMBIN FRAGMENT 1+2 IN SPOT URINE 

FOLLOWING MAJOR ORTHOPAEDIC SURGERY 

L. C. Borris* (DK), M. Breindahl, M. Lassen, C. Ryge, F. Misselwitz 

ENDOGENOUS THROMBIN POTENTIAL (ETP) IN PLASMA FROM PATIENTS WITH AMI 

DURING ANTITHROMBOTIC TREATMENT 

E. Brodin* (NO), I. Seljeflot, H. Arnesen, H. Appelbom, J. B. Hansen 

HEMOSTATIC MARKERS AS PROGNOSTIC FACTORS IN ATRIAL FIBRILLATION. 

PRELIMINARY RESULTS OF A PROSPECTIVE STUDY 

V. Caruso* (AR), F. Alberto, S. S. Meschengieser, K. Vizcaychipi, S. Grosso, 

A. Sánchez-Luceros, P. Casais, M. F. Hendler, M. A. Lazzari 

HEMOSTATIC PROFILE IN PATIENTS WITH PERIPHERAL ARTERIAL OBSTRUCTIVE 

DISEASE (PAOD): ASSOCIATION TO ANKLE-BRACHIAL INDEX (ABI) 

A. P. L. Mota (BR), M. E. R. C. Santos, G. F. G. Lages, M. G. Carvalho*, 

F. C. L. Silva 

240



P-T-065 

P-T-066 

P-T-067 

P-T-068 

P-T-069 

LACK OF EFFECT ON MARKERS OF THROMBIN GENERATION AND FIBRINOLYSIS BY 

PARTIAL FACTOR IXA INHIBITION FOLLOWING HIP FRACTURE SURGERY 

O. E. Dahl* (UK), B. I. Eriksson, M. R. Lassen, D. P. Ward, R. Rothlein, G. Davis, 

A. G. G. Turpie 

CLINICAL EVALUATION OF A NEW QUANTITATIVE HIGHLY SENSITIVE D-DIMER 

ASSAY FOR EXCLUSION OF DEEP VEIN THROMBOSIS AND PULMONARY EMBOLISM 

P. de Moerloose* (CH), G. Palareti, C. Aguilar, C. Legnani, G. Reber, D. Peetz 

COAGULATION FACTORS AND THE PROTEIN C SYSTEM AS DETERMINANTS OF 

THROMBIN GENERATION 

A. W. J. H. Dielis* (NL), E. Castoldi, H. M. H. Spronk, R. Van Oerle, K. Hamulyák, 

J. Rosing, H. ten Cate 

D-DIMER LEVELS IN RELATION TO FACTOR V 1691 GENOTYPE AND ORAL 

ANTICOAGULATION. A CASE-CONTROL-STUDY OF 46 HOMOZYGOUS AND 

HETEROZYGOUS FACTOR V LEIDEN PATIENTS 

U. Harbrecht* (DE), C. Gnida, J. Oldenburg 

D-DIMER LEVELS IN RELATION TO FACTOR V 1691 GENOTYPE AND ORAL 

ANTICOAGULATION. A CASE-CONTROL-STUDY OF 46 HOMOZYGOUS AND 

HETEROZYGOUS FACTOR V LEIDEN PATIENTS 

U. Harbrecht* (DE), C. Gnida, J. Oldenburg 

P-T-070 

P-T-071 

P-T-072 

THROMBIN GENERATION AMONG SUDANESE ESSENTIAL HYPERTENSION PATIENTS 

F. M. Hassan* (SD), M. M. Hamid 

FIBRIN D-DIMERS IS ASSOCIATED WITH PREVALENT CARDIOVASCULAR EVENTS IN 

THE MOLI-SANI STUDY 

L. Iacoviello* (IT), A. Di Castelnuovo, A. De Curtis, S. Costanzo, A. Arcari, F. Centritto, 

F. De Lucia, I. Di Stefano, R. Di Giuseppe, S. Magnacca, A. Pampuch, E. Plescia, L. Rago, 

C. Silvestri, B. Vohnout, F. Zito, G. De Gaetano, M. B. Donati, M. Persichillo 

QUANTITATION OF D-DIMER BY LOCI TECHNOLOGY 

A. Kappel* (DE), H. Althaus, M. Ehm 


Protein C, Protein S, thrombomodulin 

P-T-073 

P-T-074 

P-T-075 

P-T-076 

ILPCA, A RECOMBINANT PC ACTIVATOR SUCCESSFULLY USED TO FORMULATE AN 

AUTOMATED PC CHROMOGENIC ASSAY IN LIQUID FORMAT 

D. Sanchez-Martinez* (US), D. Diaz, M. Smirnov, M. Triscott 

FOUR NOVEL CAUSATIVE MUTATIONS IDENTIFIED IN THE PROS1 GENE OF 

JAPANESE DEEP VEIN THROMBOSIS PATIENTS WITH PROTEIN S DEFICIENCY 

N. Sanda* (JP), Y. Fujimori, T. Kashiwagi, T. Yamada, K. Okumura, A. Takagi, T. Murate, 

T. Iwasaki, A. Katsumi, K. Yamamoto, T. Matsushita, T. Naoe, H. Saito, T. Kojima 

COMPARISON OF ENDOTHELIAL CELL PROTEIN C RECEPTOR (EPCR) MRNA FORMS 

IN MONOCYTES AND HUVEC 

B. Saposnik* (FR), P. Gaussem, A. Lokajczyk, B. Vedie, J. Emmerich, M. Aiach, 

S. Gandrille 

RECOMBINATION IN ENDOTHELIAL CELL PROTEIN C RECEPTOR GENE PROCR. 

INFERENCE FOR THROMBOPHILIC PATIENTS SCREENING 

B. Saposnik* (FR), A. Lokajczyk, M. Aiach, S. Gandrille 

241



P-T-077 

P-T-078 

P-T-079 

P-T-080 

P-T-081 

P-T-082 

P-T-083 

P-T-084 

P-T-085 

P-T-086 

THE RGDS SEQUENCE OF THE ANTICOAGULANT PROTEIN C (PC) CONTRIBUTES TO 

ITS ENDOTHELIAL CELL RECEPTOR (EPCR) BINDING 

B. Saposnik* (FR), V. Vermillard, C. Bachelot-Loza, D. Borgel, M. Aiach, S. Gandrille 

ENDOGENOUS PROTEIN C INHIBITS PULMONARY COAGULATION BUT FACILITATES 

BACTERIAL DISSEMINATION IN THE EARLY PHASE OF PNEUMOCOCCAL 

PNEUMONIA IN MICE 

M. Schouten* (NL), C. van ‘t Veer, M. M. Levi, C. T. Esmon, T. van der Poll 

PROTEIN S DEFICIENCY IN HIV INFECTED PEDIATRIC PATIENTS ON 

ANTIRETROVIRAL THERAPY 

K. Shetty* (IN) 

ANTI-PROTEIN S ANTIBODIES IN CHILDREN WITH PURPURA FULMINANS AND IN 

HEALTHY CHILDREN FOLLOWING VARICELLA AS WELL AS IN CHILDREN WITH 

THROMBOSIS 

U. Tedgard* (SE), O. Rask, R. Ljung, A. Hillarp 

PROS1 ANALYSIS IN 87 PEDIGREES WITH HEREDITARY PROTEIN S DEFICIENCY 

DEMONSTRATES STRIKING GENOTYPE-PHENOTYPE ASSOCIATIONS 

M. K. Ten Kate* (NL), M. Platteel, R. Mulder, G. Van Der Steege, J. Van Der Meer, 

G. A. F. Nicolaes 

VALIDATION OF THE PROTEIN C/S RATIO TO IDENTIFY CARRIERS OF A PROTEIN S 

GENE MUTATION 

M. K. ten Kate* (NL), R. Mulder, M. Platteel, G. van der Steege, J. van der Meer, 

A. B. Mulder 

PHYTOESTROGENS DOWN-REGULATE PROTEIN S EXPRESSION IN HEPG2 CELLS 

H. Tsuda* (JP), K. Tadokoro, Y. Hiroto, M. Kishikawa, E. Nakazono 

ACTIVATED PROTEIN C INCREASES TISSUE FACTOR EXPRESSION ON HUMAN 

UMBILICAL ENDOTHELIAL CELL BY EPCR-DEPENDENT BUT PAR-1-INDEPENDENT 

MANNER 

M. Uchiba* (JP), Y. Yonemura, K. Okajima, Y. Ando, H. Mitsuya, J. Wojta, C. Kaun, 

B. R. Binder 

THE SCREEN OF INHERITED ANTICOAGULANT PROTEINS DEFICIENCY AMONG 

NORMAL CHINESE 

X. Wei* (CN), Q. Ding, X. Wang, H. Wang 

GENETIC ANALYSIS OF HEREDITARY PROTEIN S DEFICIENCY IN TWO CHINESE 

PEDIGREES 

F. Yang* (CN), P. Jin, X. Wang, H. Wang 

Laboratory methods and experimental models 

P-T-087 

P-T-088 

POSSIBLE MECHANISMS OF THE DEVELOPMENT OF DIC SYNDROME 

B. I. Kuznik* (RU), E. V. Alfonsova, Y. A. Vitkovsky, N. N. Tsybikov 

CURRENT PRACTICE IN THROMBOSIS AND HAEMOSTASIS: A SINGLE-CENTER 

RETROSPECTIVE STUDY 

C. M. Lambert* (BE), C. R. Hermans 

242



P-T-089 

A COMPARATIVE EVALUATION OF THE CS-2000I COAGULATION ANALYSER USING 

CLOTTING, AMIDOLYTIC AND IMMUNO-TURBIDOMETRIC ASSAYS 

A. S. Lawrie* (UK), K. Kobayashi, K. Tajima, N. Matsuo, S. Hoshiko, Y. Hamaguchi, 

R. Liesner, S. J. Machin, I. J. Mackie 

P-T-090 

P-T-091 

P-T-092 

P-T-093 

QUALITY MONITORING OF FRESH-FROZEN PLASMA (FFP) AND THE EFFECT OF 

WHOLE BLOOD STORAGE AT 4 o C OVERNIGHT 

A. S. Lawrie* (UK), R. A. Cardigan, S. J. Machin, I. J. Mackie 

THE PLASMA SAMPLE DILUTION IMPROVES THE CORRELATION BETWEEN 

REAGENTS FOR PT-METHODS 

T. L. Lindahl (SE), A. Osman, K. M. Gustafsson* 

COMPARISON OF TWO ANTI-XA ASSAYS USING A SINGLE CALIBRATION CURVE FOR 

MONITORING HEPARIN ANTICOAGULATION 

D. L. McGlasson* (US), G. A. Fritsma 

EXTERNAL QUALITY CONTROL FOR THE COAGUCHEK INR MEASUREMENT 

IMPORTANT TO CONTROL TEST STRIP QUALITY: EVIDENCE FOR LIMITED 

PROPORTIONAL DIFFERENCES 

P. Meijer* (NL), C. Kluft, L. Poller, F. van der Meer, M. Keown, S. Ibrahim, 

T. van den Besselaar, A. Tripodi, J. Jespersen 

P-T-094 

P-T-095 

P-T-096 

INTER-LABORATORY VARIATION AND THE EFFECT OF THE TYPE OF FLUORIMETER 

ON THE RESULTS OF THE TECHNOTHROMBIN® THROMBIN GENERATION ASSAY 

P. Meijer* (NL), C. Kluft 

ACL TOP PERFORMANCE IN ROUTINE COAGULATION TESTING 

M. Milos* (HR), D. Coen Herak, L. Kuric, I. Horvat, R. Zadro 

THROMBELASTOGRAPHY MAY NOT ALWAYS DETECT CLINICALLY RELEVANT 

FACTOR XIII DEFICIENCY 

G. Moessmer* (DE) 


P-T-097 

P-T-098 

P-T-099 

P-T-100 

P-T-101 

A COMPARATIVE STUDY OF LOW MOLECULAR WEIGHT HEPARIN (LMWH) 

MONITORING BY ANTI-XA LEVELS, OVERALL HAEMOSTASIS POTENTIAL (OHP) AND 

CALIBRATED AUTOMATED THROMBOGRAM (CAT) ASSAYS 

L. Tay (AU), M. Aboud, C. M. Ward, M. C. Morel-Kopp* 

INFLUENCE OF ADDING 4% BSA IN THE BETHESDA ASSAY FOR FACTOR VIII 

INHIBITOR QUANTIFICATION 

A. Moret* (ES), V. Cortina, S. Haya, M. A. Perales, A. R. Cid, J. A. Aznar 

FIRST EXPERIENCE WITH THROGA (THROMBIN GENERATION ASSAY) IN 

IDENTIFICATION OF HYPER- AND HYPOCOAGULABILITY 

G. Nowak* (DE), A. Wiesenburg 

MONITORING UNFRACTIONATED HEPARIN IN A PATIENT WITH RENAL AND HEPATIC 

INSUFFICIENCY YIELDS DISCORDANT RESULTS COMPARING ANTI-XA ASSAY AND 

PARTIAL THROMBOPLASTIN TIME. A CASE REPORT 

R. F. Padmore* (CA), M. Calvert 

ACCURACY AND COST EVALUATION OF A PORTABLE INR MONITOR 

O. Paoletti (IT), A. Alatri, G. Morstabilini, A. Fugazza, S. Testa* 

243



P-T-102 

P-T-103 

P-T-104 

P-T-105 

P-T-106 

P-T-107 

P-T-108 

P-T-109 

P-T-110 

P-T-111 

P-T-112 

EVALUATION OF A NEW INR PORTABLE MONITOR 

O. Paoletti (IT), A. Alatri, G. Morstabilini, M. Mazzolari, S. Testa* 

PROTHROMBIN TIME: COMPARISON BETWEEN DIFFERENT REAGENTS 

O. Paoletti (IT), A. Alatri, G. Morstabilini, S. Testa* 

PT INR: COMPARISON BETWEEN TWO DIFFERENT POINT OF CARE SYSTEMS 

O. Paoletti (IT), A. Alatri, G. Morstabilini, S. Testa* 

HAEMOSTATS BONDED WITHIN INTERMOLECULAR COMPLEXES AND THEIR EFFECT 

ON PLATELET COUNT DECREASE IN ANTICOAGULATED BLOOD 

M. Pecka* (CZ) 

THROMBELASTOGRAPHY STUDY OF HEMOSTATIC AGENTS 

H. T. Peng (CA), M. D. Blostein*, D. Gamble, H. Huang, P. N. Shek 

EVALUATION OF THE COAGUCHEK® XS PLUS SYSTEM IN A SWISS COMMUNITY 

SETTING 

A. Deom (CH), G. Reber*, D. Tsakiris, F. Hannes, W. J. Plesch 

INR RESULTS OF THE COAGUCHEK XS PLUS SYSTEM ARE EQUIVALENT TO THOSE 

OF THE COAGUCHEK XS SYSTEM 

W. J. Plesch* (DE), T. Wolf, B. Dikkeschei 

PERFORMANCE OF THE COAGUCHEK XS PLUS SYSTEM USING LIQUID QUALITY 

CONTROL SAMPLES 

W. J. Plesch* (DE), T. Wolf, B. Dikkeschei 

OPTIMIZATION OF COAGULATION FACTOR ASSAYS FOR IMPROVED ACCURACY 

OVER AN EXTENDED LINEAR RANGE 

J. Polgar* (US), J. Havelick, Q. Li, N. Laurent, U. Mahesh, D. Matte, Z. Gruman, 

P. Haley, E. Doenges, C. M. Holland, I. Csapo, C. Crowley, M. Doyle, M. Triscott 

INFLUENCE OF THE SOURCE OF PHOSPHOLIPIDS FOR APTT-BASED FIX ASSAYS 

AND POTENTIAL CONSEQUENCES FOR THE DIAGNOSIS OF MILD/MODERATE 

HAEMOPHILIA B 

C. Pouplard (FR), A. Lequerrec*, M. Trossaert, B. Delahousse, C. Guerois, 

B. Giraudeau, Y. Gruel 

APPLICABILITY OF A THROMBIN GENERATION TEST IN LABORATORY SCREENING 

A. E. Pusateri (US), L. Grimm, V. King* 

244



Haemorrhagic disorders 

Haemophilia A and B 

P-T-113 

P-T-114 

P-T-115 

P-T-116 

COMBINED POLYMORPHISM MARKERS FOR CARRIER AND PRENATAL DIAGNOSIS 

OF HAEMOPHILIA IN CHINA 

Y. Lu* (CN), X. Wang, Q. Ding, H. Wang 

RECOMBINATION IN ONE HAEMOPHILIA A FAMILY 

Y. Lu* (CN), X. Wang, Q. Ding, H. Wang 

EARLY VIRAL KINETICS PORTENDS THE LONG-TERM OUTCOME OF COMBINED 

THERAPY WITH PEGYLATED INTERFERON (PEG-IFN) PLUS RIBAVIRIN IN 

HEMOPHILIACS WITH HCV/HIV COINFECTION 

M. E. Mancuso* (IT), M. G. Rumi, E. Santagostino, R. Soffredini, A. Coppola, A. Rocino, 

S. Linari, M. Colombo, P. M. Mannucci 

PORT IS NOT A SAFE AND SUITABLE VENOUS ACCESS FOR IMMUNE TOLERANCE 

TREATMENT (ITT) IN HEMOPHILIC CHILDREN 

M. E. Mancuso* (IT), E. Santagostino, S. M. Siboni, P. M. Mannucci 

P-T-117 

P-T-118 

P-T-119 

IMMUNE TOLERANCE INDUCTION TO FVIII IN HEMOPHILIA A MICE USING 

SUBCUTANEOUSLY IMPLANTED FVIII GENE-MODIFIED ENDOTHELIAL PROGENITOR 

CELLS 

H. Matsui* (CA), A. Labelle, C. Hegadorn, P. Thompson, E. Burnett, C. Hough, D. Lillicrap 

U.S. INHIBITOR PILOT PROJECT: STUDY DESIGN AND METHODS VALIDATION 

J. M. Soucie* (US), C. H. Miller, M. Creary, W. C. Hooper, T. C. Abshire, D. B. Brettler, 

P. Bockenstedt, J. Dipaola, G. Massey, A. Neff, A. Shapiro, M. Tarantino, B. M. Wicklund, 

D. Dimichele, U. D. C. Working Group 

NON-CATHETER SUPERIOR CAVA VEIN THROMBOSIS IN A PATIENT WITH 

HEMOPHILIA B AND HIGH TITRE INHIBITOR 

M. E. Mingot* (ES), A. Heiniger 


P-T-120 

P-T-121 

P-T-122 

P-T-123 

P-T-124 

HANDHELD COMPUTERS: AN EFFECTIVE SYSTEM TO RECORD HOME-THERAPY 

DATA OF PATIENTS WITH HAEMOPHILIA 

R. Nunez* (ES), N. F. Perez, R. Perez Garrido, M. Brasser, A. Kimmet 

LONG-TERM PHARMACOVIGILANCE UPDATE WITH A RECOMBINANT FVIII 

CONCENTRATE FOR THE TREATMENT OF HEMOPHILIA A 

J. Oldenburg* (DE), P. Petrini, A. Faradji, A. Tagliaferri, I. Pabinger, S. Knaub, 

C. Zacharias, H. Lenk For Int. Helixate® Nexgen Phv Group 

EXERCISE IMPROVES THE GLOBAL HEMOSTATIC EFFICACY IN SEVERE 

HEMOPHILIA A DOGS, AS DETERMINED BY THROMBELASTOGRAPHY 

M. Othman* (CA), S. Webster, Y. Chirinian, D. Lillicrap 

MOLECULAR AND FUNCTIONAL CHARACTERIZATION OF FVIII MUTATIONS IN A 

FEMALE WITH SEVERE HEMOPHILIA A 

A. Dos Santos (BR), S. A. L. Montalvão, C. Furlan Freguia, E. V. De Paula, 

J. M. Annichino-Bizzacchi, R. M. Camire, M. C. Ozelo* 

MILD HAEMOPHILIA A (P. A1824T) ASSOCIATED WITH HEREDITARY COAGULATION 

FACTOR XII DEFICIENCY AND HETEROZYGOUS PROTHROMBIN 20210G/A MUTATION 

R. Perez (ES), R. Nunez*, R. Garcia-Lozano, O. Fernandez 

245



P-T-125 

P-T-126 

P-T-127 

P-T-128 

P-T-129 

THE UK NATIONAL EXTERNAL QUALITY ASSESSMENT SCHEME (UK NEQAS) FOR 

MOLECULAR GENETIC TESTING IN HAEMOPHILIA 

D. J. Perry* (UK), A. Goodeve, M. Hill, I. Jennings, S. Kitchen, I. Walker 

OVERWEIGHT IN DUTCH HAEMOPHILIA PATIENTS 

M. Peters* (NL), F. F. G. Hofstede, P. P. W. Kamphuisen, K. K. Fijnvandraat, I. I. Plug 

SELF-RATED HEALTH PREDICTS MORTALITY IN PATIENTS WITH HEMOPHILIA 

I. Plug* (NL), F. R. Rosendaal, J. G. van der Bom 

IDENTIFICATION OF FACTOR VIII GENE MUTATIONS IN 120 HAEMOPHILIA A 

PATIENTS: DETECTION OF 26 NOVEL MUTATIONS AND CORRELATION WITH FVIII 

INHIBITOR DEVELOPMENT 

Y. Repesse* (FR), D. Ferandiz, M. Slaoui, P. Gautier, A. Le Querrec, J. Lavergne, 

A. Borel Derlon 

ABNORMAL PATTERN FOR FVIII GENE INTRON 1 INVERSION IN ONE BRAZILIAN 

FAMILY 

S. M. Rezende (BR), S. F. Pio*, G. Correa, D. Zouain 

P-T-130 FAILURE OF IMMUNE TOLERANCE INDUCTION IN HAEMOPHILIA B PATIENTS WITH C, 

T 6460 NONSENSE MUTATION 

N. I. Rodriguez* (US), W. Hoots, D. L. Brown, M. Womack, M. Cantini, M. A. Escobar 

P-T-131 

P-T-132 

P-T-133 

P-T-134 

P-T-135 

P-T-136 

P-T-137 

REGULATION OF DEVELOPMENT AND FUNCTION ENDOTHELIAL CELLS BY 

XENOGENIC IMMUNOGLOBULINS 

V. I. Rugal* (RU), O. A. Rukavitsin 

ACUTE CORONARY STENT THROMBOSIS IN A PATIENT WITH SEVERE HAEMOPHILIA 

ON DUAL ANTIPLATELET THERAPY 

L. Rusen* (RO), C. Lambert, C. Hermans 

ENDOTHELIAL DYSFUNCTION IN HEMOPHILIA PATIENTS 

M. T. Sartori* (IT), F. Bilora, E. Zanon, C. Varvarikis, G. Saggiorato, E. Campagnolo, 

G. Cella 

DOUBLE MUTATION, A 2-BP DELETION AND VAL 211ILE, IN THE BLOOD 

COAGULATION FACTOR IX GENE IN A PATIENT WITH SEVERE HEMOPHILIA B 

I. Seita* (JP), K. Shinozawa, H. Kato, A. Koh, A. Tsujikawa, T. Suzuki, K. Amano, 

H. Inaba, K. Fukutake 

CONTRIBUTION OF NATURAL ANTICOAGULANT AND FIBRINOLYTIC FACTORS IN 

MODULATING THE CLINICAL SEVERITY OF HEMOPHILIA PATIENTS 

S. Shetty* (IN), S. Vora, B. Kulkarni, L. Mota, M. Vijapurkar, L. Quadros, K. Ghosh 

SUCCESSFUL TREATMENT OF HIGH TITRE FACTOR VIII (FVIII) INHIBITOR IN TWO 

PATIENTS WITH MILD AND MODERATE HAEMOPHILIA A WITH RITUXIMAB ALONE 

M. Sigaud* (FR), S. Voisin, A. Lefrancois, M. Fouassier, C. Ternisien, M. Hamidou, 

M. Trossaert 

NATURAL CLEARANCE OF HEPATITIS C VIRUS INFECTION AND HUMAN LEUKOCYTE 

ANTIGEN CLASS II ALLELES IN CHILDREN WITH HAEMOPHILIA 

R. Simanis* (LV), J. Eglite, L. Viksna, S. Lejniece, A. Sochnevs, Z. Kovalova 

246



Haemophilia therapy 

P-T-138 

P-T-139 

P-T-140 

P-T-141 

P-T-142 

INHIBITOR DEVELOPMENT IN PATIENTS WITH HEMOPHILIA A TREATED WITH 

SUCROSE-FORMULATED RECOMBINANT FACTOR VIII 

M. Maas-Enriquez* (DE), E. Gorina, N. Bajwa, G. Lemm 

HOME CLINICAL ASSISTANCE: SICILIAN SURVEY ON THE HCA SUPPORT FOR THE 

MANAGEMENT OF THE PROPHYLAXIS IN PAEDIATRIC HAEMOPHILIAC PATIENTS 

G. Mancuso* (IT), F. Gagliano, G. Bruno, M. Rizzo, M. Mansueto 

PHYSICAL EXAMINATION IN PATIENTS WITH SEVERE HEMOPHILIA UNDER 

PROPHYLACTIC TREATMENT - EFFICACY OF AN EARLY LONG-TERM PROPHYLAXIS? 

S. Masurat* (DE), A. Weidenhammer, K. Christensen, T. Spranger, A. Takla, G. Auerswald 

HAEMOPHILIA TREATMENT IN SERBIA FROM 2000 TO 2006 – HOW TO REACH ONE 

UNIT PER CAPITA IN LOW ECONOMIC CAPACITY COUNTRY 

D. Mikovic* (RS), G. Jankovic, L. Rakic, M. Kovac, A. Maslac 

IMPACT OF FVIII PRODUCT CHANGE IN SEVERE HAEMOPHILIA A PATIENTS 

PREVIOUSLY TREATED WITH PLASMA-DERIVED FVIII 

M. E. Mingot* (ES), D. Bardan, A. Martín, A. Heiniger 

P-T-143 

P-T-144 

P-T-145 

FINAL RESULTS OF A FEASIBILITY STUDY ON AN ELECTRONIC MONITORING 

SYSTEM IN HEMOPHILIA CARE 

W. Mondorf* (DE), H. Pollmann 

RESTORING INITIAL THROMBIN GENERATION DOES NOT NORMALIZE CUTANEOUS 

WOUND HEALING IN HEMOPHILIA B 

A. G. McDonald (US), J. Brock, U. Hedner, M. Ezban, H. R. Roberts, D. M. Monroe, 

M. Hoffman* 

THE CLINICAL RESULTS OF P32 RADIOSYNOVECTOMY IN HEMOPHILIC PATIENTS 

WITH CHRONIC SYNOVITIS 

S. J. Mortazavi* (IR), S. Asadollahi, M. Farzan, S. Shahriaran, M. Aghili, S. Izadyar, 

M. Lak 


P-T-146 

P-T-147 

P-T-148 

P-T-149 

P-T-150 

EVALUATION OF THE SAFETY AND PHARMACOKINETICS OF A RAPID-ACTING 

RECOMBINANT FVII ANALOGUE, NN1731, IN HEALTHY MALE SUBJECTS 

J. Møss* (DK), B. Scharling, M. Ezban, T. Møller Sørensen 

POSTMARKETING SURVEILLANCE STUDY OF SUCROSE-FORMULATED 

RECOMBINANT FACTOR VIII FOR SEVERE HEMOPHILIA A: FINAL RESULTS 

R. Musso* (IT), E. Santagostino, A. Faradji, M. Maas-Enriquez 

PHARMACOKINETICS OF A MIXTURE OF FVIIA AND FX IN RATS 

Y. Nakatomi* (JP), H. Matsui, M. Tsuji, A. Shiranita, T. Nakamura, T. Nakashima, 

S. Gokudan, H. Miyazaki, S. Oonishi, E. Kusumoto, K. Tomokiyo, Y. Ogata, T. Shigaki 

IMMUNE-TOLERANCE IN HAEMOPHILIA A USING PLASMA-DERIVED FACTOR VIII 

CONCENTRATE FANHDI 

J. Needham* (UK), A. Roy, Y. Stebbings, H. Lewis, G. Mathias 

EFFICACY AND SAFETY OF A SOLVENT-DETERGENT TREATED AND 15-NM FILTERED 

HUMAN COAGULATION FACTOR IX ADMINISTERED BY CONTINUOUS INFUSION IN 

HAEMOPHILIA B PATIENTS UNDERGOING SURGICAL PROCEDURES 

C. Négrier* (FR), S. Claeyssens, P. Gautier, M. Bertrand, C. Beaufort, N. Knuchel, 

F. Bridey, V. Chamouard, R. Fleury 

247



P-T-151 

P-T-152 

P-T-153 

P-T-154 

P-T-155 

P-T-156 

PRION PROTEIN REMOVAL DURING MANUFACTURING OF HIGH-PURITY VWF/FVIII 

CONCENTRATES 

A. Neisser-Svae* (AT), G. Gruber, M. Stadler, L. Biesert, T. Schmidt, J. Roemisch, 

T. Svae 

EFFECTS OF THE FACTOR V G1691A MUTATION AND THE FACTOR II G20210A 

VARIANT ON THE CLINICAL EXPRESSION OF SEVERE HEMOPHILIA A (< 1%) IN 

CHILDREN 

U. Nowak-Gottl (DE), K. Kurnik*, C. Escuriola Ettingshausen, R. Schobess, N. Bogdanova 

NEEDLE INDUCED HAEMARTHROSIS: A MURINE MODEL OF HEMOPHILIC SYNOVITIS 

K. Ovlisen* (DK), A. T. Kristensen, M. Tranholm 

SERIOUS BLEEDS IN HAEMOPHILIAC A CHILDREN AND CONTINUOUS INFUSION (CI) 

B. Pautard* (FR), T. Tinot, V. Li Thiao Te, B. Horlé, C. Vinciguerra, B. Roussel 

THE STABILITY OF A PLASMA-DERIVED FACTOR VIII PRODUCT DURING SIMULATED 

CONTINUOUS INFUSION 

H. Pham* (AU), J. Tzouroutis, T. Martinelli 

THE EFFECT OF ACTIVATED FACTOR IX ON THE FACTOR IX COAGULANT AND 

NAPTT ACTIVITY OF A HIGH-PURITY FACTOR IX CONCENTRATE 

W. M. Pickering* (UK), E. Gray 

Recombinant activated Factor VII or APCC 

P-T-157 

P-T-158 

P-T-159 

P-T-160 

P-T-161 

P-T-162 

P-T-163 

ASSESSMENT OF THROMBOTIC ADVERSE EVENTS (TAES) WITH ACTIVATED 

PROTHROMBIN COMPLEX CONCENTRATES (APCCS): 17 YEAR EXPERIENCE 

B. M. Ewenstein* (US), B. S. Yoon, G. Spotts, D. Lee 

ANAMNESIS IN PATIENTS WITH HEMOPHILIA AND INHIBITORS WHO RECEIVE 

ACTIVATED PROTHROMBIN COMPLEX CONCENTRATES FOR PROPHYLAXIS 

N. P. Ewing* (US), L. Pullens, C. De Guzman 

RECOMBINANT COAGULATION FACTOR VIIA IN THERAPY OF MASSIVE POST- 

PARTUM BLEEDING AT PATIENT WITH IDIOPATHIC THROMBOCYTOPENIA (ITP) 

T. A. Fedorova* (RU), E. A. Chernukha, T. K. Puchko, O. V. Rogachevskiy 

LONGTERM PROPHYLACTIC TREATMENT WITH RECOMBINANT FACTOR VIIA 

(NOVOSEVEN) IN SEVERE CONGENITAL FACTOR VII DEFICIENT PATIENTS 

R. B. Zotz* (DE), R. E. Scharf, A. Gerhardt 

THE ANALYSIS OF TREATMENT BY RFVIIA IN CARDIO SURGICAL BLEEDING 

M. Hulikova* (SK) 

RANDOMISED, OPEN, PROSPECTIVE, MULTICENTER PILOT STUDY TO EVALUATE 

THE EFFICACY AND SAFETY OF ACTIVATED RECOMBINANT FACTOR VIIA 

(NOVOSEVEN) IN ACUTE INTRACEREBRAL HAEMORRHAGE IN PATIENTS TREATED 

WITH ORAL ANTICOAGULANT OR ANTIPLATELET AGENTS 

A. Iorio* (IT), E. Marchesini, A. Falcou, V. Caso, M. Pastorello, V. Tiscione, P. Ballarino, 

F. Altomonte, G. Baldi, G. Agnelli, D. Toni 

CAN THROMBIN GENERATION (TG) BE USED TO MONITOR RFVIIA TREATMENT: 

IN VIVO “MINI- PK” STUDY IN HEMOPHILIA A PATIENTS 

G. Kenet (IL), T. Livnat*, U. Martinowitz, I. Tamarin, B. Ravid, A. Zivelin 

248



P-T-164 

P-T-165 

P-T-166 

P-T-167 

P-T-168 

P-T-169 

INTRA-SUBJECT VARIABILITY OF THROMBOELASTOGRAPHIC PARAMETERS 

FOLLOWING RFVIIA IN VIVO ADMINISTRATION IN HAEMOPHILIA PATIENTS: 

A MULTI-CENTRE, RANDOMIZED TRIAL 

G. Kenet* (IL), C. B. Stenmo, A. Blemings, W. Wegert, J. Goudemand, M. Krause, 

W. Schramm, J. Ingerslev, U. Martinovitz 

STUDY OF RECOMBINANT FACTOR VIIA ACTION MECHANISM: A MATHEMATICAL 

MODEL 

M. A. Khanin* (RU), K. V. Tyurin, A. Platonov 

EFFECT OF RFVIIA ON BLEEDING IN HES HEMODILUTED RABBITS 

B. Lauritzen* (DK) 

RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) IN THE TREATMENT OF CRITICAL 

HAEMORRHAGE. A SINGLE CENTRE EXPERIENCE 

M. Lopez Fernandez (ES), M. Amor Otero*, C. Andón Saavedra, J. Batlle Fonrodona 

SECONDARY PROPHYLAXIS WITH RECOMBINANT ACTIVATED FACTOR VII (RFVIIA) 

IN A SEVERE HAEMOPHILIA A PATIENT WITH ANTI-FACTOR VIII INHIBITORS 

A. Marquès-Verdier* (FR), C. Chaleteix, B. Soulié, J. O. Bay 

PRIMARY PROPHYLAXIS WITH RECOMBINANT FACTOR VIIA IN A PATIENT WITH 

HAEMOPHILIA A AND INHIBITOR 

M. Q. Molina* (ES), V. J. Yuste, M. A. Román, I. F. Bello, J. R. Garrido, F. H. Navarro, 

M. M. Salces 

P-T-170 

P-T-171 

P-T-172 

PROPHYLAXIS WITH RECOMBINANT FVIIA 

M. Q. Molina* (ES), I. F. Bello, V. J. Yuste, M. A. Román, M. M. Salces, J. R. Garrido, 

F. H. Navarro 

ILIOPSOAS ABSCESS IN A 4-YEAR-OLD BOY WITH SEVERE HAEMOPHILIA 

S. J. Mortazavi* (IR) 

THE USE OF FEIBA DURING SURGERIES IN HAEMOPHILIA PATIENTS WITH 

INHIBITORS TO FACTOR VIII AND IX 

C. Negrier* (FR), K. W. Hoots, H. Gajek, R. Berg, R. Fleury, D. Stephens, E. Skvortsova 


Von Willebrand disease 

P-T-173 

P-T-174 

P-T-175 

P-T-176 

INVESTIGATION OF ACQUIRED VON WILLEBRAND'S SYNDROME IN PATIENTS WITH 

HYPOTHYROIDISM 

N. M. Antonijevic* (RS), D. Mikovic, M. Kovac, S. Popovic, V. Sreckovic, A. Beletic, 

B. Jakovljevic, J. Perunicic, M. Petakov, S. Savic, Z. Vasiljevic, B. Trbojevic 

STRUCTURAL AND THERMODYNAMIC EFFECTS OF TYPE 2M AND TYPE 2B VWD 

MUTATIONS IN THE A1 DOMAIN OF VWF 

M. Auton* (US), J. Moake, M. A. Cruz 

CLINICAL AND BIOLOGICAL ASPECTS OF VON WILLEBRAND DISEASE IN ALGERIA 

L. Badereddine* (DZ), L. Baghli, B. Benhadda 

SAFETY AND EFFICACY OF VON WILLEBRAND FACTOR/FACTOR VIII CONCENTRATE 

FOR PROPHYLAXIS DURING ELECTIVE SURGERY IN SUBJECTS WITH VON 

WILLEBRAND DISEASE 

J. Bernstein* (US), J. C. Gill, C. A. Leissinger, J. Dipaola, M. V. Ragni, R. Shopnick, 

L. A. Valentino, C. Friedman, S. Knaub 

249



P-T-177 

P-T-178 

P-T-179 

P-T-180 

P-T-181 

P-T-182 

P-T-183 

P-T-184 

P-T-185 

P-T-186 

P-T-187 

250 

A BAYESIAN APPROACH TO THE DIAGNOSIS OF TYPE 1 VON WILLEBRAND DISEASE 

A. Tosetto* (IT), G. Castaman, F. Rodeghiero 

BLEEDING SCORE IS INCREASED IN AFFECTED RELATIVES WITH TYPE 1 VON 

WILLEBRAND DISEASE AND ABNORMAL MULTIMERIC PATTERN IDENTIFIED IN THE 

EU MCMDM-1 VWD STUDY 

G. Castaman* (IT), A. Tosetto, F. Rodeghiero, A. Goodeve, A. B. Federici, J. Batlle, 

D. Meyer, C. Mazurier, J. Goudemand, J. Eikenboom, E. Fressinaud, R. Schneppenheim, 

U. Budde, J. Ingerslev, Z. Vorlova, D. Habart, L. Holmberg, S. Lethagen, J. Pasi, F. Hill, I. Peake 

HETEROGENEITY OF PHENOTYPES IN PATIENTS WITH VON WILLEBRAND DISEASE 

ASSOCIATED WITH NULL MUTATIONS: AN OBSERVATION IN FAMILIES WITH THREE 

NOVEL MUTATIONS 

G. Castaman* (IT), S. H. Giacomelli, R. Ghiotto, K. Bertoncello, M. Bernardi, D. Madeo, 

A. Tosetto, F. Rodeghiero 

PREVALENCE OF VON WILLEBRAND’S DISEASE IN PREMENOPAUSAL WOMEN WITH 

IRON DEFICIENCY ANEMIA AND MENORRHAGIA 

Y. Chen* (TW), S. Cheng, T. Chao, W. Tsai, S. Huang, S. Hu, J. Chiang 

SENSITIVITY OF THE PLATELET FUNCTION ANALYZER (PFA-100) AS A SCREENING 

TEST FOR LABORATORY DIAGNOSIS OF VON WILLEBRAND DISEASE 

D. Coen Herak* (HR), M. Milos, R. Zadro 

ALTERED BINDING OF PURIFIED TYPE 2M VICENZA VON WILLEBRAND FACTOR TO 

PLATELET RECEPTOR ALPHAIIBBETA3 AND GPIB-V-IX COMPLEX 

L. De Marco* (IT), G. Castaman, M. R. Cozzi, M. Mazzucato, A. Steffan, M. Battiston, 

F. Rodeghiero 

A MUTATION IN EXON 27 OF THE VWF GENE CAUSING TYPE 2M AND TYPE 3 VON 

WILLEBRAND DISEASE IN THREE PATIENTS IN A FAMILY FROM THE WEST OF 

SCOTLAND 

M. S. Enayat* (UK), A. M. Guilliatt, A. Alvi, C. R. Tait, F. G. H. Hill 

2B OR NOT 2B? DISPARATE DISCRIMINATION OF FUNCTIONAL VWF DISCORDANCE 

USING DIFFERENT ASSAYS OR METHODOLOGIES FOR VWF LEADS TO SUCCESS OR 

FAILURE IN THE EARLY IDENTIFICATION OF TYPE 2B VWD 

E. J. Favaloro* (AU), R. Bonar, A. Street, K. Marsden 

EFFICACY AND SAFETY OF HIGHLY PURIFIED VWF/FVIII CONCENTRATES IN THE 

TREATMENT OF INHERITED VON WILLEBRAND DISEASE: RESULTS FROM THE 

RETROSPECTIVE ITALIAN STUDY ON 103 CASES 

A. B. Federici* (IT), M. G. Mazzucconi, G. Barillari, R. Musso, E. Zanon, G. Castaman, 

R. Targhetta, G. Mancuso, G. Muleo, A. Coppola, M. D'Incà, G. Gamba, M. Latella, 

P. C. Schinco, L. Valdrè, P. M. Mannucci 

FINAL ANALYSIS OF A PROSPECTIVE-MULTICENTRE STUDY TO EVALUATE 

EFFICACY AND SAFETY OF A TRIPLE-SECURED VON WILLEBRAND FACTOR (VWF) 

A. B. Federici* (IT), A. Borel-Derlon, V. Roussel-Robert, J. Goudemand, C. A. Lee, 

I. Scharrer, C. Rothschild, E. Berntorp, Z. Tellier, F. Bridey, P. M. Mannucci & French 

VWF SD-35-DH Study Group 

THE VON WILLEBRAND FACTOR (VWF) AND FACTOR VIII ACTIVITIES VERSUS VWF 

ANTIGEN RATIOS IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 1: RESULTS 

FROM THE EUROPEAN MULTICENTER MCMDM-1VWD STUDY 

A. B. Federici* (IT), A. Tosertto, J. C. Eikenboom, A. Goodeve, U. Budde, R. Bader, 

M. T. Canciani, G. Castaman, J. Battle, D. Meyer, C. Mazurier, J. Goudemand, 

R. Schneppenheim, J. Ingerslev, Z. Vorlova, D. Habart, L. Holmberg, S. Lethagen, 

J. Pasi, F. Hill, F. Rodeghiero, I. R. Peake



P-T-188 

P-T-189 

P-T-190 

P-T-191 

P-T-192 

TYPE 2B VON WILLEBRAND’S DISEASE. REPORT FROM A SINGLE CENTER IN 

ARGENTINA 

J. P. Frontroth* (AR), M. D. Hepner, G. Pieroni, G. B. Sciuccati, A. Feliú Torres, 

M. M. Bonduel 

RATE OF DE NOVO VWF MUTATIONS IN PATIENTS HISTORICALLY DIAGNOSED WITH 

TYPE 1 VWD IN THE EUROPEAN STUDY, MOLECULAR AND CLINICAL MARKERS FOR 

THE DIAGNOSIS AND MANAGEMENT OF TYPE 1 VWD (MCMDM-1VWD) 

A. Goodeve* (UK), G. Castaman, F. Rodeghiero, A. B. Federici, J. Batlle, D. Meyer, 

C. Mazurier, J. Goudemand, J. Eikenboom, R. Schneppenheim, U. Budde, J. Ingerslev, 

D. Habart, Z. Vorlova, L. Holmberg, S. Lethagen, J. Pasi, F. Hill, M. Hashemi Soteh, 

L. Baronciani, C. Hallden, A. Guilliatt, W. Lester, I. Peake 

LABORATORY DIAGNOSIS AND MONITORING OF DDAVP TREATMENT OF 

VON WILLEBRAND DISEASE BY FLOW CYTOMETRY 

P. Gresele (IT), S. Giannini*, M. Leone, A. Mezzasoma 

VICENZA MUTATION R1205H IDENTIFIED IN TWO TYPE 1 VON WILLEBRAND DISEASE 

FAMILIES FROM ISRAEL 

M. B. Hashemi Soteh* (IR), A. Inbal, I. Peake, J. Anson, A. Goodeve 

VON WILLEBRAND DISEASE TYPES 2A MUTATION (C.4789C>T, P.R1597W) IN THREE 

IRANIAN PATIENTS 

M. B. Hashemi Soteh* (IR), G. Rastegar Lari, F. Ala, M. Jazebi 

Von Willebrand factor 

P-T-193 

P-T-194 

EFFICACY OF A FVIII/VWF CONCENTRATE AS REPLACEMENT THERAPY IN 

PREVENTING EXCESSIVE BLEEDING IN SUBJECTS WITH CONGENITAL VON 

WILLEBRAND DISEASE (VWD) WHO UNDERWENT SURGICAL OR INVASIVE 

PROCEDURES 

L. M. Aledort* (US), G. Rivard, C. M. Kessler 

PRIMARY HEMOSTATIC EFFICACY OF RVWF IN A NOVEL MODEL OF VASCULAR 

INJURY IN MICE WITH SEVERE VWF DEFICIENCY 

B. Baumgartner* (AT), P. L. Turecek, B. Eder, E. M. Muchitsch, H. Gritsch, E. Fesl, 

H. P. Schwarz 


P-T-195 

P-T-196 

P-T-197 

P-T-198 

ADAMTS13 AND VWF IN PEDIATRIC PATIENTS WITH SEVERE MENINGOCOCCAL 

SEPSIS 

T. N. Bongers* (NL), M. Emonts, M. P. M. De Maat, R. De Groot, J. A. Hazelzet, 

F. W. G. Leebeek 

ADAMTS13 LEVELS ARE ASSOCIATED WITH THE RISK OF ARTERIAL THROMBOSIS 

IN YOUNG SUBJECTS 

T. N. Bongers* (NL), E. L. E. De Bruijne, D. W. J. Dippel, J. W. Deckers, 

D. Poldermans, M. P. M. De Maat, F. W. G. Leebeek 

CHARACTERIZATION OF THE INTERACTION BETWEEN VON WILLEBRAND FACTOR 

AND OSTEOPROTEGERIN 

O. D. Christophe* (FR), S. Shahbazi, C. Fribourg, P. J. Lenting, V. Terraube, D. V. Cécile 

SHEAR-INDUCED DISULFIDE BOND FORMATION REGULATES ADHESION ACTIVITY 

OF VON WILLEBRAND FACTOR 

J. Dong* (US), H. Choi, Z. Tao, C. Ball, L. Nolasco, H. Pownall, J. Moake 

251



P-T-199 

P-T-200 

P-T-201 

P-T-202 

P-T-203 

P-T-204 

P-T-205 

P-T-206 

P-T-207 

P-T-208 

P-T-209 

P-T-210 

P-T-211 

VON WILLEBRAND FACTOR (VWF)-BINDING TO COLLAGEN III UNDER 

PHYSIOLOGICAL FLOW CONDITIONS AND VWF-MEDIATED PLATELET BINDING 

B. Fuchs* (DE), C. Fisseau, C. Kannicht 

HOW ABO BLOOD GROUPS AFFECT VON WILLEBRAND FACTOR LEVELS IN 

NORMAL SUBJECTS 

L. Gallinaro* (IT), M. Cattini, A. Bertomoro, E. Pontara, F. Sartorello, C. Soldera, 

R. Padrini, A. Pagnan, A. Casonato 

HOW ABO BLOOD GROUPS AFFECT VON WILLEBRAND FACTOR LEVELS IN 

NORMAL SUBJECTS 

L. Gallinaro* (IT), M. Cattini, A. Bertomoro, E. Pontara, F. Sartorello, C. Soldera, 

R. Padrini, A. Pagnan, A. Casonato 

COLLAGEN AFFINITY TO VON WILLEBRAND FACTOR CONTAINED IN A 

THERAPEUTIC FVIII/VWF CONCENTRATE EVALUATED BY SURFACE PLASMON 

RESONANCE 

S. Grancha* (ES), J. I. Jorquera 

STABILITY OF HIGH PURITY THERAPEUTIC FVIII/VWF CONCENTRATE AFTER 

RECONSTITUTION 

S. Grancha* (ES), J. I. Jorquera 

AUTOMATED QUANTIFICATION OF VON WILLEBRAND FACTOR ACTIVITY WITH 

HEMOSIL ON THE CA 7000 COAGULOMETER: A VALIDATION STUDY 

F. Guerrero* (FR), I. Bruny, P. Sie 

THE EFFECT OF ABO BLOOD GROUP ON VON WILLEBRAND FACTOR PROPEPTIDE 

LEVELS IN NORMAL INDIVIDUALS 

S. L. Haberichter* (US), P.erson, R. G. Hoffman, J. C. Gill, R. R. Montgomery 

THE ISTH SSC VON WILLEBRAND FACTOR (VWF) ONLINE DATABASE 

D. J. Hampshire* (UK), P. D. James, D. Lillicrap, I. R. Peake, A. C. Goodeve 

VWF FUNCTIONS, ADAMTS-13 ACTIVITY AND ANTIGEN LEVELS IN PATIENTS WITH 

LIVER CIRRHOSIS 

I. Tornai (HU), M. Papp, M. L. Udvardy, J. Harsfalvi* 

IDENTIFICATION AND EXPRESSION OF R763G MUTATION ABOLISHING THE 

CLEAVAGE OF VON WILLEBRAND FACTOR PROPEPTIDE, AT THE HETEROZYGOUS 

AND HOMOZYGOUS STATE 

L. Hilbert* (FR), P. Nurden, M. Guicheteau, C. Caron, C. Mazurier 

PHARMACOKINETIC PROFILES AND PHARMACOKINETIC AND PHARMACODYNAMIC 

RELATIONSHIP OF A VWF INHIBITORY APTAMER IN THE CYNOMOLGUS MONKEY 

R. M. Hutabarat* (US), T. McCauley, A. Makim, S. Lewis, P. Merlino, M. Gilbert, 

P. Bouchard 

A NEW SIMPLE AND RELIABLE METHOD FOR INVESTIGATING THE AFFINITY 

BETWEEN COLLAGEN AND VON WILLEBRAND FACTOR IN PLASMA SAMPLES 

M. Karlman* (SE), B. Wiman 

A NEW SIMPLE AND RELIABLE METHOD FOR INVESTIGATING THE AFFINITY 

BETWEEN FACTOR VIII AND VON WILLEBRAND FACTOR IN PLASMA SAMPLES 

M. Karlman* (SE), A. Karlsson, B. Wiman 

252



P-T-212 

P-T-213 

P-T-214 

COMPARISON OF THE ASSERACHROM VON WILLEBRAND FACTOR ANTIGEN ASSAY 

AND THE LIATEST VWF ASSAY AUTOMATED ON THE AMAX 200 COAGULATION 

ANALYZER IN HUMAN AND CANINE PLASMA SAMPLES 

M. Lauzon* (CA), F. Angeloni, N. McEwen, J. McGrath, M. Johnston 

CHARACTERIZATION OF COMMERCIALLY AVAILABLE VWF-CONTAINING FVIII 

CONCENTRATES BY VWF MULTIMER ANALYSIS 

H. J. Metzner* (DE), U. Budde, M. Albers, S. Schulte 

IDENTIFICATION OF AMINO ACID RESIDUES RESPONSIBLE FOR VON WILLEBRAND 

FACTOR BINDING TO SULFATIDES BY CHARGED TO ALANINE SCANNING 

MUTAGENESIS 

T. Nakayama* (JP), T. Matsushita, J. Sadler, A. Katsumi, T. Kojima, T. Naoe, H. Saito 

Inherited and acquired platelet disorders 

P-T-215 

HIGH PREVALENCE OF IRON DEFICIENCY AMONG PATIENTS REFERRED FOR 

EVALUATION OF A BLEEDING DISORDER 

M. Pai* (CA), Y. Liu, S. Whittaker, E. Arnold, J. Seecharan, K. Moffat, K. Webert, 

N. Heddle, C. P. M. Hayward 

P-T-216 

P-T-217 

P-T-218 

BERNARD-SOULIER PLATELETS EXPOSE MORE PROCOAGULANT 

PHOSPHATIDYLSERINE (PS), WITH PAR1 AND PAR4 MEDIATING THE SYNERGISTIC 

EFFECT OF THROMBIN ON COLLAGEN-STIMULATED PS EXPRESSION 

M. L. Rand* (CA), H. Wang, K. W. A. Bang, J. Teitel, V. S. Blanchette, J. Freedman, 

A. T. Nurden 

DIAGNOSTIC EFFICACY OF SYSTEMATIC INVESTIGATION OF NON-VON WILLEBRAND 

BLEEDERS: RESULTS OF A PROSPECTIVE STUDY 

D. Rapson* (CA), M. Bowman, D. Lillicrap, P. James 

NINE NOVEL MUTATIONS IDENTIFIED IN GLYCOPROTEINS (GP) IB AND IX GENES 

AMONG 13 UNRELATED PATIENTS WITH BERNARD SOULIER SYNDROME IN INDIA 

R. Rebecca Jacob* (IN), J. Giridhara Rao, A. Viswabandya, S. Baidya, S. C. Nair, 

B. George, V. Mathews, M. Chandy, A. Srivastava 


P-T-219 

P-T-220 

P-T-221 

P-T-222 

NOVEL MOLECULAR DEFECT IN THE PLATELET ADP RECEPTOR P2Y12 OF A 

PATIENT WITH HAEMORRHAGIC DIATHESIS 

J. A. Remijn* (NL), M. J. W. Ijsseldijk, E. C. Dompeling, H. Engel, L. D. Dikkeschei, 

P. G. De Groot, R. J. Slingerland 

DETECTION OF NONMUSCLE MYOSIN-IIA, INCLUSIONS IN NEUTROPHILS, D-VARIANT 

OF FIBULIN-1 AND MUTATIONS WITHIN MYH9 GENE IN PATIENTS WITH MYH9- 

RALATED DISORDERS 

S. Rittich* (CZ), D. Mikulenkova, P. Salaj, I. Hrachovinova 

THROMBOCYTOPENIA: ANALYSIS OF 317 PATIENTS 

C. Rothschild* (BR), E. Cabral, M. P. Garanito 

EVALUATION OF OUR CASES WITH GLANZMANN THROMBASTHENIA 

Z. Salcioglu* (TR), G. Aydogan, F. Akici, Z. Baslar, H. H. S. Sayilan Sen, N. Aktay Ayaz, 

H. Aldemir, O. Yanilmaz 

P-T-223 

IDENTIFICATION OF 8 NOVEL MUTATIONS IN THE NON-MUSCLE MYOSIN HEAVY 

CHAIN 9 (MYH9 ) GENE IN 11 UNRELATED PATIENTS WITH 

MACROTHROMBOCYTOPENIA 

B. Saposnik* (FR), S. Binard, S. Elbaz, A. Nurden, P. Nurden, O. Fenneteau, 

M. F. Hurtaud-Roux, M. C. Alessi, C. Boinot, R. Favier, S. Bellucci, N. Schlegel 

253



P-T-224 

P-T-225 

P-T-226 

P-T-227 

P-T-228 

P-T-229 

P-T-230 

CUTANEOUS DELAYED-TYPE IV-HYPERSENSITIVITY REACTION (DTH) TO HEPARIN 

AND HEPARIN-INDUCED THROMBOCYTOPENIA TYPE II (HIT) – IS THERE AN 

ASSOCIATION? 

M. Schindewolf* (DE), E. Lindhoff-Last, R. J. Ludwig, W. H. Boehncke, H. Kroll 

SEVERE NEONATAL ALLOIMMUNE THROMBOCYTOPENIA CAUSED BY LOW-AVIDITY 

ANTI-HPA-1A ALLOANTIBODIES 

I. Socher* (DE), C. Andrei-Selmer, G. Bein, H. Kroll, S. Santoso 

A VERY RARE CONGENITAL BLEEDIND DISORDER-BERNARD SOULIER SYNDROME, 

FOUND IN A FAMILY IN MACEDONIA 

S. G. Stankovic* (MK), M. Ivanovski, A. Stojanovic 

DIAGNOSIS AND THERAPY OF CHILDREN WITH INHERITED DEFECTS OF PLATELET 

FUNCTION IN GERMAN SPEAKING COUNTRIES: QUALITY PROJECT THROMKID 

W. Streif* (AT), M. Olivieri, S. Weickardt, H. Rott, U. Nowak- Göttl, C. Wermes, 

C. Escuriola, H. Laws, U. Harbrecht, R. Schneppenheim, W. Eberl, R. Knöfler, W. Streif 

THE ROLE OF FC-GAMMA RECEPTOR GENE POLYMORPHISMS IN THE CLINICAL 

OUTCOME OF NEWLY DIAGNOSED ITP IN CHILDREN 

M. D. Tarantino* (US), G. Streater, L. Pumfrey, D. Nugent, S. Williams 

POLYCYTHAEMIA VERA, ANTIPHOSPHOLPID ANTIBODIES AND ACQUIRED PLATELET 

FUNCTION ABNORMALITIES 

J. Toth* (HU), J. Harsfalvi, J. Kappelmayer, T. Szanto, M. Szarvas, L. Rejto, P. Soltesz, 

M. Udvardy, L. Muszbek 

A HETEROZYGOUS MUTATION OF GPIIB IN PATIENT WITH GLANZMANN 

THROMBASTHENIA 

Z. Yu* (CN), J. Su, X. Bai, Z. Wang, C. Ruan 

Acquired coagulation disorders incl. DIC 

P-T-231 

P-T-232 

P-T-233 

P-T-234 

P-T-235 

P-T-236 

254 

SUCCESSFUL INHIBITOR-ELIMINATION W ITH RITUXIMAB IN ONE PATIENT WITH 

A CARRIER STATE FOR HEMOPHILIA A AND 4 PATIENTS WITH ACQUIRED 

HEMOPHILIA A 

A. Huth-Kühne* (DE), J. Findeklee, M. Bajanova, P. Lages, R. Zimmermann 

CLINICAL EFFICACY OF ANTI-VENOM TREATMENT IN PAPUAN NEW GUINEA 

SNAKE-BITE PATIENTS 

R. Summerhayes* (AU), V. Ignjatovic, D. Williams, K. Winkel, P. Monagle, 

B. Solchenberger 

SUCCESSFUL IMMUNE TOLERANCE INDUCTION TREATMENT OF THERAPY- 

RESISTENT ACQUIRED HAEMOPHILIA WITH HIGH INHIBITOR TITER: A CASE REPORT 

P. Ilonczai* (HU), A. Schlammadinger, Z. Oláh, K. Rázsó, Z. Bereczky, Z. Boda 

POISONING WITH SUPERWARFARIN 

L. A. Jones* (AR), A. Sánchez-Luceros, S. S. Meschengieser, P. Casais, S. Grosso, 

A. N. Blanco, M. Shearer, M. A. Lazzari 

ACQUIRED VON WILLEBRAND DISEASE IN A PATIENT WITH SYSTEMIC LUPUE 

ERYTHEMATOSUS 

F. A. Karim* (MY), Y. Ayob 

INCREASED THROMBIN GENERATION CAPACITY IN SEPTIC PATIENTS WITH DIC 

K. Kawasugi* (JP), C. Simazu, M. Noguchi, H. Tashiro, M. Gotoh, N. Shirafuji, 

J. Matsuda, Y. Miyazawa



P-T-237 

P-T-238 

P-T-239 

P-T-240 

P-T-241 

P-T-242 

COAGULATION STUDIES IN PATIENTS PRESENTING WITH HYPOTHERMIA 

M. Donald (UK), W. Morrison, M. Savory, R. Kerr* 

PLASMA LEVEL OF STROMAL DERIVED FACTOR-1 (SDF-1) IS INCREASED IN 

DISSEMINATED INTRAVASCULAR COAGULATION PATIENTS WHO HAVE A POOR 

OUTCOME: IN VITRO EFFECT OF SDF-1 ON COAGULOPATHY 

H. Kim* (KR), J. Kim, J. Chung, K. Han, S. Park, H. Cho 

INFLUENCE OF ANTIEPILEPTIC DRUGS ON THE COAGULATION 

M. Krause* (DE), C. Pudens, C. Kirchmaier, R. Großmann, R. Gerlach 

RESPONSE TO RITUXIMAB AND EPITOPE MAPPING OF INHIBITORY ANTIBODIES IN 

ACQUIRED HAEMOPHILIA 

M. Krause* (DE), C. Koenigs, C. Kessel, C. Kirchmaier, W. Kreuz 

DDAVP VERSUS VWF-CONTAINING FACTOR CONCENTRATE IN A PATIENT WITH 

ACQUIRED VON WILLEBRAND SYNDROME (AVWS) ASSOCIATED WITH ESSENTIAL 

THROMBOCYTHEMIA (ET) 

R. Kruse-Jarres* (US) 

COAGULATION PARAMETERS OF THE ISTH OVERT DIC SCORE: FIRST, THEIR 

DISTRIBUTION 

A. Leyte* (NL), S. Hogenboom, B. G. Cramer, J. P. J. Wester, R. J. Bosman, H. M. 

Oudemans-Van Straaten, H. I. Van Der Spoel, W. E. Terpstra, M. Treskes, D. F. Zandstra 

P-T-243 

P-T-244 

P-T-245 

PEPTIDE MECHANISMS REGULATION OF HEMOSTASIS IN PURULENT SURGICAL 

INFECTION 

I. D. Likhanov* (RU), M. N. Tsibikov 

ELEVATED PLASMIN-ALPHA2-ANTIPLASMIN LEVELS IN SYSTEMIC AMYLOIDOSIS 

INDICATE ACTIVATION OF THE FIBRINOLYTIC SYSTEM 

C. Maas* (NL), B. Bouma, M. F. B. G. Gebbink, B. P. C. Hazenberg, H. Lokhorst 

FACTOR V IS AN INDEPENDENT PREDICTOR OF MORTALITY IN PATIENTS WITH 

CIRRHOSIS: USEFUL TOOL IN PATIENTS WAITING FOR LIVER TRANSPLANTATION 

M. E. Martinuzzo* (AR), G. S. Cerrato, R. R. Forastiero, A. Ruf, L. Chavez, F. Cairo, 

V. Descalzi, G. Podestá, F. Villamil, S. Perez Lloret, F. Gruz, C. Fuxman 


P-T-246 

P-T-247 

P-T-248 

P-T-249 

P-T-250 

FIBRIN MONOMER BY A QUANTITATIVE ASSAY IN PATIENTS WITH DISSEMINATED 

INTRAVASCULAR COAGULATION 

F. T. Mathonnet* (FR), M. Tetegan, B. De Jonghe, M. Uzan, C. Fischer, Y. Giudicelli, 

J. Coltat, H. Outin 

ACQUIRED HEMOPHILIA IN AN HIV PATIENT 

M. E. Mingot* (ES), I. Ballesteros, I. Perez De Pedro, M. Castaño, M. Causse, 

A. Heiniger 

EVALUATION FOR HYPERCOAGULOPATHY IN THALASSEMIA MAJOR PATIENTS IN 

ISFAHAN 

A. Moafi* (IR), M. Sabri, M. Abedini 

ROLE OF HEMATOLOGIC AND SCREENING HEMOSTATIC PROFILE ON ADMISSION, IN 

PREDICTION OF DEVELOPMENT OF COMPLICATIONS IN HOSPITALIZED PATIENTS 

WITH DENGUE FEVER 

M. Murari* (IN), U. Dewan 

EARLY DIAGNOSIS OF SEPTIC DISSEMINATED INTRAVASCULAR COAGULOPATHY 

D. Oh* (KR), M. M. J. Jang, S. S. J. Lee, S. S. Y. Chong, M. M. S. Kang 

255



Platelets 

Platelets biochemistry and signal transduction 

P-T-251 

P-T-252 

P-T-253 

P-T-254 

P-T-255 

P-T-256 

P-T-257 

P-T-258 

P-T-259 

P-T-260 

P-T-261 

P-T-262 

A ROLE FOR DENSE GRANULE SECRETION IN POTENTIATION OF STORE-OPERATED 

CALCIUM ENTRY IN HUMAN PLATELETS 

A. G. S. Harper* (UK), M. J. Mason, S. O. Sage 

A ROLE FOR THE NA+/CA2+ EXCHANGER IN STORE-OPERATED CALCIUM ENTRY IN 

HUMAN PLATELETS 

A. G. S. Harper* (UK), S. O. Sage 

TRANSACTIVATION OF THE INSULIN RECEPTOR MEDIATES PAR-1 RECEPTOR 

SIGNALLING TO P85 PI3 KINASE/PKB IN HUMAN PLATELETS 

I. Hers* (UK) 

PHOSPHOPROTEIN PROFILING OF COLLAGEN PEPTIDE ACTIVATED PLATELETS: 

A FOCUS ON SERINE AND THREONINE PHOSPHORYLATION EVENTS 

J. M. Howes* (UK), K. S. Lilley, R. W. Farndale 

A GADS-INDEPENDENT PATHWAY OF PLCGAMMA2 REGULATION DOWNSTREAM OF 

THE COLLAGEN RECEPTOR, GPVI 

C. E. Hughes* (UK), C. Pedaries, J. M. Auger, J. McGlade, A. C. Pearce, S. P. Watson 

REGULATION OF PHOSPHODIESTERASE 3A IN HUMAN PLATELETS IS MEDIATED BY 

PROTEIN KINASE C 

R. W. Hunter* (UK), J. E. Harthill, C. MacKintosh, I. Hers 

LIPID RAFT-DEPENDENT ACTIVATION OF NOVEL 33-KDA SER/THR KINASE IN 

THROMBIN-STIMULATED PLATELETS 

M. Ido* (JP), K. Nakanishi, S. Tanaka, M. Bonno, H. Yamamoto, Y. Komada, 

E. C. Gabazza, T. Hayashi, K. Suzuki 

A ROLE FOR GEMS IN PLATELET GLYCOPROTEIN IB-MEDIATED PLATELET 

ACTIVATION 

W. Jin* (JP), O. Inoue, K. Inoue, N. Tamura, K. Satoh, M. C. Berndt, M. Handa, S. Goto, 

Y. Ozaki 

THE CRITICAL ROLE OF MYOSIN IIA IN PLATELET INTERNAL CONTRACTION 

G. J. Johnson* (US), L. A. Leis, M. D. Krumwiede, J. G. White 

SYNERGISM BETWEEN GI ACTIVATION AND CA2+ MOBILIZATION IN PLATELET 

THROMBOXANE A2 FORMATION 

M. Kaneko* (JP), N. Kanno, K. Satoh, Y. Ozaki, Y. Yatomi 

THE RAPID PROCOAGULANT MEMBRANE SCRAMBLING INDUCED BY CALCIUM 

IONOPHORES IN PLATELETS AND LYMPHOCYTES IS DIFFERENT FROM THAT 

INDUCED BY THAPSIGARGIN IN PLATELETS: DEMONSTRATION WITH 

CYCLOSPORIN A 

D. M. Kerbiriou-Nabias* (FR), A. Arachiche, I. Garcin, L. Combettes, D. Geldwerth, 

J. M. Freyssinet, T. Letellier, J. Dachary-Prigent 

CONTRIBUTION OF INDIVIDUAL PURINOCEPTOR SUBTYPES TO PLATELET 

ACTIVATION BY VON WILLEBRAND FACTOR UNDER STATIC CONDITIONS 

J. C. Kermode* (US), Q. Zheng 

256



P-T-263 

P-T-264 

P-T-265 

P-T-266 

P-T-267 

P-T-268 

REGULATION OF INSULIN-LIKE GROWTH FACTOR 1 IN PLATELET ACTIVATION 

S. Kim* (US), S. P. Kunapuli 

REDUNDANT AND NON-REDUNDANT ROLES FOR CLASSICAL PKC ISOFORMS IN 

THE REGULATION OF PLATELET FUNCTION 

O. Konopatskaya* (UK), J. D. Molkentin, A. W. Poole 

LDL-INDUCED PLATELET ACTIVATION INVOLVES SPECIFIC DOMAINS IN APOB100 

S. J. A. Korporaal* (NL), L. Buitrago Murcia, A. Koekman, J. N. Akkerman 

ACTIVATION OF PLATELETS BY A VON WILLEBRAND FACTOR-BINDING PEPTIDE 

SEQUENCE PRESENT IN COLLAGEN III 

B. D. Maddox* (UK), R. W. Farndale 

THE OMEGA-3 FATTY ACID DOCOSAHEXAENOATE (DHA) REDUCES 

CYCLOOXYGENASE(COX)-2 INDUCTION BY INHIBITING NADP(H) OXIDASE AND 

PKCe: POSSIBLE INVOLVEMENT OF 15-LIPOXIGENASE(LO)-1 

M. Massaro (IT), E. Scoditti, M. Carluccio, C. Storelli, A. Distante, R. De Caterina* 

PAR4 INDUCES FULL PLATELET SPREADING ON A FIBRINOGEN MATRIX: 

INVOLVEMENT OF ERK2 AND P38 AND CA2+ MOBILIZATION 

A. Mazharian* (FR), S. Roger, E. Berrou, F. Adam, A. Kauskot, P. Nurden, 

M. Jandrot-Perrus, M. Bryckaert 

P-T-269 

PLATELET ITIM PROTEINS INHIBIT BASAL SIGNALLING BY YXXL-CONTAINING 

PLATELET ACTIVATION RECEPTORS 

J. Mori* (UK), A. C. Pearce, J. C. Spalton, M. G. Tomlinson, Y. A. Senis, S. P. Watson 

Integrins and adhesive proteins 

P-T-270 

INVOLVEMENT OF THE MAP KINASE JNK1 IN THROMBUS FORMATION 

F. Adam* (FR), A. Kauskot, A. Mazharian, N. Ajzenberg, E. Berrou, A. Bonnefoy, 

M. F. Hoylaerts, M. Bryckaert 


P-T-271 

P-T-272 

P-T-273 

CHARACTERISATION OF PREDICTED OESTROGEN RESPONSE ELEMENTS IN THE 

ITGA2 GENE PROMOTER 

F. M. Al-Zahrani* (UK), M. E. Daly, P. R. Winship 

INTEGRIN-LINKED KINASE (ILK) IN PLATELET ALPHAIIB-BETA3 SIGNALING AND 

ARTERIAL THROMBOSIS 

E. G. Arias-Salgado* (ES), R. B. Rodriguez, N. Butta, S. Garcia-Munoz, R. Parrilla, 

M. S. Ayuso 

ANTITHROMBOTIC EFFECT OF RECOMBINANT DISINTEGRIN IN A MOUSE 

THROMBOSIS MODEL 

K. Chung (KR), K. Kwack*, Y. Sohn, D. Kim, S. Lee 

P-T-274 A B3 ASP217 VAL SUBSTITUTION IN A PATIENT WITH VARIANT GLANZMANN 

THROMBATHENIA SEVERELY AFFECTS INTEGRIN AIIBB3 FUNCTIONS 

G. D'Andrea* (IT), R. Bafunno, V. Longo, G. Vecchione, E. Grandone, M. Margaglione 

P-T-275 

A TAILOR-MADE PEPTIDE-AFFINITY COLUMN TO IDENTIFY NOVEL BINDING 

PARTNERS FOR A CYTOPLASMIC MOTIF OF THE PLATELET INTEGRIN ALPHA IIB 

M. Raab (IE), H. Daxecker*, M. Devocelle, A. Treumann, N. Moran 

257



P-T-276 

P-T-277 

P-T-278 

P-T-279 

P-T-280 

P-T-281 

P-T-282 

P-T-283 

P-T-284 

P-T-285 

P-T-286 

807C/T POLYMORPHISM IN THE PLATELET GLYCOPROTEIN IA GENE IN PATIENTS 

WITH RETINAL VEIN OCCLUSION 

T. Gadelha* (BR), A. Biancardi, F. Marilda, G. C. Souza, M. H. C. F. Oliveira, 

B. T. Correa 

INCREASED PLATELET AGGREGATION AFTER DDAVP ADMINISTRATION MAY BE 

EXPLAINED BY DECREASED EXPRESSION OF THE TETRASPANIN CD9 

A. P. Gadisseur (BE), I. Vrelust*, I. Vangenechten, F. Vertessen, M. Van Der Planken 

CALDAG-GEFI-DEFICIENCY CAUSES IMPAIRED BETA1, BETA2, AND BETA3 INTEGRIN 

ACTIVATION IN NEUTROPHILS AND PLATELETS: A MODEL FOR LEUKOCYTE 

ADHESION DEFICIENCY-III (LAD-III) 

T. Goerge* (US), W. Bergmeier, H. Wang, J. R. Crittenden, A. C. W. Baldwin, 

S. M. Cifuni, D. E. Housman, A. M. Graybiel, D. D. Wagner 

PLATELET GLYCOPROTEINS: PREDICTORS OR PROGRESSION MARKERS IN 

CARDIOVASCULAR DISEASE? 

D. A. Gurney* (UK), G. W. Moore, S. Rangarajan 

A ROLE FOR ß3 95–105 IN FIBRINOGEN BINDING AND PLATELET AGGREGATION 

T. A. Haas* (CA) 

A NATURAL MUTATION AND SPECIFIC ARTIFICIAL DELETIONS IN THE BETA3 

CYTOPLASMIC TAIL PREVENT ANTIBODY-MEDIATED ACTIVATION OF INTEGRIN 

ALPHAIIB-BETA3 

H. Hauschner* (IL), N. Rosenberg, U. Seligsohn 

IS BETA3-ARG261 RESPONSIBLE FOR THE EXCLUSIVE BINDING OF ALPHAIIB TO 

BETA3? 

H. Hauschner* (IL), N. Rosenberg, M. Landau, U. Seligsohn 

FCGAMMARII MEDIATES PLATELET AGGREGATION CAUSED BY DISINTEGRINS AND 

GPIIB/IIIA MONOCLONAL ANTIBODY, AP2 

P. L. Ho (TW), C. H. Chang, T. F. Huang* 

NOVEL INTERACTING PROTEINS WITH PLATELET a2β1 CYTOPLASMIC TAILS: 

RHOGDIβ AND SLAP-2 

B. F. Iserbyt* (BE), S. Katsutani, S. Staelens, G. R. Van De Walle, N. Vandeputte, I. Pareyn, 

H. Deckmyn 

IMPAIRED 'OUTSIDE-IN' INTEGRIN ALPHAIIBBETA3 SIGNALING AND THROMBUS 

STABILITY IN CD151 AND TSSC6-DEFICIENT MICE 

D. E. Jackson* (AU), L. M. Lau, M. W. Goschnick, J. L. Wee, Y. S. Liu, M. P. Hogarth, 

L. M. Robb, M. J. Hickey, M. D. Wright, L. K. Ashman 

VON WILLEBRAND FACTOR-GLYCOPROTEIN IB AND INTEGRIN ALPHA2BETA1- 

COLLAGEN INTERACTIONS MAKE COMPLEMENTARY, COLLAGEN-TYPE–SPECIFIC 

CONTRIBUTIONS TO ADHESION 

S. M. Jung* (JP), M. Moroi 

Platelets physiology and pharmacology 

P-T-287 

INHIBITION OF AMINOPHOSPHOLIPID TRANSLOCASE ACTIVITY IN 

PHOSPHATIDYLSERINE-EXPOSING HUMAN PLATELETS IS INDEPENDENT OF 

CALPAIN ACTIVITY 

A. M. Gwozdz (CA), R. Leung, H. Wang, K. W. A. Bang, M. A. Packham, J. Freedman, 

M. L. Rand* 

258



P-T-288 

P-T-289 

P-T-290 

P-T-291 

P-T-292 

P-T-293 

P-T-294 

THE DIFFERENCES OF PLATELET RESPONSE TO SNAKE VENOMS: COMPARATIVE 

STUDY OF CHILDREN AND ADULTS 

L. Kern (AU), V. Ignjatovic, K. Winkel, R. Summerhayes*, P. Monagle 

PLATELET VOLUME IN CORD BLOOD 

A. Ihara* (JP), T. Nishiura, Y. Uchida, K. Abe, F. Tanaka, K. Matsui, S. Shouno 

PLATELET DELAY TIME AS MEASURED IN THE ARTERIOLES OF RATS USING LASER 

INDUCED THROMBOSIS 

M. A. A. Kratzer* (DE), T. Yamashita, J. Yamamoto 

PLATELET ACTIVATION RESPONSE IS MORE SENSITIVE TO THROMBIN STIMULATION 

THAN IS PLATELET APOPTOSIS 

V. Leytin* (CA), D. J. Allen, E. Lyubimov, J. Freedman 

INITIAL INTRAVENOUS EXPERIENCE WITH PRT060128 (PRT128), AN ORALLY- 

AVAILABLE, DIRECT-ACTING, AND REVERSIBLE P2Y12 INHIBITOR 

H. D. Lieu* (US), P. B. Conley, P. Andre, P. T. Leese, K. Romanko, D. R. Phillips, 

M. Jurek, A. Meloni, A. Hutchaleelaha, D. D. Gretler 

SIRTINOL INHIBITS HUMAN PLATELETS AGGREGATION AND CA++ RELEASE 

F. C. Liu* (TW), C. H. Liao, Y. W. Chang, J. T. Liou, Y. J. Day 

2-AG PLAY A ROLE ON ASPIRIN RESISTANCE IN TYPE 2 DIABETES 

H. Matsuno* (JP), S. Araki, Y. Kannno, A. Kuroki, A. Kashiwagi 

P-T-295 

P-T-296 

ANOMALOUS BEHAVIOR OF PLATELETS IN RESPONSE TO TEMPERATURE 

E. Maurer-Spurej* (CA) 

VARIATIONS OF PLATELET GLYCOPROTEIN IIB-IIIA QUANTITY AFFECTS PLATELET 

AGGREGATION AND SENSITIVITY TO GLYCOPROTEIN IIB-IIIA ANTAGONISTS 

A. V. Mazurov* (RU), S. G. Khaspekova, A. M. Zabotina, Y. V. Shimanova, 

O. V. Sirotkina 


P-T-297 

P-T-298 

P-T-299 

P-T-300 

P-T-301 

A ROLE FOR ADIPONENCTIN IN HUMAN PLATELET FUNCTION? 

N. Moran* (IE), S. Sim, S. Chanchlani, A. Kiernan 

FLAVONOIDS INHIBIT PLATELET ADHESION AND AGGREGATION UNDER FLOW: 

BLOCKADE OF TXA2 RECEPTORS IN PLATELET RICH PLASMA 

L. Navarro-Núñez* (ES), M. Palomo, M. Lozano, C. Martínez, E. Pérez-Ceballos, 

V. Vicente, J. Castillo, G. Escolar, M. Díaz-Ricart, J. Rivera 

PLASMA S/R RATIO OF WARFARIN CO-VARIES WITH VKORC1 HAPLOTYPE 

M. Osman* (SE), C. Enström, T. Lindahl 

EFFECT OF CLOPIDOGREL TREATMENT ON STRESS-INDUCED PLATELET 

ACTIVATION AND MYOCARDIAL ISCHEMIA IN ASPIRIN-TREATED PATIENTS WITH 

STABLE CORONARY ARTERY DISEASE 

C. Perneby (SE), H. N. Wallén, C. Hofman-Bang, P. Tornvall, T. Ivert, N. Li, P. Hjemdahl* 

EFFECT OF PRESENCE OR ABSENCE OF RED CELLS ON EARLY GROWTH RATES OF 

PLATELET MURAL THROMBI 

I. V. Pivkin* (US), P. D. Richardson, G. E. Karniadakis 

259



TTP/HUS and ADAMTS 13 

P-T-302 

P-T-303 

P-T-304 

P-T-305 

P-T-306 

ADAMTS13 AND VON WILLEBRAND FACTOR IN THE PATIENTS WITH DIC 

T. Ono* (JP), S. Watanabe, F. Furusaki 

DETERMINATION OF ANTI-ADAMTS13 AUTOANTIBODIES IN THROMBOTIC 

TROMBOCITOPENIC PURPURA (TTP) PATIENTS: COMPARISON OF TWO DIFFERENT 

METHODS 

R. Palla* (IT), C. Valsecchi, M. T. Bajetta, M. T. Canciani, S. Lavoretano, 

P. M. Mannucci, F. Peyvandi 

ATS-13 ACTIVITY AS A COMMON MARKER OF THE ENDOTHELIAL DYSFUNCTION 

DEVELOPING IN THROMBOTIC MICROANGIOPATHIES OF DIFFERENT ORIGIN 

M. Palomo* (ES), M. Diaz Ricart, C. Carbo, M. Pino, A. Pereira, M. Lozano, E. Carreras, 

C. Altisent, E. Saperas, J. Aznar, G. Escolar 

MILD CONGENITAL ADAMTS13 DEFICIENCY DUE TO ONE MISSENSE MUTATION 

TOGETHER WITH FOUR AMINO ACID POLYMORPHISMS IN A PATIENT WITH FAMILIAL 

RECURRENT ISCHEMIC STROKE 

B. Plaimauer* (AT), M. Böhm-Weigert, G. Antoine, I. Scharrer, F. Scheiflinger 

EXPRESSION AND CHARACTERISATION OF 4 ADAMTS13 MUTATIONS IDENTIFIED IN 

PATIENTS WITH TTP (UPSHAW-SCHULMAN SYNDROME) 

A. Ribba* (FR), A. Hommais, J. Rayes, A. Houllier, B. Obert, P. Legendre, A. Veyradier, 

J. Girma 

P-T-307 ADAMTS-13 ACTIVITY, ANTIGEN AND INHIBITOR ANTIBODIES IN TTP PATIENTS – 

A SINGLE CENTER EXPERIENCE 

G. Sarig* (IL), E. J. Dann, G. Tennenbaum, J. M. Rowe, B. Brenner 

P-T-308 

P-T-309 

P-T-310 

P-T-311 

P-T-312 

P-T-313 

P-T-314 

ADAMTS 13 IN NON-THROMBOTIC THROMBOCYTOPENIC PURPURA CONDITIONS 

M. Scully* (UK), R. Liesner, C. Burgess, A. Lawrie, S. J. Machin 

SOUTH EAST ENGLAND THROMBOTIC THROMBOCYTOPENIC PURPURA REGISTRY 

M. Scully* (UK), H. Yarranton, R. Liesner, J. Cavenagh, B. Hunt, S. Benjamin, S. Machin 

TREATMENT OF IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA WITH 

MABTHERA (RITUXIMAB) 

M. Scully* (UK), R. Liesner, J. Cavenagh, B. Hunt, S. Benjamin, H. Cohen, S. J. Machin 

INTENSIVE PLASMA EXCHANGE WAKES UP PATIENT WITH TTP IN COMA 

S. G. Stankovic* (MK), L. Cevreska, O. Karanfilski 

FXI/ADAMTS13 COMPLEX IN PLASMA 

R. D. Starke (UK), A. Lawrie, M. Scully, S. Machin, I. Mackie* 

HUMAN VH1-69 GERMLINE GENE ENCODED ANTI-SPACER DOMAIN ANTIBODIES 

THAT DEVELOP IN PATIENTS WITH ACQUIRED TTP INTERFERE WITH THE BINDING 

OF ADAMTS13 TO VWF 

W. Pos* (NL), B. M. Luken, E. A. M. Turenhout, J. A. K. Kremer Hovinga, 

K. Aboulfatova, J. Dong, R. Fijnheer, J. Voorberg 

ADAMTS13 RELATED MARKERS IN PLASMA FROM PATIENTS WITH TTP 

H. Wada* (JP), T. Kobayashi, T. Nobori, T. Matsumoto, Y. Abe 

260



P-T-316 

P-T-317 

ADAMTS13 ACTIVITY AND AUTOANTIBODIES IN IDIOPATHIC TTP: RESULTS FROM 

THE SERF-TTP GROUP 

A. Zakarija* (US), H. Kwaan, N. Bandarenko, J. Cursio, D. Pandey, I. Weiss, C. Buffie, 

A. Tevar, P. Yarnold, T. Raife, T. Ortel, C. L. Bennett 

RISK FACTORS FOR THROMBOTIC THROMBOCYTOPENIC PURPURA: RESULTS OF 

THE SURVEILLANCE, EPIDEMIOLOGY AND RISK FACTORS FOR TTP (SERF-TTP) 

GROUP 

A. Zakarija (US), N. Bandarenko, H. Kwaan, D. Pandey, J. Cursio, A. Tevar, C. Buffie, 

I. Weiss, T. Ortel, J. Winters, C. L. Bennett* 

Heparin 

P-T-318 

P-T-319 

INCIDENCE OF THE VARIOUS HEPARIN DEPENDENT ANTIBODY ISOTYPES IN A 

GROUP OF PATIENTS WITH HEPARIN INDUCED THROMBOCYTOPENIA 

A. M. Vissac* (FR), M. Catala, J. J. Amiral 

NEW APPROACH FOR DETECTION OF HEPARIN DEPENDENT ANTIBODIES AND RISK 

ASSESSMENT FOR HEPARIN INDUCED THROMBOCYTOPENIA 

J. J. Amiral* (FR), M. Peyrafitte, M. Catala, A. M. Vissac 

P-T-320 

P-T-321 

P-T-322 

THE USE OF THE WARKENTIN ET AL 4T CLINICAL SCORING SYSTEM TO DETERMINE 

PROSPECTIVELY THE APPROPRIATENESS OF HIT ANTIBODY TESTING AT THE 

REGIONAL HAEMOSTASIS LABORATORY, BELFAST CITY HOSPITAL, N IRELAND 

G. M. Benson* (UK), O. McNulty, P. Cooke, P. Murray, D. O'Keeffe 

LONG TERM ANTICOAGULATION WITH FONDAPARINUX FOR DIALYSIS DEPENDENT 

PATIENT WITH HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) 

N. Bermejo* (ES), M. Martín Mateos, I. Castellano, E. Pardal, C. Cámara 

DO PATIENTS WITH HEPARIN INDUCED THROMBOCYTOPENIA HAVE ANTIBODIES TO 

ADAMTS-13 

S. J. Davidson* (UK), M. Swain 


P-T-323 

P-T-324 

P-T-325 

P-T-326 

P-T-327 

INCIDENCE OF ANTI-HEPARIN/PLATELET FACTOR 4 (AHPF4) ANTIBODIES AND 

HEPARIN-INDUCED THROMBOCYTOPENIA (HIT) IN MEDICAL PATIENTS 

M. Demir* (TR), E. Duran, O. Yigitbasi, O. Vural, T. Kurum, M. Yuksel, B. Turgut, 

E. Tekgunduz, J. M. Walenga, J. Fareed 

HEPARIN INDUCED THROMBOCYTOPENIA: COMPLIANCE WITH GUIDELINES IN 

A LARGE COMMUNITY HOSPITAL 

A. I. Depaulis (US), E. A. Robinson, W. F. Patton* 

DEFIBROTIDE AND ITS MOLECULAR FRACTIONS DO NOT CROSS-REACT WITH HIT 

ANTIBODIES. IMPLICATIONS IN THE MANAGEMENT OF HIT 

J. Fareed* (US), D. Hoppensteadt, G. Cella, H. L. Messmore, M. Iacobelli, W. Jeske, 

J. M. Walenga 

RECOMBINANT THROMBOMODULIN DOES NOT CROSS REACT WITH ANTI-HEPARIN 

PLATELET FACTOR 4 ANTIBODIES. POTENTIAL IMPLICATION FOR 

ANTICOAGULATION OF HEPARIN-INDUCED THROMBOCYTOPENIA PATIENTS 

J. Fareed* (US), D. Fareed, D. Hoppensteadt, J. M. Walenga, W. P. Jeske, R. Bick 

HEPARIN-INDUCED THROMBOCYTOPENIA IN CARDIAC SURGERY PATIENTS 

M. Neuffer (DE), D. Fischer, U. Geisen, M. Berchtold-Herz, F. Beyersdorf, K. G. Fischer* 

261



P-T-328 

P-T-329 

P-T-330 

P-T-331 

PROSPECTIVE EVALUATION OF LABORATORY TESTS FOR THE DIAGNOSIS OF 

HEPARIN-INDUCED THROMBOCYTOPENIA 

J. L. Francis* (US), A. Drexler, M. Duncan, H. Desai, M. Amaya, T. Robson, T. V. Meyer, 

E. Reyes, A. Amirkhosravi 

EXPLORING ADULT PATIENT POPULATIONS AT RISK FOR DEVELOPING HIT 

W. Dager* (US), A. Lee, R. C. Gosselin, J. King, T. Wun, K. Janatpour, J. Owings, 

R. White 

UPREGULATION OF MICROPARTICLES IN HEPARIN INDUCED THROMBOCYTOPENIA 

(HIT) AND IT’S MODULATION BY ARGATROBAN 

W. P. Jeske* (US), D. Hoppensteadt, J. M. Walenga, J. Cunanan, K. Nelson, 

H. L. Messmore, J. Fareed 

HEPARIN-INDUCED THROMBOCYTOPENIA IN A PATIENT WITH POLYCYTEMIA VERA: 

A THREATENING ASSOCIATION 

M. Kwon* (ES), A. Rodriguez Huerta, C. Pascual, G. Perez Rus, N. Patrignani, C. Muñoz, 

J. Diez Martin 

Platelet activation markers 

P-T-332 

P-T-333 

P-T-334 

P-T-335 

P-T-336 

P-T-337 

P-T-338 

P-T-339 

CLINICAL SIGNIFICANCE OF MEAN PLATELETS VOLUME IN CORONARY ARTERY 

DISEASE 

S. Aref* (EG), T. Goda 

HIGH NOREPINEPHRINE LEVEL IS ASSOCIATED WITH SIGNIFICANT PLATELET 

HYPERREACTIVITY DEMONSTRATED BY INCREASED PLATELET P-SELECTIN 

POSITIVITY, ADENOSIN DIPHOSPHATE AND COLLAGEN INDUCED AGGREGATIONS IN 

STABLE CORONARY HEART DISEASE PATIENTS ON DUAL ANTIPLATEL 

B. J. Béres* (HU), E. Tóth-Zsámboki, K. Vargová, N. Kiss, A. Kovács, Á. Husvéth, 

Á. László, T. Masszi, I. Préda, R. G. Kiss 

PLATELET AGGREGATION AND SEROTONIN ACTIVITY 

J. S. Berger* (US), R. C. Becker, T. L. Ortel, C. M. Kuhn, M. J. Helms, R. B. Williams 

PLATELET ACTIVATION AND MYOCARDIAL ISCHEMIC EVENTS IN PATIENTS 

UNDERGOING MAJOR VASCULAR SURGERY 

S. Rajagopalan* (UK), I. Ford, P. Bachoo, G. Hillis, B. Croal, M. Greaves, J. Brittenden 

CORRELATION BETWEEN SCD40L LEVELS AND METALLOPROTEINASE EXPRESSION 

WITH THE PLATELET FUNCTIONAL RESPONSE IN IMMUNOLOGICAL DISEASES 

N. V. Butta* (ES), M. Garcia-Rodriguez, E. Arias-Salgado, T. Fontela, S. Larrucea, 

I. Marin, L. Menchen, P. Hernandez-Sampelayo, R. Parrilla 

THE ADDITIVE ANTIPLATELET ACTION OF CLOPIDOGREL IN PATIENTS WITH 

CORONARY ARTERY DISEASE TREATED WITH ASPIRIN 

J. Dropinski* (PL), B. Jakiela, M. Sanak, W. Wegrzyn, M. Biernat, S. Dziedzina, 

H. Plutecka, A. Szczeklik 

EFFECT OF ANTIDEPRESSANT DRUG TREATMENT ON INFLAMMATORY AND 

PLATELET ACTIVATION BIOMARKERS IN DEPRESSION 

J. Fareed (US), A. Halaris*, J. E. Piletz, H. Zhu, O. Iqbal, D. Hoppensteadt 

ASSOCIATION BETWEEN ENHANCED SOLUBLE CD40 LIGAND AND PLATELET 

ACTIVATION IN HYPERTENSIVES WITH MICROALBUMINURIA 

P. Ferroni* (IT), M. Guagnano, M. Manigrasso, F. Santilli, C. Pettinella, V. Raparelli, 

F. Guadagni, S. Basili, G. Davì 

262



P-T-340 

P-T-341 

P-T-342 

P-T-343 

ASSOCIATION BETWEEN ENHANCED VEGF LEVELS AND PLATELET ACTIVATION IN 

HYPERTENSIVE PATIENTS 

P. Ferroni* (IT), R. Palmirotta, F. Martini, A. Spila, V. Raparelli, A. Mammarella, A. Scarno, 

G. Davì, S. Basili, F. Guadagni 

COMPARISON OF TWO ASSAYS FOR THE MEASUREMENT OF URINARY 11-DEHYRO 

THROMBOXANE B2 

G. Gilmore* (AU), J. Thom, J. Rankin, G. Yong, J. W. Eikelboom 

LACTADHERIN IS MORE SENSITIVE THAN ANNEXIN-V AT DETECTING 

PHOSPHATIDYLSERINE EXPOSURE WITHIN PLATELETS 

A. Albanyan* (UK), P. Harrison, J. T. Rasmussen, C. W. Heegard, M. Murphy 

MORPHOLOGIC EVIDENCE OF INTRAVASCULAR PLATELET ACTIVATION WITH 

GENERATION OF PLATELET MICROPARTICLES & EXOSOMES IN MURINE HEPATIC 

SCHISTOSOMIASIS AND ITS MODULATION BY PENTOXIFYLLINE TREATMENT 

A. Lotfi* (EG) 

Platelet function tests 

P-T-344 

PLASMAFHERESIS (PA) INFLUENCE ON MORPHOLOGICAL STATUS OF PLATELES 

(PLT) AT WOMEN WHITH SPONTANEOS ABORTIONES INFLAMMATORY GENESIS 

A. S. Ochan* (RU), E. V. Strelnicova 

P-T-345 

P-T-346 

CLOPIDOGREL PRODUCES DISTINCT DOSE-RESPONSE RELATIONSHIPS FOR 

INHIBITION OF PLATELET AGGREGATION (IPA) AND ANTITHROMBOTIC EFFICACY 

MEASURED IN RATS AND RABBITS 

M. L. Ogletree* (US), P. C. Wong, W. A. Schumacher, R. P. Rehfuss 

VARIABILITY IN PERFORMING PLATELET AGGREGOMETRY FOR DIAGNOSIS OF 

INBORN DISORDERS OF PLATELET FUNCTION IN GERMANY, AUSTRIA AND 

SWITZERLAND 

M. Olivieri* (DE), R. Knöfler, S. Weickardt, W. Eberl, W. Streif 


P-T-347 

P-T-348 

P-T-349 

P-T-350 

P-T-351 

MAXIMAL AND LATE ADP INDUCED PLATELET AGGREGATION IN CORONARY 

ARTERY DISEASE PATIENTS ON DUAL ANTIPLATELET THERAPY 

R. Panicca* (IT), E. Antonucci, A. Gori, R. Marcucci, E. Romano, L. Rossi, S. Claudia, 

D. Prisco, R. Abbate, G. Gensini 

PLATELET FUNCTION EVALUATION BY USING A NEW POINT-OF-CARE SYSTEM AND 

PLATELET LIGHT-TRANSMISSION AGGREGATION IN A LARGE COHORT OF 

CORONARY ARTERY DISEASE PATIENTS 

R. Panicca* (IT), E. Antonucci, E. Romano, A. Gori, R. Marcucci, M. Attanasio, S. Poli, 

D. Prisco, R. Abbate, G. Gensini 

ASPIRIN-RESISTANCE IN CHILDREN 

R. Rauch* (DE), G. Wiegand, K. Stellos, M. Girisch, M. Hofbeck, M. Gawaz 

SPECIFIC AND SENSITIVE DETECTION OF THE INHIBITION OF THE PLATELET P2Y12- 

RECEPTOR WITH THE PFA-100® SYSTEM USING A NEW CARTRIDGE DESIGN 

A. R. Rechner (DE), M. Schwarz, C. Oehler, N. Zander* 

VARIATIONS IN PLATELET FUNCTION TEST OF NORMAL INDIVIDUALS MAY AFFECT 

TEST INTERPRETATIONS 

M. Refaai* (US), R. Sarode, A. Kim 

263



P-T-352 

P-T-353 

P-T-354 

P-T-355 

P-T-356 

P-T-357 

P-T-358 

P-T-359 

P-T-360 

P-T-361 

P-T-362 

P-T-363 

CLOPIDOGREL UNRESPONSIVENESS OVERCOME BY RELOADING: ASSESSEMENT 

BY PLATELET AGGREGOMETRY AND IMPACT-R [CONE AND PLATE(LET) ANALYZER] 

S. Matetzky* (IL), B. Shenkman, H. Hod, P. Fefer, D. Varon, N. Savion 

RESPONSIVENESS TO CLOPIDOGREL AND ASPIRIN AMONG PATIENTS WITH ACUTE 

CORONARY SYNDROME AS ASSESSED BY THE IMPACT-R [CONE AND PLATE(LET) 

ANALYZER] 

B. Shenkman* (IL), S. Matetzky, H. Hod, A. Lubetsky, D. Varon, N. Savion 

TESTING AGONIST-INDUCED PLATELET AGGREGATION BY THE IMPACT-R 

B. Shenkman* (IL), Y. Einav, O. Salomon, D. Varon, N. Savion 

SPECIFIC PHENOTYPE OF PLATELETS GPIB, GPIIB, GPIIIA AND GMP-140 IN 

PATIENTS WITH LOW LIMB VARICOSE VEIN DISEASE 

Y. B. Sivachenko* (RU), A. V. Kurtova, A. P. Ryzhak, Y. E. Zueva, M. I. Kadinskaya, 

M. S. H. Vahitov 

CLOPIDOGREL NON-RESPONSIVENESS IN PATIENTS UNDERGOING PERCUTANEOUS 

CORONARY INTERVENTION: A META-ANALYSIS 

J. D. Snoep* (NL), M. M. C. Hovens, J. C. J. Eikenboom, J. G. van der Bom, 

J. W. Jukema, M. V. Huisman 

LABORATORY-DEFINED ASPIRIN RESISTANCE IS ASSOCIATED WITH A HIGHER RISK 

OF RECURRENT CARDIOVASCULAR EVENTS: A META-ANALYSIS 

J. D. Snoep* (NL), M. M. C. Hovens, J. C. J. Eikenboom, J. G. van der Bom, 

M. V. Huisman 

EFFICACY OF WHOLE BLOOD PLATELET AGGREGATION IN THE EVALUATION OF 

BLEEDING OR THROMBOTIC TENDENCIES 

M. D. Spears* (US), A. Y. Kim, J. Yassine, R. Sarode 

ASSESSMENT OF PLATELET FUNCTION IN NORMAL ADULTS: RISTOCETIN-INDUCED 

PLATELET AGGREGATION (RIPA) 

S. F. Stein* (US), A. Rice, K. Lindstrom, C. H. Miller 

THE EFFECT OF ADP RECEPTOR ANTAGONISTS AND ASPIRIN ON WHOLE BLOOD 

PLATELET AGGREGATION MEASURED BY MULTIPLE ELECTRODE AGGREGOMETRY 

O. Toth* (HU), S. Penz, A. Calatzis, H. Losonczy, W. Siess 

COMPARISON OF IMPEDANCE WHOLE BLOOD AGGREGATION AND OPTICAL 

PLATELET-RICH PLASMA AGGREGATION TO MEASURE THE ANTIPLATELET EFFECT 

OF ASPIRIN IN HEALTHY CONTROLS AND IN PATIENTS WITH PERIPHERAL ARTERY 

DISEASE (PAD) 

H. A. Tran* (AU), S. S. Anand, J. S. Ginsberg, J. I. Weitz, M. Johnston, 

J. W. Eikelboom 

COMPARISON OF A NEW CARTRIDGE* FOR THE PFA-100® WITH OTHER PLATELET 

FUNCTION ASSAYS FOR MEASURING THE EFFECT OF CLOPIDOGREL THERAPY IN 

CARDIOVASCULAR PATIENTS 

J. W. Van Werkum* (NL), J. M. Ten Berg, A. R. Rechner, J. De Haan, C. M. Hackeng 

PLATELET RESPONSIVENESS TOWARDS ANTIPLATELET MEDICATIONS BEFORE 

AND AFTER CORONARY ANGIOGRAPHY AND PERCUTENOUS CORONARY 

INTERVENTIONS AS DETERMINED BY WHOLE BLOOD AGGREGOMETRY 

K. W. Von Pape* (DE), A. Calatzis, T. Bonzel, M. Conze, M. Spannagl, H. Weisser 

264



Fibrinolysis and fibrinogen 

Fibrinogen and fibrin 

P-T-364 

P-T-365 

P-T-366 

P-T-367 

RECOMBINANT BBETA-LYS448 IS ASSOCIATED WITH SIGNIFICANT CHANGES IN 

FIBRIN STRUCTURE AND CLOT RIGIDITY 

R. Ajjan* (UK), K. F. Standeven, R. Harrand, F. Phoenix, S. Dolling, P. J. Grant, 

R. A. S. Ariens 

FIBRIN GEL POROSITY RELATES TO GLYCOSYLATED HAEMOGLOBIN IN PATIENTS 

WITH TYPE 1 DIABETES 

A. M. Antovic* (SE), N. H. Wallen, A. C. Salomonsson, P. E. Lins, U. Adamson, 

G. Jörneskog 

FIBRIN GEL POROSITY: COMPARISON OF TWO LABORATORY ASSAYS 

A. M. Antovic* (SE), G. Jörneskog, A. C. Salomonsson, P. E. Lins, U. Adamson, S. He, 

N. H. Wallen 

BLEEDING AND THROMBOTIC MANIFESTATION IN 58 PATIENTS WITH CONGENITAL 

DYSFIBRINOGENEMIA 

A. Batorova* (SK), D. Horvathova, D. Jankovicova, M. Mistrik, P. de Moerloose, 

M. Neerman-Arbez 

P-T-369 

P-T-370 

P-T-371 

HAPLOTYPES IN THE PROMOTER REGION OF BETA-FIBRINOGEN GENE AND THEIR 

RELATIONSHIP TO ISCHEMIC STROKE IN HAINAN HAN POPULATION IN CHINA 

W. Cai* (CN), H. H. X. Xing 

COMPLEMENT C3 IS A PLASMA CLOT COMPONENT AND INFLUENCES CLOT LYSIS 

A. M. Carter* (UK), R. Somani, J. Howes, A. Shore, K. F. Standeven, P. J. Grant 

CLINICAL STUDY OF MULTI-LOCUS B-FIBRINOGEN GENE POLYMORPHISMS 

W. Fang* (CN) 


P-T-372 

P-T-373 

P-T-374 

P-T-375 

P-T-376 

P-T-377 

PRONOUNCED B KNOB CAPACITY TO MODULATE FIBRIN ARCHITECTURE, 

STIFFNESS, AND PLASMIN LYSIS 

D. K. Galanakis* (US), M. M. Neerman-Arbez, T. Sheiner, D. Hubbs-Taan, C. Nagaswami, 

A. Henschen, J. Weisel 

ANALYSIS OF AFFINITY OF KNOB-HOLE INTERACTIONS RESPONSIBLE FOR FIBRIN 

POLYMERIZATION 

C. B. Geer (US), A. Tripathy, M. H. Schoenfisch, S. T. Lord*, O. Gorkun 

A NOVEL DYSFIBRINOGENEMIA DETECTED BY ELECTROPHORESIS IN A PATIENT 

PRESENTING WITH FAMILIAL VENOUS THROMBOEMBOLISM 

M. L. Hanss* (FR), C. Vergnes, C. Chevreaud, P. Ffrench, P. De Mazancourt 

GENETIC ANALYSIS IN HYPOFIBRINOGENEMIA IN ELEVEN FAMILIES 

M. Hill* (UK), J. Hanley, R. Maclean, V. Garipidou, R. Tait, G. Dolan 

POTENTIAL ROLE OF RAPID MOLECULAR SCREENING OF PATIENTS WITH 

DYSFIBRINOGENEMIA 

M. Hill* (UK), S. Krishnamurthy, E. Nicholson, R. Tait, G. Dolan 

FIBRINOGEN AND FIBRIN INDUCE SYNTHESIS OF PROINFLAMMATORY CYTOKINES 

FROM PERIPHERAL BLOOD MONONUCLEAR CELLS 

T. Jensen* (NO), P. Kierulf, P. M. Sandset, O. Klingenberg, G. B. Joø, H. C. Godal, 

O. H. Skjønsberg 

265



P-T-378 

P-T-379 

P-T-380 

P-T-381 

P-T-382 

REPLACEMENT THERAPY WITH FIBRINOGEN CONCENTRATE: INDICATIONS AND 

ADEQUACY OF USE 

C. M. Lambert* (BE), C. R. Hermans 

EFFECTS OF FIBRINOGEN LEVELS AND CLOT STRENGTH IN THE PRESENCE OF 

THROMBOCYTOPENIA 

T. H. Lang* (DE), D. Scheinichen, H. Metzler, S. Piepenbrock, A. Bornscheuer 

EFFECT OF FIBRIN MATRICES ON INCREASED PROLIFERATION AND SPREADING OF 

EARLY TERM TROPHOBLASTS AND PLACENTAL VILLI. MODULATION OF 

COAGULATION AND ANGIOGENESIS FUNCTIONS 

N. Lanir* (IL), B. Brenner, B. Paz, O. Gonen, A. Snir 

PLATELET FACTOR 4 (PF4/CXCL4) SEALS BLOOD CLOTS BY ALTERING THE 

STRUCTURE OF FIBRIN 

B. F. Le Bonniec* (FR), A. A. Amelot, M. Tagzirt, G. Ducouret, R. Lai Kuen 

DIRECT EVIDENCE OF SPECIFIC INTERACTIONS OF FIBRINOGEN ALPHA C REGIONS 

WITH THE CENTRAL E REGION AND WITH EACH OTHER 

R. I. Litvinov* (US), G. Tsurupa, S. Yakovlev, L. Medved, J. W. Weisel 

Plasminogen activators 

P-T-383 

P-T-384 

P-T-385 

P-T-386 

P-T-387 

P-T-388 

P-T-389 

P-T-390 

INHIBITION OF PLASMINOGEN/PLASMINOGEN ACTIVATOR SYSTEM BY 

ANGIOSTATIN-LIKE PLASMINOGEN FRAGMENTS IS INVOLVED IN MECHANISM OF 

ANTIANGIOGENESIS 

R. B. Aisina* (RU), L. I. Mukhametova, D. A. Gulin, S. S. Larin, K. B. Gershkovich, 

M. Y. Levashov, S. D. Varfolomeyev 

CARDIAC TPA RELEASE DURING SYMPATHETIC NERVE STIMULATION IN PIGS 

DECREASES BY REPEATED STIMULATIONS 

T. Aspelin* (NO), M. Eriksen, J. A. Björkman, T. Lyberg, A. Ilebekk 

ENHANCEMENT OF SINGLE-CHAIN UROKINASE ACTIVITY BY PLATELET PROTEINS 

K. M. Baeten* (UK), N. A. Booth 

THROMBOSIS IN PRETERM INFANTS: A REPORT OF FIVE CASES TREATED WITH 

HIGH DOSE OF TISSUE PLASMINOGEN ACTIVATOR (R-TPA) 

J. D. A. Carneiro* (BR), E. A. D'Amico, L. A. Matsumoto, M. P. Garanito, M. V. Santos, 

R. R. Machado, D. A. F. Chamone 

THE DYNAMICS OF THE BINDING OF PLASMINOGEN AND TPA TO IMMOBILIZED HIGH 

MOLECULAR WEIGHT FIBRIN DEGRADATION PRODUCTS 

P. Cook* (CA), M. E. Nesheim, K. A. Munro 

EVALUATION OF THROMBOLYTIC THERAPY WITH TISSUE-TYPE PLASMINOGEN 

ACTIVATOR (T-PA) FOR PROSTHETIC VALVE THROMBOSIS IN CHILDREN: A SINGLE 

INSTITUTION EXPERIENCE 

A. V. Damme* (CA), S. Williams, C. A. Caldarone, A. K. Chan, L. R. Brandao 

DEFIBROTIDE DIRECTLY ENHANCE THE ACTIVITY OF PLASMIN 

C. Echart* (IT), C. Repice, L. Ferro, M. Iacobelli 

EFFECTS OF 7 KDA STREPTOKINASE FRAGMENT ON THE RABBIT HAEMOSTASIS 

SYSTEM 

S. P. Gavrylyuk* (UA), M. E. Kucherenko, O. M. Savchuk 

266



P-T-391 

P-T-392 

P-T-393 

P-T-394 

P-T-395 

P-T-396 

BETA-ADRENERGIC RECEPTORS MODULATION OF T-PA RELEASE VIA NO 

SYNTHASE-DEPENDENT PATHWAY IN NORMOTENSIVE SUBJECTS AND 

HYPERTENSIVE PATIENTS 

C. Giannarelli* (IT), A. Virdis, F. De Negri, L. Ghiadoni, A. Magagna, A. Salvetti, S. Taddei 

EPINEPHRINE INDUCES LOCAL T-PA RELEASE VIA A NITRIC OXIDE-DEPENDENT 

PATHWAY IN HUMAN FOREARM 

C. Giannarelli* (IT), A. Virdis, F. De Negri, L. Ghiadoni, A. Magagna, A. Salvetti, S. Taddei 

NEW VASOPRESSIN ANALOG REMESTYPE INCREASES PLASMINOGEN ACTIVATOR 

IN RAT BLOOD 

M. E. Grigorjeva* (RU), M. G. Golubeva 

INFLUENCE OF THE STREPTOKINASE 36 KDA FRAGMENT ON THE PLASMIN 

ACTIVITY 

T. V. Grinenko* (UA), G. L. Volkov, E. I. Yusova 

ISOLATION AND CHARACTERIZATION OF PLASMINOGEN-ACTIVATING PROTEINASE 

FROM AGKISTRODON HALYS HALYS VENOM 

V. L. Karbovskyy* (UA), A. N. Savchuk 

ISOLATION AND CHARACTERIZATION OF PLASMINOGEN-ACTIVATING PROTEINASE 

FROM AGKISTRODON HALYS HALYS VENOM 

V. L. Karbovskyy* (UA), A. N. Savchuk 

P-T-397 

Vascular biology 

Tissue remodelling 

THE NOVEL PROTEIN-PROTEIN INTERACTION IN MAMMALIAN HAEMOSTASIS 

SYSTEM INDUCING BY STREPTOKINASE 

I. M. Krasnobryzha* (UA), O. M. Savchuk, T. M. Platonova 


P-T-398 

P-T-399 

P-T-400 

P-T-401 

P-T-402 

NEOINTIMAL CELLS IN WIRE-INJURED ARTERIES HAVE A MIXED ENDOTHELIAL 

CELL (EC) / VASCULAR SMOOTH MUSCLE CELL (VSMC) PHENOTYPE WHICH IS 

THROMBIN-DEPENDENT 

D. Chen* (UK), J. M. Abrahams, R. I. Lechler, J. H. McVey, A. Dorling 

GENETIC ABLATION OF JAM-A IMPAIRS SURVIVAL AFTER MYOCARDIAL INFARCT 

V. G. Cooke* (US), E. Gao, T. Tsuda, U. P. Naik 

EFFECT OF SCLEROSANTS ON ANTITHROMBOTIC MECHANISMS, ENDOTHELIAL 

CELLS AND FIBRINOLYSIS 

T. Exner* (AU), K. Parsi, A. Herbert, D. D. F. Ma 

ROLE OF TISSUE REMODELLING IN HYPERTROPHIC MYOCARDIOPATHY 

V. Roldan* (ES), F. Marin, J. Gimeno, F. Ruiz-Espejo, R. Gonzalez-Conejero, 

A. Garcia-Honrubia, V. Vicente 

TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE 1 (TIMP-1) PREDICTS 

RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY IN END STAGE SYSTOLIC 

HEART FAILURE 

V. Roldan* (ES), F. Marin, J. Martinez, A. Hernandez, A. Ibañez, M. Ortego, J. Navarro, 

C. Moro, V. Vicente 

267



Statins 

P-T-403 

P-T-404 

P-T-405 

P-T-406 

P-T-407 

P-T-408 

P-T-409 

P-T-410 

ACUTE EFFECT OF STATINS ON THE REGULATION AND EXPRESSION OF 

CANDIDATE GENES (CD36, MMP-9 AND IL-8) IN ATHEROSCLEROSIS IN HIV-INFECTED 

PATIENTS 

F. De Lorenzo* (UK), J. Martin, M. Boffito, J. McGregor 

IMPROVEMENT OF THIOLACTONASE ACTIVITY OF PARAOXONASE 1 BY 

SIMVASTATIN IN PATIENTS WITH CORONARY ARTERY DISEASE 

T. B. Domagala* (PL), P. Grzanka, K. Kotula-Horowitz, A. Szczeklik 

FLUVASTATIN INHIBITS REGULATED SECRETION OF ENDOTHELIAL CELL VON 

WILLEBRAND FACTOR IN RESPONSE TO DIVERSE SECRETAGOGUES 

R. J. Fish* (CH), H. Yang, C. Viglino, R. Schorer, S. Dunoyer-Geindre, E. K. O. Kruithof 

EFFECT OF ATORVASTATIN ON MARKERS OF INFLAMMATION AND PLATELET 

AGGREGATION IN PATIENTS WITH CHRONIC HEART FAILURE 

O. Korzh* (UA), G. Kotchuev, S. Krasnokutskiy 

NO EFFECT OF LIPID LOWERING BY SIMVASTATIN OR SIMVASTATIN AND EZETIMIBE 

ON PLATELET FUNCTION IN PATIENTS WITH TYPE 2 DIABETES OR IMPAIRED 

GLUCOSE TOLERANCE AND CORONARY ARTERY DISEASE 

R. E. Malmström* (SE), M. Settergren, F. Böhm, L. Rydén, J. Pernow, P. Hjemdahl 

ATORVASTATIN NEUTRALIZED THE UP-REGULATION OF THROMBOSPONDIN 

INDUCED BY THROMBIN IN ENDOTHELIAL CELLS 

V. Martínez-Sales* (ES), V. Vila, M. Ferrando, E. Reganon 

INFLUENCE OF LECTIN-LIKE OX-LDL RECEPTOR-1 (LOX-1) AND NITRIC OXIDE 

SINTHASE (NOS) POLYMORPHISMS IN ATORVASTATIN ANTITHROMBOTIC ACTION 

AND CARDIOVASCULAR EVENTS RATE 

L. Puccetti (IT), R. Brandini*, F. Bruni, A. Pasqui, M. Pastorelli, F. Ciani, A. Auteri, 

A. Ghezzi 

ASSOCIATION BETWEEN ASPIRIN RESISTANCE AND INCREASED THROMBIN 

GENERATION AT THE SITE OF MICROVASCULAR INJURY: THE EFFECT OF 

SIMVASTATIN 

A. Undas* (PL), Z. Siudak, K. Brummel-Ziedins, W. Tracz, E. Stepien, A. Szczeklik, 

K. Mann 

Extracellular matrix 

P-T-411 

P-T-412 

P-T-413 

268 

FACTOR VII ACTIVATING PROTEASE INHIBITS THE UROKINASE PLASMINOGEN 

ACTIVATION SYSTEM AND STIMULATES GELATINASES (MATRIX 

METALLOPROTEINASES-2 AND -9) IN VASCULAR SMOOTH MUSCLE AND 

ENDOTHELIAL CELLS 

S. M. Kanse* (DE), O. Uslu, K. Hersemeyer, L. Muhl, J. Daniel, K. T. Preissner, 

D. Sedding 

PRETERM BIRTH AND FETAL GROWTH RESTRICTION HAVE AN IMPACT ON ELASTIC 

AND COLLAGENIC STRUCTURES OF HUMAN UMBILICAL ARTERIES 

E. Lamy (FR), L. Tauzin, F. Risso, C. Chareyre, P. Charpiot, U. Simeoni, F. Dignat-George* 

MUTATION SCREENING ANALYSIS OF TGFBR1 GENE IN PATIENTS WITH MARFAN 

SYNDROME 

L. Lucarini* (IT), L. Evangelisti, M. Attanasio, C. Fatini, E. Sticchi, E. Romano, A. Cellai, 

G. Pepe, R. Abbate, G. Gensini



P-T-414 

P-T-415 

P-T-416 

STUDY OF THE STRUCTURAL DETERMINANTS OF ARTERIAL VESSEL WALL 

THROMBOGENICITY 

N. Wohner* (HU), E. Komorowicz, K. Kolev 

TGFBETA1 IS RESPONSIBLE FOR HIGH-GLUCOSE-INDUCED ENRICHMENT OF 

PERICELLULAR MATRIX WITH HYALURONIC ACID. DIFFERENT MECHANISMS FOR 

ENDOTHELIAL AND MESANGIAL CELLS 

N. Yevdokimova* (UA), S. Komisarenko 

FUNCTIONAL STRUCTURE OF THE SOMATOMEDIN B DOMAIN OF VITRONECTIN 

A. Zhou* (UK) 

Adhesion receptors 

P-T-417 EVIDENCE FOR AN ALTERNATIVE REGULATION OF THE ACTIVITY OF THE BETA 3 

INTEGRIN ALPHA v BETA 3 IN THE ABSENCE OF THE HIGHLY CONSERVED ALPHA- 

SUBUNIT GFFKR MOTIF 

I. Ahrens* (DE), J. Heeskens, N. Bassler, I. Neudorfer, C. Bode, K. Peter 

P-T-418 

INTERACTION AND FUNCTIONAL ASSOCIATION OF PROTEIN-DISULFIDE ISOMERASE 

WITH αVβ3 INTEGRIN ON ENDOTHELIAL CELLS 

C. S. Cierniewski* (PL), J. Szymanski, M. Swiatkowska, G. Padula 

P-T-419 

P-T-420 

P-T-421 

CONSTITUTIVELY ACTIVE OR INACTIVE I DOMAINS AS PROBES FOR INTEGRIN 

BINDING TO COLLAGEN 

R. W. Farndale (UK), S. W. Hamaia*, N. Allcott, A. R. Peachey, R. Fernandez, N. Raynal 

FACTOR VII ACTIVATING PROTEASE (FSAP) REGULATES CELL ADHESION AND 

MOTILITY BY MULTIPLE MECHANISMS 

S. M. Kanse* (DE), M. Soto-Ribeiro, K. T. Preissner, B. Wehrle-Haller 

DETERMINATION OF THE INTEGRIN BINDING PROPERTIES OF THE PUTATIVE 

INTEGRIN-BINDING MOTIFS OF ADAM PROTEINS USING MUTANTS BASED UPON A 

DENDROASPIN SCAFFOLD 

X. Lu* (UK), M. Xia, D. Lu, M. Scully, V. Kakkar 


P-T-422 

P-T-423 

P-T-424 

P-T-425 

SELECTIVE BINDING TO INTEGRIN ALPHA-9-INTEGRIN EXPRESSING CELLS OF 

MUTANTS OF DISINTEGRIN-LIKE DOMAIN OF ADAM-15 CONTAINING THE PUTATIVE 

INTEGRIN BINDING MOTIF OF ADAM-2, -12 AND -19, RESPECTIVELY 

D. Lu* (UK), M. Xia, M. Scully, X. Lu, V. Kakkar 

THE ROLES OF TUMOR NECROSIS FACTOR- AND CELL ADHESION MOLECULES IN 

PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND HEART FAILURE 

T. Ma* (TW), G. Jong 

CIRCULATING ANTIBODIES TO HEAT SHOCK PROTEINS AND THEIR ASSOCIATION 

WITH ATHEROTHROMBOTIC PHENOTYPES 

V. S. Rao* (IN), R. S. Pratima, B. K. Natesha, J. Shanker, S. Kanjilal, M. Mukherjee, 

V. V. Kakkar 

LIGAND-RECEPTOR AFFINITY AND RHO-FAMILIY GTPASES IN INTEGRIN 

ALPHA2BETA1-MEDIATED PROCESSES 

C. Smerling* (UK), R. W. Farndale 

P-T-426 

MURINE GPVI ANTIBODY DOES NOT INDUCE GPVI-DEPLETION BUT REDUCES IN 

VIVO THROMBOSIS WITH MINIMAL BLEEDING RISK IN RATS 

N. N. Tandon (US), S. Lockyer*, H. Li, A. Concepcion, X. Gong, Y. Matsumoto, 

H. Takizawa, J. Kambayashi, Y. Liu 

269



Thrombotic disorders and antithrombotic therapy 

Antiphospholipid antibodies and syndrome 

P-T-427 

P-T-428 

P-T-429 

P-T-430 

P-T-431 

P-T-432 

P-T-433 

P-T-434 

P-T-435 

P-T-436 

P-T-437 

EFFECTS OF A TOLL-LIKE RECEPTOR ANTAGONIST AND ANTI-ANNEXIN A2 

ANTIBODIES ON BINDING AND ACTIVATION OF DECIDUAL CELLS BY ANTI-- 

BETA2GLYCOPROTEIN I ANTIBODIES 

M. Borghi* (IT), E. Raschi, S. Scurati, C. Grossi, P. Chen, S. S. Pierangeli, P. Meroni 

ROLE OF P38 MITOGEN ACTIVATED PROTEIN KINASE IN ANTIPHOSPHOLIPID 

ANTIBODY-MEDIATED THROMBOSIS AND ENDOTHELIAL CELL ACTIVATION 

M. Vega-Ostertag* (US), Z. Romay-Penabad, D. Ferrara, M. Colden-Stanfield, X. Lui, 

S. S. Pierangeli 

PLATELET ACTIVATION REINFORCES THE PROCOAGULANT PHENOTYPE INDUCED 

BY MURINE MONOCLONAL ANTI-PHOSPHOLIPID ANTIBODIES 

A. Membre* (FR), D. Wahl, J. P. Max, P. Lacolley, T. Lecompte, V. Regnault 

LONG-TERM OBSERVATION OF 280 PATIENTS WITH SYSTEMIC LUPUS 

ERYTHEMATOSUS AND 74 PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID 

SYNDROME: 10-YEAR FOLLOW-UP 

T. M. Reshetnyak* (RU), E. N. Alexandrova, I. B. Stivelband, A. A. Novikov, 

E. L. Nasonov 

ELEVATED PLASMA LEVELS OF FACTOR VIIA-ANTITHROMBIN COMPLEXES IN 

PATIENTS WITH ANTIPHOSPHOLIPID ANTIBODIES 

R. A. S. Roubey* (US), T. Lovell, J. H. Morrissey 

THE MANAGEMENT OF HIGH RISK PREGNANT PATIENTS WITH PRIMARY 

ANTIPHOSPHOLIPID SYNDROME 

A. Ruffatti* (IT), G. De Silvestro, P. Marson, V. Pengo, M. Bortolati, M. Favaro, M. Tonello, 

D. Minucci 

THROMBOPATH KIT HAS INCREASED SENSITIVITY TO PROTHROMBOTIC LUPUS 

ANTICOAGULANTS 

M. Smirnov* (US), D. Diaz, M. Triscott, R. Marlar 

ENDOTHELIAL FUNCTION IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND 

HISTORY OF VENOUS THROMBOSIS 

M. Stalc* (SI), P. Poredos, P. Peternel, M. Tomsic, T. Kveder 

ASSOCIATION OF IGG ANTI-OXLDL/B2GPI AND B2GPI-DEPENDENT ANTI- 

CARDIOLIPIN (ACL) ANTIBODIES WITH VASCULAR THROMBOSIS IN PATIENTS WITH 

ANTIPHOSPHOLIPID SYNDROME (APS) 

G. Svanas* (US), M. Boisen, D. Oottamasathein, E. Matsuura, L. R. Lopez 

THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS) DIAGNOSED 

USING UPDATED CLASSIFICATION CRITERIA 

J. Swadzba* (PL), J. Musial, T. Iwaniec, A. Szczeklik 

ANTIPHOSPHOLIPID ANTIBODIES AND THE ANTIPHOSPHOLIPID SYNDROME IN 

PATIENTS WITH SYSTEMIC LUPUS ÉRYTHÉMATOSUS 

K. Taouli* (DZ), R. A. Reghis, S. J. F. Schved, B. O. Boudghene Stambouli, 

S. R. Hamidou 

270



P-T-438 

P-T-439 

P-T-440 

P-T-441 

P-T-442 

ANTIPHOSPHOLIPID ANTIBODY SYNDROME (APS): THE ANNEXIN V COMPETITION 

ASSAY AS A DIAGNOSTIC TOOL 

A. Tomer* (IL) 

THE CLINICAL RELEVANCE OF PLATELET HETEROGENEITY AND ACTIVATION IN 

PATIENT WITH ANTIPHOSPHOLIPID SYNDROME 

I. Vasilenko* (RU), A. Savushkin, T. Reshetnyak, I. Bichkova, I. Nesterenko, A. Zaguzin 

EFFECTS OF ANTI-BETA2-GLYCOPROTEIN I ANTIBODIES FROM APL PATIENTS WITH 

APS OR WITH LEPROSY IN AN IN VIVO MODEL OF APS 

M. E. Vega-Ostertag* (AR), R. R. Forastiero, M. Martinuzzo, G. De Larrañaga, 

S. S. Pierangeli 

SIGNIFICANCE OF PLASMA SOLUBLE ENDOTHELIAL PROTEIN C RECEPTOR AND 

TISSUE FACTOR PATHWAY INHIBITOR IN PATIENTS WITH ANTIPHOSPHOLIPID 

ANTIBODIES 

D. G. Wahl* (FR), C. Perret-Guillaume, P. Kaminsky, P. Lacolley, V. Regnault, 

T. Lecompte 

ANTI CD20 MONOCLONAL ANTIBODIES THERAPY FOR RESISTANT 

ANTIPHOSPHOLIPID SYNDROME 

A. Winder* (IL), A. Arad, E. Rachmilewitz 

P-T-443 

P-T-444 

CLINICAL SIGNIFICANCE OF PLATELET-DERIVED MICROPARTICLE (PDMP) IN APS: 

PLASMA LEVELS OF PDMP WERE SIGNIFICANTLY ELEVATED IN APS PATIENTS WITH 

ARTERIAL THROMBOSES 

M. Yamazaki* (JP), Y. Kadohira, M. Maekawa, Y. Ontachi, H. Asakura, E. Morishira, 

S. Nakao 

ANTIPHOSPHOLIPID ANTIBODIES ASSOCIATED WITH MULTIPLE COAGULATION 

FACTOR DEFICIENCY IN SEVEN CHINESE PATIENTS 

F. Yang* (CN), X. Wang, P. Jin, Q. Ding, H. Wang 

Thrombophilia and familial thrombosis 


P-T-445 

P-T-446 

P-T-447 

P-T-448 

P-T-449 

ONE-THIRD OF JAPANESE PATIENTS WITH DEEP VEIN THROMBOSIS CARRIED THE 

GENETIC MUTATIONS IN PROTEINS S, C AND ANTITHROMBIN GENES: 

THE SUB-GROUP STUDY OF BLOOD COAGULATION ABNORMALITY, THE STUDY 

GROUP OF RESEARCH ON MEASURES FOR INTRACTABLE DISEASES IN JAPAN 

J. Ishikawa (JP), Y. Sato, S. Takeshita, K. Kokame, R. Kimura, S. Honda, T. Kawasaki, 

E. Suehisa, H. Tsuji, S. Madoiwa, Y. Sakata, T. Kojima, M. Murata, Y. Ikeda, T. Miyata* 

GIESSEN THROMBOPHILIA STUDY: MANIFESTATION AGE OF THROMBOEMBOLISM 

IN THROMBOPHILIA 

B. Kemkes-Matthes* (DE), M. Nees, R. Fischer 

PERINATAL ISCHEMIC STROKE AND THE INCIDENCE OF MATERNAL AND NEONATAL 

THROMBOPHILIA 

G. Kenet (IL), M. J. Simchen*, G. Goldstein, A. Lubetsky, I. Tamarin, M. Dulitzki, E. Schiff 

INFLUENCE OF THROMBOPHILIA ON VASCULAR ACCESS SURVIVAL IN CHRONIC 

HEMODIALYSIS PATIENTS 

M. Orlovic* (DE), I. Fritsche, H. Landgraf, F. Seibt, H. Pommer, R. Klamroth 

THE USE OF HAEMOSTASIS TESTS IN THE FOLOW UP OF A PATIENT WITH 

ANTITHROMBIN DEFICIENCY DURING THE PREGNANCY AND AFTER DELIVERY 

M. Kovac* (RS), D. Mikovic, L. Rakic, A. Maslac, Z. Mikovic, V. Mandic 

271



P-T-450 

P-T-451 

P-T-452 

P-T-453 

P-T-454 

P-T-455 

P-T-456 

P-T-457 

P-T-458 

P-T-459 

P-T-460 

P-T-461 

P-T-462 

P-T-463 

ROLE OF THROMBOPHILIC RISK FACTORS IN PATIENTS WITH RETINAL VEIN 

OCCLUSION 

V. Krcova* (CZ), L. Slavik, M. Rehak, S. Faude, S. Faude, P. Wiedemann, E. Fric, 

J. Rehak, A. Siegemund 

STICKY PLATELET SYNDROME (SPS) AND PLATELET GLYCOPROTEIN 

POLYMORPHISMS 

P. Kubisz (SK), J. Musial, J. Stasko*, J. Ivankova, M. Dobrotova, I. Plamenova, 

L. Bartosova, P. Chudy 

DNR ANALYSIS RESULTS IN THROMBOSES PATIENTS: THE FIRST DATA IN LATVIA 

S. Lejniece* (LV), A. Lejnieks, J. Steinbergs, I. Vasiljeva, V. Boka, I. Udre 

ARE PATIENTS WITH THROMBOPHILIA AND A HISTORY OF VENOUS 

THROMBOEMBOLISM AT HIGHER RISK TO ARTERIAL THROMBOTIC EVENTS? 

B. Linnemann* (DE), M. Schindewolf, D. Zgouras, M. Erbe, M. Jarosch-Preusche, 

B. Luxembourg, E. Lindhoff-Last 

COINHERITANCE OF FV-LEIDEN MUTATION AND FV-HR2 

P. E. Makris* (GR), M. P. Makris, S. I. Papamichos, A. Kanidis 

EVALUATION OF PRO-TIME MICROCOAGULLATION SUSTEM 

P. E. Makris* (GR), S. I. Papamichos, M. P. Makris 

MOLECULAR MARKERS OF BLOOD HYPERCOAGULABILITY IN HETEROZYGOUS 

CARRIERS OF FACTOR V LEIDEN MUTATION 

P. S. Miljic* (RS), I. Elezovic, V. Djordjevic, M. Colovic 

COMMON THROMBOPHILIAS IN 85 INDIAN PATIENTS WITH ARTERIAL THROMBOSIS 

M. N. Mishra* (IN), R. Kalra, S. Rohatgi 

A LARGE DELETION OF THE PROS1 GENE IN A DEEP VEIN THROMBOSIS PATIENT 

WITH PROTEIN S DEFICIENCY 

T. Yin (JP), S. Takeshita, Y. Sato, T. Sakata, Y. Shin, S. Honda, T. Kawasaki, H. Tsuji, 

T. Kojima, S. Madoiwa, Y. Sakata, M. Murata, Y. Ikeda, T. Miyata* 

HEPARIN EYE DROPS ARE EFFECTIVE AS LONG TERM THERAPY FOR LIGNEOUS 

CONJUNCTIVITIS 

P. Monagle* (AU), J. Elder, D. McConville, S. Mitchell 

INTRACELLULAR DEGRADATION OF NATURALLY OCCURRING PROTEIN C (PC) 

MUTANTS 

M. Nishio* (JP), T. Koyama, M. Nakahara, N. Egawa, S. Hirosawa 

D-DIMER MEASUREMENT AND THROMBOPHILIA SCREENING IN THE FOLLOW-UP OF 

PATIENTS WITH A HISTORY OF VENOUS THROMBOEMBOLISM 

E. Ombandza (FR), M. Samama*, J. Conard, M. Horellou, I. Elalamy 

CLINICAL, GENETIC, FUNCTIONAL AND CONFORMATIONAL HETEROGENEITY OF 

CONGENITAL ANTITHROMBIN DEFICIENCY. RESULTS FROM 27 UNRELATED CASES 

A. Ordóñez* (ES), I. Sánchez, A. Miñano, R. González-Conejero, D. Hernández-Espinosa, 

J. Aznar, I. Alberca, N. Gómez, F. López, C. De Cos, H. Cano, M. Navarro, 

J. Gutierrez-Pimentel, P. Marcos, D. García-Malo, P. Llamas, D. Marín, R. Lecumberri, 

J. J. Sánchez-Blanco, I. Zuazu, V. Vicente, J. Corral 

NO INCREASED SIGNS OF ATHEROSCLEROTIC ALTERATIONS IN CARRIERS OF 

INHERITED THROMBOPHILIA WITH OR WITHOUT PREVIOUS VENOUS THROMBOSIS 

G. Palareti (IT), L. Valdre*, E. Favaretto, V. Bovina, C. Legnani 

272



P-T-464 

PREVALENCE OF FACTOR V LEIDEN, PROTHROMBIN G20210A, AND 

5,10-METHYLENETETRAHYDROFOLATE REDUCTASE C677T GENE MUTATIONS IN 

A HEALTHY RUSSIAN POPULATION 

E. A. Kalashnikova (RU), S. N. Kokarovtseva, O. V. Sirotkina, A. M. Sheydina, 

T. F. Kovalenko, L. I. Patrushev* 

Genetic determinants and epidemiology 

P-T-465 

P-T-466 

P-T-467 

THE ABCB1 (MDR1) C3435T POLYMORPHISM DOES NOT INFLUENCE 

PHARMACODYNAMIC RESPONSE TO CLOPIDOGREL IN HEALTHY SUBJECTS 

J. S. Hulot* (FR), E. Villard, M. Azizi, C. Vrignaud, V. Remones, M. Aiach, P. Lechat, 

P. Gaussem 

THE OCCURRENCE OF FACTOR V LEIDEN MUTATION IN HUNGARIAN HELLP 

SYNDROME PATIENTS 

P. Hupuczi* (HU), B. Nagy, G. Szabo, E. Berkes, B. Rigo, I. Sziller, Z. Papp 

ASSOCIATION OF C-REACTIVE PROTEIN AND WHITE BLOOD CELL COUNT WITH 

PHYSICAL ACTIVITY IN HEALTHY SUBJECTS 

F. Zito* (IT), E. Plescia, S. Costanzo, A. Di Castelnuovo, A. Arcari, F. Centritto, A. De 

Curtis, R. Di Giuseppe, I. Di Stefano, S. Magnacca, A. Pampuch, L. Rago, C. Silvestri, 

B. Vohnout, M. B. Donati, G. De Gaetano, L. Iacoviello, F. De Lucia, M. Persichillo 

P-T-468 

P-T-469 

ASSOCIATION OF C-REACTIVE PROTEIN AND ALCOHOL INTAKE IN HEALTHY MEN 

AND WOMEN FROM THE MOLI-SANI POPULATION 

A. Arcari* (IT), A. Di Castelnuovo, S. Costanzo, F. Centritto, A. De Curtis, R. Di Giuseppe, 

S. Magnacca, I. Di Stefano, A. Pampuck, E. Plescia, L. Rago, C. Silvestri, B. Vohnout, 

F. Zito, M. B. Donati, G. De Gaetano, L. Iacoviello, F. De Lucia, M. Persichillo 

INTERLEUKINS GENES TAG-SNP HAPLOTYPES AND RISK OF MYOCARDIAL 

INFARCTION: A POPULATION BASED CASE-CONTROL STUDY 

L. Iacoviello* (IT), B. Tayo, A. Di Castelnuovo, G. Quaquaruccio, Y. Liang, J. Dorn, 

N. Novak, M. B. Donati, M. Trevisan 


P-T-470 

P-T-471 

P-T-472 

P-T-474 

P-T-475 

VENOUS THROMBOSIS IN UNUSUAL SITES: A SINGLE INSTITUTION EXPERIENCE 

P. Iannaccaro* (IT), R. Santoro, G. Muleo 

APOE GENE POLYMORPHISM CAN MODIFY THE RISK OF VENOUS 

THROMBOEMBOLISM 

S. I. Kapustin* (RU), Y. S. Drizhun, V. M. Shmeleva, N. B. Saltykova, L. P. Papayan, 

M. N. Blinov 

GENETIC POLYMORPHISM OF THE PLATELET ADP-RECEPTOR P2Y12 MODIFIES THE 

RISK OF PULMONARY EMBOLISM IN PATIENTS WITH DEEP-VEIN THROMBOSIS 

S. I. Kapustin* (RU), N. A. Klenkova, V. A. Kobilyanskaya, N. B. Saltykova, V. D. Kargin, 

L. P. Papayan, M. N. Blinov 

THE ROLE OF DNA POLYMORPHISMS IN GENES CODING THE HOMOCYSTEINE AND 

FOLATE METABOLIZING ENZYMES IN ISCHAEMIC HEART DISEASE 

N. A. Klenkova* (RU), S. I. Kapustin, O. A. Smirnova, V. M. Shmeleva, L. P. Papayan, 

M. N. Blinov 

POLYMORPHISMS IN THE IL6 GENE IN FAMILIES WITH EARLY-ONSET CORONARY 

ARTERY DISEASE (CAD) -INDIAN ATHEROSCLEROSIS RESEARCH STUDY 

A. Maitra* (IN), P. Ganapathy, D. Debabratha, V. S. Rao, B. K. Natesha, M. Mukherjee, 

V. V. Kakkar 

273



P-T-476 

P-T-477 

P-T-478 

P-T-479 

P-T-480 

P-T-481 

P-T-482 

P-T-483 

P-T-484 

P-T-485 

P-T-486 

COAGULATION FACTOR XI LEVELS AND THE LDL RECEPTOR-RELATED PROTEIN 

(LRP) GENOTYPE 

G. Marchetti* (IT), B. Lunghi, C. Legnani, M. Cini, M. Pinotti, G. Palareti, F. Bernardi 

COMMON GENE MUTATIONS AND VENOUS THROMBOEMBOLISM: DISTINCT ROLES 

IN DIFFERENT CLINICAL SETTINGS 

M. Margaglione* (IT), D. Colaizzo, P. Vergura, M. A. Guardascione, F. Cappucci, 

G. L. Tiscia, L. Iannaccone, E. Grandone, N. Cocomazzi, L. Amitrano 

THE RELATIVE EFFECTS OF VKORC1 AND CYP2C9 VARIANTS ON CLINICAL 

OUTCOMES IN WARFARIN PATIENTS 

L. M. Meckley* (US), A. K. Wittkowsky, M. J. Rieder, A. E. Rettie, D. L. Veenstra 

PLASMA LEVELS OF CLOTTING FACTORS ARE POSITIVELY CORRELATED IN 

HEALTHY POPULATION: A COMPREHENSIVE PERSPECTIVE TO ASSESS 

THROMBOTIC RISK? 

D. Mezzano* (CL), O. Panes, V. Matus, B. Muñoz, M. Goycoolea, J. Pereira, T. Quiroga 

P2RY12 RECEPTOR POLYMORPHISMS (SNPS) IN PATIENTS WITH A HISTORY OF 

MYOCARDIAL INFARCTION 

G. Murugesan* (US), L. Zhang, S. Jang, T. Kaldus, J. Barnard, Q. Wang, P. Gaussem, 

E. J. Topol, K. Kottke-Marchant 

STUDY OF THE METHYLENETETRAHYDROFOLATE REDUCTASE C677T 

POLYMORPHISM IN HELLP SYNDROME PATIENTS 

B. Nagy* (HU), P. Hupuczi, B. Rigo, G. Szabo, E. Berkes, I. Sziller, Z. Papp 

AQUAPORIN 2 GENE VARIATIONS, LEVELS OF VON WILLEBRAND FACTOR AND 

FACTOR VIII AND THE RISK OF VENOUS THROMBOSIS 

A. Y. Nossent* (NL), J. C. J. Eikenboom, H. L. Vos, R. M. Bertina, F. R. Rosendaal 

INFLUENCE OF HERITABILITY AND HOUSEHOLD COMPONENTS ON LIPID 

CONCENTRATIONS AND CLOTTING FACTOR LEVELS IN 282 PEDIATRIC STROKE 

FAMILIES 

U. Nowak-Gottl* (DE), C. Langer, S. Bergs, S. Thedieck, R. D. Strater, M. Stoll 

THE RELATIONSHIP OF P2Y1 ADP RECEPTOR POLYMORPHISMS AND ISCHEMIC 

VASCULAR DISEASE 

E. Park* (KR), S. Park, I. Kim, S. Yoon, S. Park, J. Park, H. Yun-Choi, J. Kim, S. Park, 

Y. Hong, S. Lee 

FREQUENCIES OF CYP2C9, CYP2C19, CYP1A2, CYP3A4, CYP3A5, MDR1 ALLELIC 

VARIANTS IN PATIENTS WITH DIFFERENT ACENOCOUMAROL DOSE REQUIREMENTS 

I. Paskaleva* (BG), R. Saraeva, E. Doncheva, C. Eap, V. Ganev 

PSEUDO-HOMOZYGOUS APC RESISTANCE DUE TO COINHERITANCE OF 

HETEROZYGOUS FACTOR V-R506Q AND FV TYPE I DEFICIENCY 

A. Pavlova* (DE), R. Loreth, D. Delev, J. Oldenburg 

274



Cancer and thrombosis 

P-T-487 

P-T-488 

P-T-489 

P-T-490 

P-T-491 

VENOUS THROMBOSIS (VTE) HAS AN ADVERSE IMPACT ON THE SURVIVAL IN 

PATIENTS WITH MALIGNANCY 

S. Paneesha* (UK), A. Lokare, Z. Lester, T. Nokes, R. Arya, T. Farren, A. McManus, 

D. O'Shaughnessy, F. Pressley, N. Scriven, P. Rose 

PROSPECTIVE, RANDOMIZED OPEN TRIAL OF ENOXAPARIN IN PATIENTS WITH 

ADVANCED PANCREATIC CANCER UNDERGOING FIRST-LINE CHEMOTHERAPY 

U. Pelzer* (DE), H. Oettle, H. Riess, M. Stauch, B. Opitz, T. Scholten, J. Stieler 

VENOUS THROMBOEMBOLISM AND CANCER: THE PERCEIVE REGISTRY 

G. A. Petralia* (UK), M. Rickard, M. Baginski, N. Saba, J. Wong, I. Pabinger, 

A. Young on behalf of the Perceive Investigators, A. K. Kakkar 

HYPERCOAGULABLE STATE IN MULTIPLE MYELOMA PATIENTS TREATED OR NOT 

WITH THALIDOMIDE 

A. D. Petropoulou* (FR), G. T. Gerotziafas, F. Rendu, M. M. Samama, I. Elalamy 

HEPARIN TREATMENT INCREASES TYROSINE PHOSPHORYLATION OF PROTEINS IN 

BREAST CANCER CELLS: DIFFERENCES IN THE EFFECT OF LMWH AND UFH 

T. M. Razzaq* (UK), M. F. Scully, R. Wait, A. K. Kakkar 

P-T-492 

P-T-493 

THIOSULFINATES MODULATE PLATELET ACTIVATION AND MONOCYTE FUNCTION 

BY REACTION WITH SURFACE FREE SULFHYDRYLS AND INTERNAL 

THIOL-CONTAINING PROTEINS 

F. Merhi (FR), P. Badol, M. David-Dufilho, B. Bauvois, F. Rendu* 

ISRAELI PEDIATRIC ONCOLOGY REGISTRY ON CENTRAL VENOUS LINE RELATED 

COMPLICATIONS 

S. Revel-Vilk* (IL), G. Kenet, H. Tamary, Y. Levy-Shraga, J. Yacobovich, P. Stepenski, 

S. Shick, S. Fischer, A. Toren, I. Yaniv, M. Weintraub 


P-T-494 

P-T-495 

P-T-496 

P-T-497 

CANCER AND VENOUS THROMBOEMBOLISM: ROLE OF GENETIC POLYMORPHISMS 

IN SELECTINS AND TISSUE FACTOR 

J. C. Reverter* (ES), C. Font, J. Monteagudo, M. Corbella, C. Freire, J. Pijoan, 

P. Gascon, D. Tassies 

LACK OF ASSOCIATION OF ANTIPHOSPHOLIPID ANTIBODIES WITH CORONARY 

ATHEROSCLEROSIS IN PATIENTS UNDERGOING CORONARY ANGIOGRAPHY 

R. A. S. Roubey* (US), B. Hertzberg, C. Patterson, R. Stouffer, S. Wu, P. C. Charles, 

S. Mapara, E. Hilliard, R. Lineberger 

A SURVEY ON POST-SURGERY OUTCOMES IN PATIENTS WITH ESSENTIAL 

THROMBOCYTHEMIA AND POLYCYTHEMIA VERA IN A RETROSPECTIVE COHORT 

M. Ruggeri* (IT), F. Rodeghiero, A. Tosetto, G. Castaman, F. Scognamiglio, G. Finazzi, 

F. Delaini, C. Micò, A. Vannucchi, E. Antonioli, V. De Stefano, T. Zà, L. Gugliotta, 

A. Tieghi, M. G. Mazzucconi, T. Barbui 

A HIGH PLATELET COUNT INDEPENDENTLY PREDICTS VENOUS 

THROMBOEMBOLISM IN CANCER PATIENTS 

R. Simanek* (AT), R. Vormittag, G. Alguel, C. Ay, D. Dunkler, P. Quehenberger, 

C. Zielinski, U. Jaeger, I. Pabinger 

275



P-T-498 

P-T-499 

P-T-500 

P-T-501 

P-T-502 

P-T-503 

P-T-504 

P-T-505 

THE PERSISTANCE OF RESIDUAL VEIN THROMBOSIS, AFTER AN EPISODE OF DEEP 

VEIN THROMBOSIS, AND THE RISK OF NEW OVERT CANCER AND 

CARDIOVASCULAR DISEASE 

S. Siragusa* (IT), V. Cigna, A. Malato, F. Fulfaro, L. Lo Coco, R. Anastasio, I. Abbene, 

G. Saccullo, A. Casuccio 

THE EFFECT OF ANTICOAGULANTS ON CANCER RISK AND SURVIVAL: 

SYSTEMATIC REVIEW 

V. Tagalakis* (CA), C. Robinson-Cohen, M. Blostein, S. R. Kahn 

THE RGD-CONTAINING PEPTIDE DERIVED FROM PLATELET DISABLED-2 INHIBITS 

DU145 PROSTATE CANCER CELL-INDUCED PLATELET AGGREGATION 

C. Tseng* (TW), L. Chen, C. Huang, J. Cheng, C. Liao 

SCREENING FOR OCCULT MALIGNANCY IN PATIENTS WITH IDIOPATHIC VENOUS 

THROMBOEMBOLISM. THE TROUSSEAU INVESTIGATORS 

F. F. Van Doormaal* (NL), H. Otten, H. R. Buller 

DETECTION OF HYPERCOAGULABILITY IN PATIENTS WITH THYROID CANCER 

P. Van Dreden (FR), A. Rousseau, S. Fontaine, T. Exner, B. J. Woodhams* 

LOW MOLECULAR WEIGHT HEPARIN (LMWH) DALTEPARIN REDUCES THE 

PROTHROMBOTIC AND PROANGIOGENIC POTENTIAL OF MICROVASCULAR 

ENDOTHELIAL CELLS ELICITED BY TUMOR CELLS 

A. Vignoli* (IT), M. Marchetti, L. Russo, D. Balducci, A. Falanga 

LYMPHOCYTE PLATELET ADHESION IN THROMBOPHILIC PATIENTS WITH LUNG 

SURGERY 

Y. A. Vitkovsky* (RU), I. G. Bogdanov, A. S. Bogdanova, S. N. Dimova, 

A. M. Ryabchenko 

APPLICATION OF LOW MOLECULAR-WEIGHT HEPARIN (NARDROPARINE) IN 

PATIENTS WITH LUNG CANCER 

E. Vorobiova* (GE), M. Akhvlediani, N. Pargalava, R. Gagua, M. Aloeva 

P-T-506 EXPRESSION OF TISSUE FACTOR (TF), FACTOR X, PROTHROMBIN FRAGMENT 1+2 

(F 1+2) AND FIBRIN IN BREAST CANCER: COMPARISON BETWEEN PRIMARY TUMOR 

AND METASTATIC LESIONS IN REGIONAL LYMPH NODES 

M. Z. Wojtukiewicz* (PL), E. Sierko, Z. Sawicki, L. Zimnoch, W. Kisiel 

P-T-507 

P-T-508 

P-T-509 

A SYSTEMATIC REVIEW OF THE INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) 

AND EFFECTIVENESS OF PROPHYLAXIS IN PATIENTS WITH MULTIPLE MYELOMA 

(MM) RECEIVING THALIDOMIDE 

C. M. Wu* (CA), A. Y. Lee 

CAUSE OF DEATH AMONG PATIENTS WITH LOCAL OR REGIONAL STAGE CANCER 

OF THE BREAST AND LUNG WHO DEVELOP VENOUS THROMBOEMBOLISM (VTE) 

T. Wun* (US), H. Chew, H. Zhou, D. Harvey, R. White 

RNAPC2, A NOVEL INHIBITOR OF TISSUE FACTOR/FACTOR VIIA COMPLEX, 

SUPPRESSES LIVER AND LUNG METASTASES IN MOUSE MODELS OF COLORECTAL 

CANCER 

J. Zhao* (US), G. Aguilar, S. R. Deitcher, M. D. Levy, W. D. Funk, A. Abo 

276



Deep vein thrombosis and pulmonary embolism 

P-T-510 

P-T-511 

P-T-512 

P-T-513 

CYTOMEGALOVIRUS AND HIGH RISK OF (RECURRENT) VENOUS THROMBOSIS 

AFTER RENAL TRANSPLANTATION 

W. M. Lijfering* (NL), A. P. J. De Vries, N. J. G. M. Veeger, W. J. Van Son, 

S. J. L. Bakker, J. Van Der Meer 

LOW MOLECULAR WEIGHT HEPARIN IN PATIENTS WITH RENAL INSUFFICIENCY: 

ANALYSIS OF ANTI-XA LEVELS AND CREATININE CLEARANCE 

W. Lim* (CA), L. Wang, M. Sridhara, M. Wang, J. Douketis, M. Rodger, M. Crowther 

ETIOLOGY, CLINICAL COURSE AND TREATMENT OUTCOME OF PATIENTS WITH 

INFERIOR VENA CAVA THROMBOSIS 

B. Linnemann* (DE), H. Schmidt, M. Schindewolf, D. Zgouras, M. Erbe, R. Grossmann, 

E. Lindhoff-Last 

MALE GENDER INCREASES RISK OF VTE RECURRENCE AFTER SPONTANEOUS AND 

RISK-ASSOCIATED FIRST VENOUS THROMBOEMBOLISM 

B. Linnemann* (DE), M. Schindewolf, D. Zgouras, M. Erbe, M. Jarosch-Preusche, 

E. Lindhoff-Last 

P-T-514 

P-T-515 

P-T-516 

EFFECT OF THE IMPLEMENTATION OF A VENOUS THROMBOEMBOLISM 

PROPHYLAXIS GUIDELINE IN THE MANAGEMENT OF SURGICAL AND ORTHOPEDIC 

PATIENTS IN A PRIVATE TERTIARY HOSPITAL 

F. H. A. Maffei* (BR), A. C. Sato, F. Torggler Filho, A. Atallah 

HCAN CHANGES IN HEMOSTATIC PARAMETERS EXPLAIN THE INCREASED 

INCIDENCE OF DVT IN ELDERLY? 

I. Mahé* (FR), C. Boulanger, C. Bal Dit Sollier, G. Simoneau, J. Bergmann, A. Tedgui, 

L. Drouet 

HIGH ABSOLUTE RISKS AND PREDICTORS OF VENOUS AND ARTERIAL 

THROMBOEMBOLIC EVENTS IN PATIENTS WITH NEPHROTIC SYNDROME 

B. K. Mahmoodi* (NL), M. K. Ten Kate, F. Waanders, N. J. G. M. Veeger, G. J. Navis, 

J. Van Der Meer 


P-T-517 

P-T-518 

P-T-519 

P-T-520 

P-T-521 

ASSOCIATION OF VENOUS THROMBOEMBOLISM AND OLANZAPINE 

R. Maly* (CZ), J. Masopust, L. Hosak, A. Urban 

CONFIRMATION OF EFFICACY, SAFETY AND COST EFFECTIVENESS OF 

FRAXIPARINE® FORTE IN THE OUTPATIENT TREATMENT OF DEEP VENOUS 

THROMBOSIS 

J. Maly* (CZ), P. Dulicek, M. Pecka, L. Vodickova, R. Maly 

POST-THROMBOTIC SYNDROME (PTS) AFTER TOTAL HIP REPLACEMENT (THR): 

INCIDENCE AND CORRELATES 

M. J. Mant* (CA), D. T. Eurich, D. B. Russell, S. R. Majumdar 

THROMBOPHILIA IS FREQUENT IN SUPERFICIAL VEIN THROMBOSIS AND IS 

ASSOCIATED WITH RECURRENCE 

R. Marcucci (IT), G. Ciuti, D. Poli, M. Lenti, E. Blagojevic, M. Falciani, A. Abdullahi, 

G. Gensini, R. Abbate, D. Prisco* 

MASSIVE VENOUS THROMBOEMBOLISM IN A PEDIATRIC PATIENT: A CASE REPORT 

M. Mariz* (PT), S. Morais, L. Corbillón, M. Pereira, M. Guedes, M. Medina, R. Matos, 

M. Campos 

277



P-T-522 

P-T-523 

P-T-524 

P-T-525 

P-T-526 

P-T-527 

P-T-528 

P-T-529 

P-T-530 

P-T-531 

P-T-532 

P-T-533 

P-T-534 

APPLICABILITY OF D-DIMER IN RULING OUT VENOUS THROMBOEMBOLISM (VTE) IN 

ELDERLY MEDICAL PATIENTS: COMPARISON BETWEEN IMMUNOTURBIDIMETRIC 

AND ELISA (ELFA) METHODS 

L. Masotti* (IT), G. Landini, L. Villani, F. Antonelli 

ELEVATED D-DIMER LEVELS IN PATIENTS WITH DEEP VEIN THROMBOSIS 

T. Matsumoto* (JP), H. Wada, Y. Abe, T. Kobayashi, T. Nobori, N. Yamada 

AN ASSESSMENT OF THE EFFECTIVENESS OF INFERIOR VENA CAVA FILTERS IN 

PREVENTION OF PULMONARY EMBOLISM BASED UPON DEMONSTRATION OF 

TRAPPED EMBOLUS AT THE TIME OF FILTER RETRIEVAL 

S. C. McKenzie* (AU), D. Leggett, M. Neels, J. Harper, H. Gibbs 

AN AUSTRALIAN EXPERIENCE OF RETRIEVABLE INFERIOR VENA CAVA FILTERS IN 

PATIENTS WITH INCREASED RISK OF THROMBOEMBOLIC DISEASE 

S. C. McKenzie* (AU), D. Leggett, M. Neels, J. Harper, H. Gibbs 

QUANTIFICATION OF THE MEASUREMENT UNCERTAINTY FOR D-DIMER ASSAY 

RESULTS AROUND THE CUT-OFF LEVEL: IMPROVED DECISION RULES REQUIRED? 

P. Meijer* (NL), F. Haas, C. Kluft 

DELAY IN STARTING ORAL ANTICOAGULATION IN PATIENTS WITH ACUTE VENOUS 

THROMBOEMBOLISM (VTE): ANALYSIS FROM THE MASTER REGISTRY 

M. Moia* (IT), G. Agnelli, W. Ageno, G. Palareti, D. Imberti, R. Pistelli, R. Rossi, 

M. Verso 

ACTIVATED PROTEIN C INHIBITION BY PROTEIN C INHIBITOR IS NOT ACCELERATED 

BY THE SYNTHETIC PENTASACCHARIDE FONDAPARINUX 

J. Müller* (DE), B. Pötzsch, S. Page, K. Madlener 

CLINICALLY SUSPECTED ACUTE RECURRENT PULMONARY EMBOLISM: 

A DIAGNOSTIC CHALLENGE 

M. Nijkeuter* (NL), H. M. Kwakkel-Van Erp, M. Sohne, L. W. Tick, M. J. H. M. Kruip, 

E. F. Ullmann, M. H. H. Kramer, H. R. Buller, M. H. Prins, F. W. G. Leebeek, 

M. V. Huisman 

DECLINING RATE OF VENOUS THROMBOEMBOLISM IN PATIENTS EVALUATED FOR 

PULMONARY EMBOLISM IN TWO UNITED STATES EMERGENCY DEPARTMENTS AND 

LOW RATE OF EMPIRIC ANTICOAGULATION 

K. E. Nordenholz* (US), A. M. Mitchell, J. A. Kline 

EVALUATION OF 50 POTENTIAL MARKERS OF PULMONARY EMBOLISM FOR USE IN 

THE EMERGENCY DEPARTMENT 


TANDEM MEASUREMENT OF D –DIMER AND MYELOPEROXIDASE DECREASES 

UNNECESSARY PULMONARY VASCULAR IMAGING IN EMERGENCY DEPARTMENT 

PATIENTS EVALUATED FOR PULMONARY EMBOLISM 


PREVALENCE AND DISTRIBUTION OF DEEP VEIN THROMBOSIS IN PATIENTS WITH 

SYMPTOMATIC PULMONARY EMBOLISM 

M. Ochi* (JP), T. Yamaki, M. Nozaki, H. Sakurai, M. Takeuchi, K. Soejima, T. Kono 

BODY MASS INDEX, MILD HYPERHOMOCYSTEINEMIA AND VENOUS 

THROMBOEMBOLISM RISK 

E. J. Oger (FR), G. Le Gal*, A. Delluc, K. Lacut, F. Couturaud, D. Mottier 

278



P-T-535 

P-T-536 

P-T-537 

P-T-538 

P-T-539 

P-T-540 

EARLY HOME THERAPY AND OUTCOME AMONG 675 PATIENTS WITH PULMONARY 

EMBOLISM 

C. Olsson* (SE), R. Linné, J. Elf, B. Jonson, M. Bajc 

ISOLATED DISTAL DEEP VEIN THROMBOSIS (ID-DVT) IN THE MASTER MULTICENTER 

ITALIAN REGISTRY 

G. Palareti* (IT), G. Agnelli, W. Ageno, M. Moia, D. Imberti, R. Pistelli, R. Rossi, 

M. Verso 

SECONDARY THROMBOPHYLAXIS USING ANTIPLATELET AGENTS AND LONG TERM 

MONITORING AFTER 1ST UNPROVOKED EPISODE OF VENOUS THROMBOEMBOLISM 

E. S. Papadakis* (GR), G. Papaioannou, M. Topalidou, M. Braimi, I. Korantzis 

RECURRENT VENOUS THROMBOEMBOLISM LINKED TO LOW PLASMA HDL 

N. M. Pecheniuk (US), H. Deguchi, J. H. Griffin, P. A. Kyrle, S. Eichinger* 

UNEXPLAINED HIGH D-DIMER 

C. Pechlaner* (AT), P. Eller, C. Heingärtner, F. Hartig, G. Falkensammer, A. Griesmacher 

USEFULNESS OF PERFUSION LUNG SCAN COMBINED WITH CLINICAL ASSESSMENT 

TO RULE OUT PULMONARY EMBOLISM 

A. Penaloza* (BE), D. Blocklet, B. N. T. Tang, C. Melot, S. Motte 

P-T-541 

P-T-542 

P-T-543 

D-DIMER TESTING AND RECURRENT VENOUS THROMBOEMBOLISM AFTER 

UNPROVOKED PULMONARY EMBOLISM 

V. Pengo* (IT), B. Cosmi, C. Legnani, F. Marzot, A. Tosetto, S. Testa, A. Ghirarduzzi, 

G. Palareti 

ANTITHROMBOTIC PROPHYLAXIS AND THERAPY. THE HUNGARIAN CONSENSUS 

AND EXPERIENCE, 2007 

G. P. Pfliegler On Behalf Of The Hungarian Consensus Conference* (HU) 

LONG TERM OUTCOMES OF DEEP-VEIN THROMBOSIS IN ASIA AFTER MAJOR 

ORTHOPEDIC SURGERY: THE AIDA EXTENSION STUDY 

F. Piovella* (IT), M. Barone, C. Beltrametti, C. J. Wang, L. H. Lee, W. C. Lee, 

A. G. Turpie, A. S. Gallus, A. Planes, R. Passera 


P-T-544 

P-T-545 

P-T-546 

P-T-547 

QUALITY OF OAT AND VTE RECURRENCE 

D. Poli* (IT), E. Antonucci, R. Marcucci, A. Cellai, A. Rogolino, M. Attanasio, A. Corsi, 

R. Abbate, G. Gensini, D. Prisco 

ROLE OF D-DIMER IN COMBINATION WITH F1+2, RVO AND THROMBOPHILIA IN THE 

RISK OF RECURRENCE OF PATIENTS WITH A FIRST VTE EPISODE AFTER OAT 

WITHDRAWA 

D. Poli* (IT), E. Antonucci, M. Falciani, L. Lucarini, L. Evangelisti, N. Pucci, S. Poli, 

R. Abbate, G. Gensini, D. Prisco 

SMOKING INCREASES THE RISK OF VENOUS THROMBOSIS 

E. R. Pomp* (NL), F. R. Rosendaal, C. J. M. Doggen 

TRENDS IN THE DIAGNOSTIC WORK-UP OF DEEP VENOUS THROMBOSIS OF THE 

LEG BETWEEN 1999 AND 2004 

E. R. Pomp* (NL), K. J. Van Stralen, I. D. Bezemer, C. J. M. Doggen, H. R. Büller, 

F. R. Rosendaal 

279



P-T-548 

P-T-549 

P-T-550 

P-T-551 

P-T-552 

P-T-553 

P-T-554 

P-T-555 

P-T-556 

P-T-557 

P-T-558 

COMPARISON OF FOUR CLINICAL PREDICTION MODELS IN PATIENTS WITH 

SUSPECTED PULMONARY EMBOLISM 

M. Pengo (IT), V. Pengo, E. Bernardi, P. Prandoni* 

QUALITY OF ORAL ANTICOAGULANT TREATMENT AND RISK OF SUBSEQUENT 

RECURRENT THROMBOEMBOLISM IN PATIENTS WITH DEEP VENOUS THROMBOSIS. 

A PROSPECTIVE COHORT STUDY 

P. Prandoni* (IT), B. A. Hutten, C. J. J. Van Dongen, R. Pesavento, M. H. Prins 

THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM AFTER DISCONTINUING 

ANTICOAGULATION IN PATIENTS WITH ACUTE PROXIMAL DEEP VEIN THROMBOSIS 

OR PULMONARY EMBOLISM. A PROSPECTIVE COHORT STUDY 

P. Prandoni* (IT), F. Noventa, A. Ghirarduzzi, V. Pengo, E. Bernardi, R. Pesavento, 

M. Iotti, D. Tormene, P. Simioni, A. Pagnan 

THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM AMONG HETEROZYGOUS 

CARRIERS OF FACTOR V LEIDEN OR PROTHROMBIN G20210A MUTATION. 

A SYSTEMATIC REVIEW OF PROSPECTIVE STUDIES 

A. Marchiori (IT), L. Mosena, M. H. Prins, P. Prandoni* 

CONVENIENCE OF THE NEW LONG-ACTING ANTICOAGULANT IDRAPARINUX (IDRA) 

VERSUS VITAMIN K ANTAGONIST (VKA) IN PATIENTS WITH DEEP VENOUS 

THROMBOSIS (DVT) 

M. H. Prins (NL), P. Leguet*, H. Gilet, A. Roborel De Climens 

MULTINATIONAL DEVELOPMENT OF A QUESTIONNAIRE ASSESSING PATIENT 

SATISFACTION WITH ANTI-COAGULANT TREATMENT 

M. H. Prins (NL), B. Arnould, P. Leguet*, P. Caire, G. Raskob, A. Marrel 

ASSOCIATION BETWEEN ASYMPTOMATIC DEEP-VEIN THROMBOSIS DETECTED BY 

SCREENING VENOGRAPHY AND SYMPTOMATIC VENOUS THROMBOEMBOLISM IN 

PATIENTS UNDERGOING ELECTIVE HIP OR KNEE SURGERY – A SYSTEMATIC 

REVIEW 

D. J. Quinlan (UK), J. W. Eikelboom, O. E. Dahl*, B. I. Eriksson, P. S. Sidhu, J. Hirsh 

D-DIMER REPORTING: WHAT’S THE PROBLEM FOR THE ELECTRONIC HEALTH 

RECORD? AN ONTARIO PERSPECTIVE 

A. Raby* (CA), M. Crowther, G. Flynn 

THROMBOPROPHYLAXIS IN HIGH-RISK ADOLESCENT INPATIENTS 

L. J. Raffini* (US), D. Davis, T. Trimarchi, M. Martucci, C. Manno 

ELEVATED PLASMA GAS6 LEVELS ARE ASSOCIATED WITH CLOT BURDEN AND 

UNDERLYING MALIGNANCY IN DEEP-VEIN THROMBOSIS 

D. Rao* (CA), C. Holcroft, S. R. Kahn, M. Blostein 

DURATION OF SYMPTOMS AND D-DIMER TESTING FOR VENOUS 

THROMBOEMBOLISM RULING-OUT 

S. M. Rezende (BR), M. De Bastos*, A. B. F. Carneiro-Proietti, T. Bogutchi, 

M. R. D. De Bastos 

280



Ischaemic heart disease 

P-T-559 

P-T-560 

P-T-561 

P-T-562 

DOWN REGULATION OF THROMBOTIC AND INFLAMMATORY MEDIATORS IN 

PATIENTS WITH ACUTE CORONARY SYNDROME TREATED WITH CLOPIDOGREL. 

RELEVANCE TO THE OBSERVED CLINICAL EFFECTS 

J. Fareed* (US), D. Fareed, R. Bick, D. Hoppensteadt, W. P. Jeske, B. E. Lewis, 

J. M. Walenga 

CARDIOVASCULAR DISEASE, HYPERHOMOCYSTEINEMIA AND ATHEROTHROMBOTIC 

RISK FACTORS IN PSORIATIC PATIENTS 

G. Gamba* (IT), R. Longoni, L. Fornara, L. Bocchi, N. Montani, V. Brazzelli 

CONTRAINDICATIONS TO ANTICOAGULANTS ARE COMMON IN PATIENTS 

REQUIRING VENOUS THROMBOEMBOLISM PROPHYLAXIS 

H. Gibbs* (AU), R. Collins, J. Gibbs 

POST - CORONARY INTERVENTION RECURRENT ISCHEMIA IN THE PRESENCE OF 

ADEQUATE PLATELET INHIBITION BY DUAL ANTIPLATELET THERAPY: WHAT ARE 

WE OVERLOOKING? 

P. A. Gurbel* (US), K. P. Bliden, I. Navickas, E. Cohen, U. S. Tantry 

P-T-563 

P-T-564 

P-T-565 

TRANSITION TO AN UNSTABLE CORONARY SYNDROME IS MARKED BY 

HYPERCOAGUABILITY, PLATELET ACTIVATION, HEIGHTENED PLATELET 

REACTIVITY, AND INFLAMMATION: RESULTS OF THE THROMBOTIC RISK 

PROGRESSION (TRIP) STUDY 

U. S. Tantry (US), K. P. Bliden, R. P. Kreutz, J. Dichiara, P. A. Gurbel* 

MECHANISMS ASSOCIATED WITH FAILURE OF THROMBOLYTIC THERAPY TO 

RECANALIZE THE INFARCT ARTERY IN ACUTE MYOCARDIAL INFARCTION 

M. G. Huisse* (FR), L. Feldman, M. C. Guillin, P. G. Steg 

THE ROLES OF SERUM MATRIX METALLOPROTEINASES IN PATIENTS WITH 

CORONARY ARTERY DISEASE AND ATRIAL FIBRILLATION TO HEART FAILURE 

G. Jong* (TW), T. Ma 


P-T-566 

P-T-567 

P-T-568 

P-T-569 

P-T-570 

CONSIDERATION OF MODIFIED CUT-OFFS FOR ANTHROPOMETRIC VARIABLES IN 

DEFINING METABOLIC SYNDROME AMONG ASIAN INDIANS WITH CORONARY 

ARTERY DISEASE (CAD) 

S. Kanjilal (IN), J. Shanker*, V. S. Rao, B. K. Natesha, M. Mukherjee, V. V. Kakkar 

CORRELATION OF METABOLIC SYNDROME WITH ATHEROGENIC PHENOTYPES IN 

INDIAN POPULATION 

S. Kanjilal (IN), J. Shanker*, V. Rao, B. K. Natesha, M. Mukherjee, V. V. Kakkar 

MEASUREMENT OF THROMBIN GENERATION IN PATIENTS AT RISK FOR 

ATHEROTHROMBOSIS 

V. Kaufmann* (AT), J. Mager, B. Laemmle, B. R. Binder, M. Redondo 

INCREASED LEVELS OF D—DIMER IN PATIENTS WITH MYOCARDIAL INFARCTION 

K. Kawasugi* (JP), C. Simazu, M. Noguchi, H. Tashiro, M. Gotoh, N. Shirafuji, 

J. Matsuda, Y. Miyazawa 

DECREASE OF SOLUBLE P-SELECTIN AND INHIBITION BOTH, ACTIVATED FACTOR 

XA AND THROMBIN AFTER I.V.ENOXAPARIN DURING PCI 

J. Kvasnicka* (CZ), J. Horak, I. Malikova, T. Kvasnicka, Z. Necasova 

281



P-T-571 

P-T-572 

P-T-573 

P-T-574 

P-T-575 

ASPIRIN PREVENTS PLATELET ACTIVATION AFTER CORONARY ARTERY BYPASS 

SURGERY DESPITE AN INCREASE IN THROMBOXANE A2 SYNTHESIS 

L. Macchi (FR), F. Favreau*, C. Jayle, L. Bosc, L. Christiaens 

INCIDENCE OF ANTITHROMBIN LEVEL ON “HEMOFILTER CIRCUIT” THROMBOSIS 

DURING EARLY CONTINUOUS VENOVENOUS HEMOFILTRATION IN POST 

CARDIOPULMONARY BYPASS PATIENTS 

H. Lanquetot (FR), T. Leprince, C. Boinot, S. Ragot, C. Jayle, L. Macchi* 

ACETYLSALICYLIC ACID (ASA) RESISTANCE IN PATIENTS WITH ISCHEMIC HEART 

DISEASE (IHD) AS BIOINDICATOR OF THE TREATMENT STRATEGY 

J. Maly* (CZ), M. Pecka, R. Pudil, R. Maly, P. Dulicek, J. Gregor, D. Vokurkova 

POST-TREATMENT PLATELET FUNCTION PREDICTS MYOCARDIAL INJURY IN ACUTE 

MYOCARDIAL INFARCTION PATIENTS UNDERGOING PRIMARY PCI 

R. Marcucci (IT), R. Paniccia, A. Gori, E. Antonucci, E. Romano, S. Poli, C. Giglioli, 

D. Prisco, G. Gensini, R. Abbate* 

PLATELET P-SELECTIN IS ASSOCIATED WITH CIRCULATING NEUTROPHIL 

ACTIVATION AT THE VERY ONSET OF MYOCARDIAL INFARCTION 

N. Maugeri* (IT), C. Godino, V. Evangelista, M. Mussardo, F. Figini, A. Colombo, 

D. Cianflone, A. Manfredi, A. Maseri 

Cerebrovascular disease 

P-T-576 

P-T-577 

P-T-578 

P-T-579 

P-T-580 

P-T-581 

P-T-582 

P-T-583 

HEREDITARY THROMBOPHILIC DEFECTS IN IRANIAN PATIENTS WITH CEREBRO 

VASCULAR ACCIDENT 

M. Ahmadinejad* (IR), D. Bashash, S. Zolfaghari, A. Talebian, J. Dadgar, M. Tabatabaii 

A ROLE FOR PLATELET ACTIVATION IN LACUNAR STROKE? 

N. Ajzenberg* (FR), P. Lavallée, J. Labreuche, M. Guillin, P. Amarenco, T. Dupré, 

P. Nicaise 

SOLUBLE ENDOTHELIAL PROTEIN C RECEPTOR AND CYTOKINE LEVELS IN 

TURKISH PEDIATRIC STROKE PATIENTS 

N. Akar* (TR), G. Deda, Y. Egin, D. Yürürer 

TPA IN CHILDREN WITH ARTERIAL ISCHEMIC STROKE: CASES FROM THE IPSS 

COMPARED WITH LITERATURE-BASED CASES 

C. Amlie-Lefond* (US), A. Chan, R. Ichord, G. Deveber and members of the IPSS 

PROTHROMBOTIC FACTORS IN INFANTS WITH NEONATAL CEREBRAL INFARCTION 

G. Barillari* (IT), E. Bigotto, A. Janes, G. De Stasio, R. Giacomello, F. Maccagno 

BENIGN OUTCOME OF OBJECTIVELY PROVEN SPONTANEOUS RECANALIZATION OF 

INTERNAL CAROTID ARTERY OCCLUSION: LONG-TERM FOLLOW UP 

G. Camporese* (IT), N. Labropoulos, F. Verlato, E. Bernardi, G. Salmistraro, 

D. Kontothanassis, R. Ragazzi, M. Barban, A. Dalla Pozza, G. M. Andreozzi 

REAL EFFECT OF WARFARIN THERAPY PREVENTING STROKE IN PATIENTS WITH 

ATRIAL FIBRILLATION 

R. Y. Cotrina* (PE) 

SOCIAL COSTS OF ANTICOAGULANT TREATMENT FOR ATRIAL FIBRILLATION 

E. Filippucci* (IT), A. Blass, P. Parise, S. Grasselli, A. Ascani, F. Brunetti, M. Verducci, 

G. Fattore, G. Aguzzi, I. Colangelo, G. Agnelli 

282



P-T-584 

P-T-585 

P-T-586 

P-T-587 

P-T-588 

P-T-589 

THE SAFETY OF ANTICOAGULANTS IN PEDIATRIC ARTERIAL ISCHEMIC STROKE: 

PRELIMINARY RESULTS 

T. S. Finkelstein (CA), L. R. Brandao*, A. Kirton, A. K. Chan, S. Williams, D. Macgregor, 

Y. Finkelstein, A. Pontigon, M. Adams, G. Deveber 

ARTERIAL STIFFNESS, ENDOTHELIAL FUNCTION AND THE RISK OF ISCHAEMIC 

STROKE 

I. Ford* (UK), K. K. Kalal, I. MacKay, M. Greaves, J. Brittenden 

THROMBOTIC MARKERS AND MITRAL VALVE PROLAPSE IN MIGRAINE WITH AND 

WITHOUT AURA AT CHILDHOOD ONSET 

R. Longoni (IT), P. Ondei, N. Montani, L. Bocchi, G. Gamba*, A. Gamba 

RISK FACTOR PROFILE ASSOCIATED WITH ICD IN SPANISH POPULATION 

A. García-Raso (ES), V. P. Moreno, A. Drozdowskyj, M. J. García-Bueno, C. Sánchez, 

A. García-Torres, P. Llamas*, R. Mata 

COMPARISON OF EFFICACY AND SAFETY OF INTRAVENOUS AND INTRA-ARTERIAL 

THROMBOLYSIS IN ACUTE ISCHEMIC STROKE 

Y. He* (CN), Z. Fu, M. Yin, L. Qiu, L. Ma 

FIBRINOGEN HAPLOTYPES AND PLASMA LEVELS SHOW INDEPENDENT 

ASSOCIATION TO ISCHEMIC STROKE 

K. Jood* (SE), J. Danielson, C. Ladenvall, C. Blomstrand, C. Jern 

P-T-590 

P-T-591 

C936T MUTATION IN THE VEGF GENE AS AN INDEPENDENT RISK FACTOR FOR 

PATIENTS WITH SILENT BRAIN INFARCTION 

N. Kim* (KR), S. Hong, O. Kim, H. Kim, H. Park, S. Bae, D. Oh 

GENDER-SPECIFIC ASSOCIATION OF VASCULAR ENDOTHELIAL GROWTH FACTOR 

POLYMORPHISMS (VEGF -2578C>A AND -634G>C) AND THE RISK OF ISCHEMIC 

STROKE 

N. Kim* (KR), H. Park, O. Kim, S. Bae, S. Hong, D. Oh, H. Yoon, S. Park 


P-T-592 

HEMORRHAGIC TRANSFORMATION OF ARTERIAL ISCHEMIC STROKE IN CHILDREN 

A. Kirton (CA), T. Schechter, L. Brandao, S. Laughlin, A. Chan*, S. Williams, 

D. MacGregor, A. Pontigon, G. Deveber 

Hormones, pregnancy, women's issues 

P-T-593 

P-T-594 

P-T-595 

P-T-596 

LOW MOLECULAR WEIGHT HEPARIN IN PREGNANCY - INFLUENCE ON BIRTH 

WEIGHT AND DURATION OF PREGNANCY IN WOMEN WITH THROMBOPHILIA 

R. Klamroth* (DE), S. Gottstein, E. Essers, J. Fischer, K. Joschko, H. Landgraf 

SAFETY AND EFFICACY OF TINZAPARIN ADMINISTRATION DURING PREGNANCY 

P. Kotsi* (GR), C. Tsoucala, I. Anastasopoulou, A. Sarantopoulos, G. Kanellopoulou, 

T. Adraktas, A. Karafoulidou 

MONITORING AND DOSAGE MODULATION OF ENOXAPARIN DURING PREGNANCY 

C. Lambert* (BE), B. Dessomme, V. Deneys, C. Hermans 

PATHOGENETIC PROPHYLAXIS OF RECCURENT FETAL LOSS SYNDROME IN 

PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME AND GENETIC THROMBOPHILIA 

A. D. Makatsariya* (RU), S. M. Baimuradova, V. O. Bitsadze, E. V. Donina, 

S. V. Akinshina 

283



P-T-597 

P-T-598 

P-T-599 

P-T-600 

P-T-601 

P-T-602 

P-T-603 

P-T-604 

P-T-605 

P-T-606 

P-T-607 

SCREENING FOR THROMBOPHILIA: RETROSPECTIVE STUDY IN WOMEN WITH 

GESTACIONAL VASCULAR COMPLICATIONS 

M. Mariz* (PT), L. Corbillón, J. Abreu Lima, M. Pereira, R. Matos, J. Braga, S. Morais, 

M. Campos 

A RANDOMIZED, CONTROLLED TRIAL TO EVALUATE THE EFFICACY OF LMWH ON 

PREGNANCY OUTCOME OF WOMEN WITH PREVIOUS PREGNANCY COMPLICATIONS. 

H.A.P.P.Y. STUDY 

I. Martinelli* (IT), T. Battaglioli, P. M. Mannucci 

CORRELATION BETWEEN DIFFERENT FIBRINOLYTIC TESTS IN PATIENTS WITH 

OBSTETRIC COMPLICATIONS 

M. E. Martinuzzo* (AR), Y. P. Adamczuk, M. L. Iglesias Varela, G. S. Cerrato, 

R. R. Forastiero 

CUTANEOUS REACTION TO LOW MOLECULAR WEIGHT HEPARIN AND 

HOMOZYGOUSIS FOR FACTOR V LEIDEN MUTATION DURING PREGNANCY: A CASE 

REPORT 

F. T. Mathonnet* (FR), M. Uzan, C. Fischer, J. Nizard, E. Jaouen, P. Rozenberg, 

N. Tabary, Y. Ville, Y. Giudicelli 

PROPHYLACTIC APPROACH TO WOMEN WITH THROMBOPHILIA AND REPEATED 

SPONTANEOUS ABORTIONS 

G. Mitic* (RS), P. Filipov, L. Povazan, V. Canak, M. Maticki, A. M. Lucic, A. Novakov 

Mikic 

FV LEIDEN, FII G20210A AND MTHFR T677T GENOTYPES: IS THEIR EVALUATION A 

USEFUL TOOL IN THE ETIOLOGICAL APPROACH OF THE EARLY RECURRENT 

PREGNANCY LOSSES IN THE GREEK POPULATION? 

A. Mougiou* (GR), M. Karakantza, G. Androutsopoulos, G. Decavalas, N. Zoumbos 

PLASMA COAGULATION TESTS AND GENETIC THROMBOPHILIC MUTATION STUDIES 

ARE MANDATORY FOR PREVENTING THE IDIOPATHIC RECURRENT ABORTIONS OR 

REPEATED FETAL LOSS IN HEALTHY WOMEN 

R. Musso* (IT), F. Nardo, D. Cultrera, G. Sortino, M. Azzaro, A. Cipolla, E. Di Francesco, 

M. Musso, A. Musso 

THE THERAPEUTICAL STRATEGIES ARE EFFECTIVE TO PREVENT THE RECURRENT 

ABORTIONS, REPEATED FETAL LOSS OR THE INTRAUTERINE FETAL GROWTH 

RETARDATION IN WOMEN WITH COAGULATION ABNORMALITIES AND/OR GENETIC 

THROMBOPHILIC MUTATIONS 

R. Musso* (IT), F. Nardo, D. Cultrera, G. Sortino, M. Azzaro, A. Cipolla, E. Di Francesco, 

M. Musso, A. Musso 

THE GENETIC ANALYSIS OF DEEP VEIN THROMBOSIS DURING PREGNANCY AND 

PERINATAL ASSOCIATED DISORDERS IN JAPANESE 

R. Neki* (JP), T. Ikeda, T. Fujita, J. Ishikawa, Y. Sato, T. Miyata 

ONCE DAILY TINZAPARIN SODIUM (175 INTERNATIONAL UNITS PER KG) IS SAFE 

AND EFFECTIVE FOR ANTENATAL THROMBOPROPHYLAXIS IN HIGH RISK 

PREGNANCIES AND FOR TREATMENT OF ANTENATAL VENOUS THROMBOEMBOLIC 

EVENTS 

F. B. Ni Ainle* (IE), N. Appleby, A. Wong, B. Byrne, C. Regan, M. Milner, T. Hassan, 

B. Nolan, B. White, J. O'Donnell 

TREATMENT OF VTE DURING PREGANCY WITH A ONCE-DAILY REGIMEN OF LMWH 

F. Parent* (FR), X. Jaïs, M. Wolf, C. Boyer-Neuman, G. Simonneau 

284



P-T-608 

P-T-609 

P-T-610 

P-T-611 

INHERITED AND ACQUIRED THROMBOPHILIA IN PATIENTS WITH METABOLIC 

SYNDROME IN OBSTETRIC-GYNECOLOGIC PRACTICE 

E. B. Perederyaeva* (RU), T. B. Pshenichnikova, A. D. Makatsaria 

FACTOR V LEIDEN AND PLACENTAL PATHOLOGY 

M. Procházka* (CZ), R. Laurini, K. Marsál, J. Procházková, P. G. Lindqvist 

ESTROGEN TREATMENT OF CONSTITUTIONAL TALL STATURE IN GIRLS: 

RISK OF THROMBOSIS OR BLEEDING? 

O. Rask* (SE), K. Nilsson, E. Berntorp 

IS THE RISK OF VENOUS THROMBOEMBOLISM HIGHER WITH CYPROTERONE 

CONTRACEPTIVES? 

S. Regina* (FR), D. Leroux, C. Pouplard, B. Fimbel, B. Delahousse, Y. Gruel 

Homocysteine 

P-T-613 

P-T-614 

EVALUATION OF MILD HHCY IN THE DEVELOPMENT OF ATHEROSCLEROSIS IN 

APOE-DEFICIENT AND NORMAL MICE 

A. C. M. Aléssio* (BR), N. F. Höehr, R. Haddad, L. C. Oliveira, 

J. M. Annichino-Bizzacchi 

ASSOCIATION OF HYPERHOMOCYSTEINEMIA WITH RESTENOSIS 

S. Ammar* (TN), N. Ben Romdhane, S. Chabrak, R. Mechmeche 

P-T-615 

P-T-616 

HOMOCYSTEINE INDUCES VCAM-1 GENE EXPRESSION THROUGH NF-KB AND 

NAD(P)H OXIDASE ACTIVATION: PROTECTIVE ROLE OF MEDITERRANEAN DIET 

POLYPHENOLIC ANTIOXIDANTS 

M. A. Carluccio (IT), M. Massaro, M. Carluccio, E. Scoditti, A. Distante, C. Storelli, 

R. De Caterina* 

ASSOCIATION BETWEEN PLASMA LEVELS OF HOMOCYSTEINE (HCY) AND SMOKING 

IN PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE (PAOD) 

A. P. L. Mota (BR), M. E. R. C. Santos, A. P. S. M. Fernandes, F. C. L. Silva, 

M. G. Carvalho* 


P-T-617 

P-T-618 

P-T-619 

P-T-620 

P-T-621 

PLASMA LEVELS OF HOMOCYSTEINE (HCY) AND OTHER PARAMETERS 

INTERRELATED IN PATIENTS WITH PERIPHERAL ARTERIAL OBSTRUCTIVE DISEASE 

(PAOD) 

A. P. L. Mota (BR), M. E. R. C. Santos, A. P. S. M. Fernandes, F. C. L. Silva, 

M. G. Carvalho* 

HYPERHOMOCYSTEINEMIA IS ASSOCIATED WITH APC RESISTANCE 

B. M. Binetti (IT), I. Martinelli, M. Cattaneo, N. Semeraro, M. Colucci* 

MODERATE HYPERHOMOCYSTEINEMIA IS ASSOCIATED WITH REDUCED PLASMA 

FIBRINOLYTIC CAPACITY AND INCREASED TAFI LEVELS 

M. Colucci* (IT), F. Semeraro, M. Cattaneo, I. Martinelli, N. Semeraro 

EVALUATION OF A NEW LATEX-BASED HOMOCYSTEINE ASSAY 

P. C. Cooper* (UK), K. P. Hickey, S. M. Cooper, S. Kitchen, M. Makris 

HOMOCYSTEINE AS INDICATOR OF OSTEOPOROSIS. THE INCHIANTI STUDY 

A. Corsi (IT), F. Lauretani, S. Bandinelli, A. Gori*, S. Fedi, L. Ferrucci, R. Abbate 

285



P-T-622 

P-T-623 

P-T-624 

P-T-625 

P-T-626 

ANALYSIS OF FOLATE-RELATED GENES FOR ASSOCIATION WITH PLASMA 

HOMOCYSTEINE LEVEL IN A SNP-MICROARRAY APPROACH 

M. Den Heijer* (NL), S. H. H. M. Vemeulen, B. Franke, M. J. Coenen, M. Schijvenaars, 

H. Scheffer, H. J. Blom 

CATECHOL-O-METHYLTRANSFERASE GENOTYPE IS ASSOCIATED WITH PLASMA 

TOTAL HOMOCYSTEINE LEVELS AND MAY INCREASE RECURRENT VENOUS 

THROMBOSIS RISK 

M. Den Heijer* (NL), H. Gellekink, J. Muntjewerff, S. Vermeulen, A. R. Hermus, 

H. J. Blom 

THE NIJMEGEN HAEMOSTASIS ASSAY (NHA) IN THE VITRO-STUDY: RELATION WITH 

HOMOCYSTEINE, B-VITAMIN TREATMENT AND RECURRENCE RISK 

M. Den Heijer* (NL), P. Lap, A. Loof, W. L. Van Heerde 

METABOLIC SYNDROME AND HYPERHOMOCYSTEINEMIA IN PATIENTS WITH DEEP 

VEIN THROMBOSIS: A CASE-CONTROL STUDY 

F. Dentali* (IT), W. Ageno, E. Romualdi, P. Prandoni, R. Pesavento, A. Ghirarduzzi, 

A. Venco 

HYPERHOMOCYSTEINEMIA AND THROMBOSIS: THE DIAGNOSTIC ROLE OF POST 

METHIONINE-LOAD TEST 

C. Durante (IT), R. Boschian B., F. Pivetta, O. Poles, S. Zanolin, L. De Marco, A. Steffan* 

New antithrombotic agents and approaches 

P-T-627 

P-T-628 

P-T-629 

P-T-630 

P-T-631 

P-T-632 

CORRECTION HAEMOSTASIOLOGIC AND RHEOLOGIC DISTURBANCES AT THE 

PATIENTS WITH ISCHEMIC HEART AND BRAIN DESIASES BY MEANS OF 

COMBINATION OF PHARMACOLOGICAL DRUGS AND EXTRACORPOREAL 

AUTOBLOOD-MAGNET-THERAPY 

N. G. Kruchinsky* (BY), A. I. Teplyakov, D. K. Zubovsky 

THE EFFECT OF AGE AND GENDER ON THE PHARMACOLOGY AND SAFETY OF THE 

ORAL, DIRECT FACTOR XA INHIBITOR RIVAROXABAN 

D. Kubitza* (DE), M. Becka, W. Mueck, M. Zuehlsdorf 

ANTIPLATELET AND ANTITHROMBOTIC ACTIVITY OF NP-313, 2-ACETYLAMINO-3- 

CHLORO-1,4-NAPHTHOQUINONE, A NOVEL CPLA2 AND CYTOSOLIC CA 2 + 

MOBILIZATION INHIBITOR 

H. L. Kuo* (TW), J. C. Lien, S. C. Kuo, C. H. Chung, C. H. Chang, T. F. Huang 

ANTIPLATELET ACTIVITY OF FENOFIBRATE, A PPARALPHA AGONIST, WAS 

MEDIATED BY BLOCKING OF CYTOSOLIC CALCIUM MOBILIZATION AND 

THROMBOXANE A2 RECEPTOR 

J. Lee* (KR), Y. Jin, Y. Lim, J. Yu, J. Lee, M. Tudev, J. Im, E. Park, T. Kim, M. Lee, 

Y. Yun 

EFFECTS AND MECHANISMS OF BUYANG HUANWU DECOCTION ON THE CELL 

VIABILITY AND TF EXPRESSION INDUCED BY ANGII IN ENDOTHELIAL CELLS 

J. L. Li* (CN), S. L. Xiong, W. H. Zhu 

SEROTONERGIC MECHANISMS IN HAEMOSTASIS: A CONNECTION BETWEEN MAJOR 

DEPRESSION AND THROMBOTIC RISK 

I. Lopez-Vilchez* (ES), M. Serra, A. Alonso, F. Navalon, R. Hernandez, E. Gomez, 

C. Gasto, G. Escolar, A. M. Galan 

286



P-T-633 

P-T-634 

P-T-635 

P-T-636 

P-T-637 

P-T-638 

INHIBITION OF MEASURED THROMBIN GENERATION IN HUMAN PLASMA BY 

APIXABAN: A PREDICTIVE MATHEMATICAL MODEL BASED ON EXPERIMENTALLY 

DETERMINED RATE CONSTANTS 

J. M. Luettgen* (US), Z. Wang, D. A. Seiffert, A. R. Rendina, R. M. Knabb, 

M. L. Ogletree 

THE PREVENTION OF THROMBFORMATION UNDER INFLUENCE OF A COMPLEX 

PREPARATION OF PLANT ANTICOAGULANT 

G. Y. Lyapin* (RU), T. Y. Obergan 

THE PREVENTION OF THROMBFORMATION UNDER INFLUENCE OF A COMPLEX 

PREPARATION OF PLANT ANTICOAGULANT 

G. Y. Lyapin* (RU), T. Y. Obergan 

CHARACTERISATION OF THE ACTIVE FORM OF THE NOVEL ORAL DIRECT 

THROMBIN INHIBITOR AZD0837 IN COAGULATION ASSAYS 

C. Mattsson* (SE), A. Lundin, J. Ulvinge 

ANTITHROMBOTIC ACTIVITIES IN PHARMACOLOGICAL MODELS OF A LONG-ACTING 

REVERSIBLE SYNTHETIC OLIGOSACCHARIDE 

L. Millet* (FR), P. Savi, J. Herault, P. Duchaussoy, M. Petitou, P. Schaeffer, F. Bono, 

J. Herbert 

N-METHYLNICOTINAMIDE INHIBITS ARTERIAL THROMBOSIS IN HYPERTENSIVE RATS 

A. Mogielnicki* (PL), K. Kramkowski, W. Buczko 

P-T-639 

P-T-640 

ACTIVATED PROTHROMBIN COMPLEX CONCENTRATE, RECOMBINANT FACTOR VIII 

AND FACTOR IX REVERSE PROLONGED CLOTTING TIME INDUCED BY DU-176B, 

A DIRECT FACTOR XA INHIBITOR, IN HUMAN PLASMA 

Y. Morishima* (JP), T. Fukuda, Y. Honda, T. Shibano 

COMPARISON OF ANTITHROMBOTIC PROPERTIES OF A DIRECT FXA INHIBITOR, 

DU-176B, WITH AN ANTITHROMBIN DEPENDENT FXA INHIBITOR, FONDAPARINUX, IN 

A CAPILLARY PERFUSION CHAMBER THROMBOSIS MODEL 

Y. Morishima (JP), T. Shibano*, N. Tsuji, T. Fukuda 


P-T-641 

P-T-642 

P-T-643 

P-T-644 

EFFECT OF A FACTOR XA INHIBITOR DU-176B ON INTRACEREBRAL HEMORRHAGE 

IN RATS: A WIDER SAFETY MARGIN COMPARED WITH A THROMBIN INHIBITOR 

Y. Morishima* (JP), Y. Shirasaki, F. Kito, Y. Honda, T. Shibano 

EFFECTS OF DU-176B, A NOVEL DIRECT FACTOR XA INHIBITOR, ON 

PROTHROMBINASE ACTIVITY AND PLATELET AGGREGATION IN VITRO 

T. Shibano* (JP), N. Tsuji, F. Kito, T. Fukuda, T. Furugohri, Y. Morishima 

PHARMACOLOGICAL CHARACTERIZATION OF AN ORAL DIRECT THROMBIN 

INHIBITOR, MCC-977: HIGH THROMBIN SPECIFICITY AND LOW HEMORRHAGIC 

PROFILE 

M. Nakajima* (JP), M. Suga, K. Sugawara, M. Katsu, S. Yuki, J. Anabuki, T. Yamamoto, 

Y. Abe, Y. Kitada 

THE ANTI-COAGULANT AND THE ANTI-THROMBOTIC EFFECT OF MCC-977, A NOVEL 

ORALLY-ACTIVE THROMBIN INHIBITOR 

M. Nakajima* (JP), M. Suga, K. Sugawara, K. Yamada, J. Anabuki, T. Yamamoto, 

Y. Kitada 

287



P-T-645 

P-T-646 

P-T-647 

COMPARISON OF ANTIPLATELET AND ANTITHROMBOTIC EFFECTS OF PRASUGREL 

AND AZD6140 

T. Ogawa* (JP), C. Isobe, M. Kakusaka, Y. Yokouchi, Y. Niitsu, A. Sugidachi, F. Asai, 

J. A. Jakubowski 

DEVELOPING ANTIDOTE CONTROLLED ANTIPLATELET THERAPIES BY TARGETING 

THE VWF - GP IB-IX-V INTERACTION 

S. Oney* (US), J. Layzer, S. M. Nimjee, N. S. Que, D. Ginsburg, J. A. Lopez, 

G. M. Arepally, R. C. Becker, B. A. Sullenger 

WARFARIN ANTICOAGULATION INTENSITY IN SPECIALIST-BASED AND IN 

COMPUTER -ASSISTED DOSING PRACTICE 

P. T. Onundarson* (IS), K. A. Einarsdottir, B. R. Gudmundsdottir 

Clinical trials: oral anticoagulants incl. New compounds 

P-T-648 

P-T-649 

P-T-650 

P-T-651 

P-T-652 

P-T-653 

P-T-654 

P-T-655 

PHARMACOGENETICS OF ORAL ANTICOAGULATION - VKORC1-HAPLOTYPES 

DETERMINE THE INTER-INDIVIDUAL VARIABILITY 

C. Geisen* (DE), B. Luxembourg, K. Sittinger, S. W. Toennes, M. Watzka, 

E. Lindhoff-Last, E. Seifried, J. Oldenburg 

BRIDGING THERAPY IN PATIENTS TREATED WITH LMWH AND COUMARIN INDUCES 

DEEP INHIBITION OF THROMBIN GENERATION 

G. T. Gerotziafas* (FR), C. Dupont, I. Elalamy, E. Verdy 

OVER-ANTICOAGULATION ASSOCIATED WITH COMBINED USE OF COUMARIN 

ANTICOAGULANTS AND TOPICAL ECONAZOLE OR BIFONAZOLE IN ELDERLY 

PATIENTS 

I. Gouin-Thibault (FR), J. Alexandra, E. Pautas, A. Gouronnec, N. Le Strat, V. Siguret* 

SPECIFIC MULTI-RULE EXPERT SYSTEM FOR ELDERLY INPATIENT ANTICOAGULANT 

CONTROL 

I. Gouin-Thibault* (FR), V. Siguret, V. Vieillefond, C. Visseaux, C. Levy, C. Boccara, 

C. Bal Dit Sollier, J. Cambus, L. Drouet, I. Mahé, M. Horellou, E. Pautas 

EVALUATION OF THE FACTOR XA (FXA) INHIBITOR, PRT054021 (PRT021), AGAINST 

ENOXAPARIN IN A RANDOMIZED TRIAL FOR THE PREVENTION OF VENOUS 

THROMBOEMBOLIC EVENTS AFTER TOTAL KNEE REPLACEMENT (EXPERT) 

A. G. Turpie* (CA), M. Gent, K. Bauer, B. L. Davidson, W. Fisher, M. Huo, K. Borow, 

V. B. Frame, C. Michalsky, D. D. Gretler, K. Romanko, U. Sinha 

RESULTS OF A ONE-YEAR REGISTRY OF BLEEDING COMPLICATIONS OF VITAMIN K 

ANTAGONIST THERAPY OUTSIDE A CONTROLLED POPULATION 

K. M. Halbritter* (DE), J. Beyer, W. Oettler, B. Kleinstück, S. M. Schellong 

LONG LASTING ANTICOAGULANT EFFECTS OF ONCE WEEKLY SUBCUTANEOUS 

INJECTIONS OF IDRAPARINUX TO TREAT PATIENTS FOR PROPHYLAXIS OF 

RECURRENT VENOUS THROMBOEMBOLISM 

J. Harenberg* (DE), C. Weiss 

ANTICOAGULANT MANAGEMENT USING AN INTERNET BASED MONITORING 

SYSTEM 

P. L. Harper* (NZ), S. Stott, C. Ford, P. Ngata 

288



P-T-656 

P-T-657 

P-T-658 

P-T-659 

P-T-660 

D-DIMER VALUE AND ECHOCARDIOGRAPHIC CHANGES AS PREDICTORS OF 

THROMBOEMBOLIC COMPLICATIONS AFTER THE FONTAN OPERATION 

M. F. Hendler* (AR), F. Alberto, S. S. Meschengieser, W. M. Conejeros, M. I. Roman, 

A. Sanchez-Luceros, P. Casais, A. Schlichter, G. O. Kreutzer, M. A. Lazzari 

BETAINE (TRIMETHYLGLYCINE), A NOVEL ORAL ANTICOAGULANT WITH COMBINED 

NITRIC OXIDE AND TISSUE FACTOR PATHWAY INHIBITOR RELEASE POTENTIAL. 

IMPLICATIONS IN THE MANAGEMENT OF VASCULAR DISEASES 

O. M. Iqbal* (US), J. Messadek, R. Ennamany, D. Fareed, D. Hoppensteadt, J. Fareed 

MATRIX METALLOPROTEINASE-3, TISSUE INHIBITOR OF METALLOPROTEINASES-1 

AND WARFARIN TREATMENT 

M. Kozak* (SI), M. Bozic, M. Stegnar 

RIVAROXABAN – AN ORAL, DIRECT FACTOR XA INHIBITOR – HAS NO CLINICALLY 

RELEVANT INTERACTION WITH ACETYLSALICYLIC ACID OR NAPROXEN 

D. Kubitza* (DE), M. Becka, W. Mueck, M. Zuehlsdorf 

DETERMINATION OF VKORC1 AND CYP2C9 GENOTYPES IS OF LIMITED VALUE 

DURING CHRONIC ANTICOAGULATION WITH ACENOCOUMAROL 

C. Lambert* (BE), J. Gala, B. Dessomme, V. Deneys, C. Hermans 

P-T-661 

P-T-662 

P-T-663 

RISK FACTOR FOR ORAL ANTICOAGULANT TREATMENT OVERDOSE: A CASE 

CONTROL STUDY IN AN EMERGENCY UNIT 

V. Le Cam-Duchez* (FR), G. Cadiou, Y. Benhamou, R. Varin, I. Tiret, J. M. Kerleau, 

B. Veber, B. Dieu, J. Y. Borg, H. Lévesque 

ACCEPTABILITY AND EFFICACY OF PATIENT SELF-TESTING IN PATIENTS NEW TO 

THE ANTICOAGULATION CLINIC 

I. Longair (UK), C. Gardiner, M. A. Pescott, H. Erwin, S. J. Machin, H. Cohen* 

LACK OF EFFECT OF INFLUENZA IMMUNISATION ON ANTICOAGULANT CONTROL IN 

PATIENTS ON LONG-TERM WARFARIN 

P. K. MacCallum* (UK), M. Madhani, S. Mt-Isa, D. Ashby 


P-T-664 

P-T-665 

QUALITY OF ANTICOAGULANT MANAGEMENT: A 4-YEAR ANALYSIS OF TREATMENT 

AND COMPLICATIONS IN ANTICOAGULATION SERVICE IN LJUBLJANA 

A. Mavri* (SI), A. Kramaric 

A NATIONAL FIELD STUDY OF QUALITY ASSESSMENT (QA) OF COAGUCHEK 

MONITORS 

P. Meijer* (NL), C. Kluft, L. Poller, F. J. M. Van Der Meer, M. Keown, S. Ibrahim, 

A. M. H. P. Van Den Besselaar, A. Tripodi, J. Jespersen 

Clinical trials: parenteral drugs (e.g.heparins/LMWH/fondaparinux) 

P-T-666 

P-T-667 

ANTITHROMBIN III IN COMPARISON WITH FRESH FROZEN PLASMA IN PATIENTS 

WITH DISSEMINATED INTRAVASCULAR COAGULATION ACCOMPANIED BY 

ANTITHROMBIN III DEFICIENCY 

E. L. Neporada (RU), N. A. Vorobyeva*, O. V. Turundaevskaya, G. N. Melnikova 

IMMUNE RESPONSE AFTER FIRST AND SECOND IV INJECTION OF AVIDIN USED AS 

THE NEUTRALIZING AGENT FOR BIOTINYLATED IDRAPARINUX 

I. Paty* (FR), N. Paquet, M. Sibille, P. Cortez, F. Berard, J. F. Nicolas 

289



P-T-668 

P-T-669 

P-T-670 

P-T-671 

P-T-672 

P-T-673 

P-T-674 

P-T-675 

P-T-676 

P-T-677 

P-T-678 

P-T-679 

ENOXAPARIN VERSUS HEPARIN PROPHYLAXIS FOR VENOUS THROMBOEMBOLISM 

AFTER ABDOMINAL ONCOLOGIC SURGERY: A RANDOMIZED DOUBLE-BLIND 

CONTROLLED TRIAL 

M. Petrov* (RU), A. Anosov, N. Piskunova 

ENOXAPARIN VERSUS UNFRACTIONATED HEPARIN FOR VENOUS 

THROMBOEMBOLISM (VTE) PROPHYLAXIS IN ACUTE ISCHEMIC STROKE PATIENTS 

G. F. Pineo* (CA), G. W. Albers, C. Bladin, C. Fieschi, A. A. Gabbai, C. S. Kase, 

W. O’Riordan, D. G. Sherman 

CERTIFY, A PHASE III STUDY COMPARING CERTOPARIN WITH UNFRACTIONATED 

HEPARIN IN ELDERLY, ACUTELY ILL MEDICAL PATIENTS 

H. B. Riess* (DE), C. Sieder, S. Schellong, S. Haas, U. Tebbe, H. Gerlach, J. Adams 

BEMIPARIN THROMBOPROPHYLAXIS IN ELDERLY MEDICAL PATIENTS: 

THE "ANCIANOS" STUDY 

L. Rodríguez-Mañas (ES), R. Gómez-Huelgas, G. Monteagudo, R. Maeso, 

A. Gómez-Outes*, J. Martínez-González 

A RANDOMIZED, CONTROLLED, DOUBLE BLIND STUDY OF BEMIPARIN VS 

UNFRACTIONATED HEPARIN AS BRIDGING THERAPY OF ORAL ANTICOAGULATION 

THERAPY IN INVASIVE PROCEDURES OR AMBULATORY SURGERY. DESIGN OF THE 

BERTA STUDY 

A. Santamaría (ES), J. Fontcuberta* 

USE OF FONDAPARINUX IN PATIENTS WITH HEPARIN-INDUCED 

THROMBOCYTOPENIA TYPE II 

M. Schindewolf* (DE), E. Lindhoff-Last, B. Luxembourg 

PHARMACOKINETICS OF DALTEPARIN IN PROPHYLACTIC DOSAGE IN PATIENTS 

WITH IMPAIRED RENAL FUNCTION 

P. Schmid* (CH), D. Brodmann, A. G. Fischer, W. A. Wuillemin 

EVALUATION OF A NEW FUNCTIONAL CLOTTING ASSAY FOR THE MONITORING OF 

HEPARIN AND HEPARINOID ANTICOAGULANTS BASED ON THROMBIN AND/OR 

FACTOR XA INHIBITION WITH CLINICAL PATIENT PLASMAS AT THREE UNIVERSITY 

MEDICAL CENTERS 

R. Schöni* (CH), J. Walenga, M. Samama, J. Harenberg, A. F. Drenth, C. Le Courvoisier- 

Flaujac, C. Giese, K. Rudin, B. Bühler, M. Wilmer 

ENOXAPARIN 40 MG VERSUS NADROPARIN 0.3 ML IN THE PREVENTION OF VENOUS 

THROMBOEMBOLISM (VTE) IN COLORECTAL CANCER SURGERY ACCORDING TO 

AGE AND CREATININE CLEARANCE (CRCL) 

G. Simonneau* (FR), P. Mismetti 

COADMINISTRATION OF THE ORAL DIRECT THROMBIN INHIBITOR DABIGATRAN 

ETEXILATE AND DICLOFENAC HAS LITTLE IMPACT ON THE PHARMACOKINETICS OF 

EITHER DRUG 

J. Stangier* (DE), K. Rathgen, H. Stähle, K. Reseski, T. Körnicke 

BIOEQUIPOTENCY OF IDRAPARINUX AND BIOTINYLATED IDRAPARINUX AFTER 

SINGLE DOSE IN HEALTHY SUBJECTS 

M. Trellu* (FR), Y. Perez, J. Ortiz, S. Cheng, I. Paty 

FONDAPARINUX 1.5 MG ONCE DAILY IN THE PROPHYLAXIS OF VENOUS 

THROMBOEMBOLISM (VTE): EFFICACY AND SAFETY IN RENALLY-IMPAIRED 

PATIENTS FROM A DOSE-RANGING STUDY IN MAJOR ORTHOPEDIC SURGERY 

A. G. Turpie* (CA) 

290



P-T-680 

P-T-681 

P-T-682 

PHARMACOKINETICS (PK) OF SUBCUTANEOUS FONDAPARINUX 1.5 MG IN PATIENTS 

WITH MODERATE RENAL IMPAIRMENT (MRI) 

D. Boyle* (US), A. G. Turpie 

REPLACING ORAL ANTICOAGULANTS WITH TINZAPARIN SODIUM IN PATIENTS 

UNDERGOING LAPAROSCOPIC CHOLECYSTECTOMY: SAFETY AND COST 

CONSIDERATIONS 

S. K. Volteas* (GR), A. Babos 

ANTI XA ASSAYS FOR DANAPAROID: ASSESSMENT OF PRE ANALYTICAL AND 

ANALYTICAL VARIABLES 

A. Wemyss* (UK), J. M. Smith, A. Woolley, J. Storr, E. Hampton, R. MacLean, S. Kitchen 

Clinical trials: antiplatelet agents 

P-T-683 

PR-15 A NOVEL INTRAVENOUS INHIBITOR OF PLATELET ADHESION: A PHASE I 

DOSE ASCENDING PHARMACOKINETIC, PHARMACODYNAMIC, AND TOLERANCE 

STUDY 

S. Combe* (UK), K. Rosport, A. Kennedy 

P-T-684 

P-T-685 

P-T-686 

EFFECT OF BIVALIRUDIN VS. BIVALIRUDIN WITH EPTIFIBATIDE ON PLATELET 

ACTIVATION AND AGGREGATION IN PATIENTS RECEIVING CHRONIC CLOPIDOGREL 

THERAPY UNDERGOING ELECTIVE PCI 

P. A. Gurbel* (US), K. P. Bliden, J. Dichiara, M. Antonino, T. B. Gesheff, U. S. Tantry, 

O. V. Bailon 

EFFECTS OF A FLAVANOL-RICH COCOA BEVERAGE ON PLATELET AND LEUCOCYTE 

FUNCTION IN MAN 

J. A. May* (UK), S. C. Fox, S. Heptinstall, C. Kwik-Uribe 

NON-RESPONSE TO ASPIRIN (ASA) IN PATIENTS WITH PERIPHERAL ARTERIAL 

OCCLUSIVE DISEASE (PAOD); A PROSPECTIVE STUDY 

S. Prochnow* (DE), B. Linnemann, J. Schwonberg, H. Mani, E. Lindhoff-Last 


P-T-687 

P-T-688 

P-T-689 

P-T-690 

P-T-691 

HIGH INCIDENCE OF CLOPIDOGREL NON-RESPONSIVENESS IN PATIENTS WITH 

CORONARY ARTERY DISEASE – A REAL WORLD SITUATION 

A. Schaefer* (DE), S. Weinberger, M. Eigenthaler, G. Ertl, J. Bauersachs 

NON-RESPONSE TO CLOPIDOGREL IN PATIENTS WITH PERIPHERAL ARTERIAL 

OCCLUSIVE DISEASE (PAOD); A PROSPECTIVE STUDY 

J. Schwonberg* (DE), B. Linnemann, S. Prochnow, H. Mani, E. Lindhoff-Last 

PLATELET RESPONSE DOES NOT CHANGE DURING LONG-TERM-TREATMENT 

(8YEARS) WITH 50 OR 100 MG ACETYLSALICYLIC ACID (ASA) FOR SECONDARY 

PREVENTION 

H. Sinzinger* (AT), H. Kritz, R. Berent, P. Schmid, D. Steinbrenner 

NO DECREASE IN THROMBIN FORMATION AT THE SITE OF MICROVASCULAR 

INJURY IN PATIENTS TREATED WITH CLOPIDOGREL 

A. Undas* (PL), E. Stepien, A. Branicka, K. Zmudka, W. Tracz 

PREVALENCE OF “ASPIRIN RESISTANCE” IN CHILDREN 

D. L. Yee* (US), B. Dinu, C. Sun, 

291



Patient education 

P-T-692 

P-T-693 

P-T-694 

P-T-695 

P-T-696 

P-T-697 

P-T-698 

KNOWLEDGE RETENTION IMPROVES OUTCOMES FOR CHILDREN REQUIRING 

VITAMIN K ANTAGONISTS 

M. E. Bauman* (CA), K. Black, M. Massicotte 

THROMBOPHILIA TESTING IN A DEVELOPING COUNTRY REFERRAL CENTER: 

A 3-YEAR OBSERVATIONAL STUDY 

P. Casais* (AR), S. S. Meschengieser, M. A. Lazzari 

EVALUATION OF THE HYPERLIPIDEMIA AND HYPERGLYCEMIA IN PROGESTERONE 

ONLY PILL USERS 

M. Kashanian* (IR), M. Fekrat 

IMPACTS OF GENETIC TESTING FOR THROMBOPHILIA ON FIRST DEGREE 

RELATIVES OF PATIENTS WITH VENOUS THROMBOEMBOLISM AND A 

THROMBOPHILIA - A CROSS-SECTIONAL SURVEY 

M. L. Louzada* (CA), P. S. Wells, M. A. Rodger, C. R. Dunn, B. Wilson 

PSYCHOLOGICAL IMPACTS OF GENETIC TESTING FOR THROMBOPHILIA ON FIRST 

DEGREE RELATIVES OF PATIENTS WITH VENOUS THROMBOEMBOLISM AND A 

THROMBOPHILIA – A PILOT STUDY 

M. L. Louzada* (CA), P. S. Wells, C. R. Dunn, N. Langlois, B. Wilson, S. R. Kahn, 

M. A. Rodger, D. R. Anderson, M. J. Kovacs 

DO POINT OF CARE DEVICES IMPROVE OUTCOMES IN PATIENTS ON ORAL 

ANTICOAGULANT THERAPY 

P. S. Wells* (CA), A. Brown, J. Jaffey, M. Poon 

REDUCTION IN EMERGENCY DEPARTMENT VISITS BY PATIENTS ATTENDING 

AN ANTICOAGULATION CLINIC 

P. Whittaker* (US), J. L. Donovan 

Innovation and technology 

Structural biology and drug design 

P-T-699 

P-T-700 

BIOCHEMICAL AND MECHANICAL PROPERTIES OF INTRALUMINAL THROMBUS 

FROM HUMAN ABDOMINAL AORTIC ANEURYSM 

M. Camera* (IT), R. Ballerio, R. Spirito, E. Di Martino, F. Boschetti, E. Tremoli 

DIFFERENTIATION OF LOW MOLECULAR WEIGHT HEPARINS AS STUDIED BY 

MOLECULAR WEIGHT PROFILE AND HEPARINASE-I DEPOLYMERIZATION: 

PHARMACOLOGIC IMPLICATIONS 

A. Brubaker (US), W. P. Jeske, D. Hoppensteadt, J. Maddineni, M. Kujawski, J. Fareed* 

292

Mise en page 1 - ISTH 2009

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?